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One of the mechanisms by which papillomaviruses establish persistent infection of 
the host is by tethering their genomes to host chromosomes during mitosis. This 
ensures maintenance and partitioning of the viral genomes to daughter cells after each 
cell division. Although studies have shown that the viral E2 protein links the viral 
genome to host chromosomes in several papillomaviruses, the exact molecular 
mechanism of this interaction has yet to be elucidated for the beta-papillomaviruses. 
The studies described in this dissertation aimed to characterize the interaction of the 
E2 protein of the human papillomavirus type 8 (HPV8), a type of beta-
papillomavirus, with mitotic chromosomes. The E2 protein consists of a conserved N-
terminal transactivation domain and a C-terminal DNA binding and dimerization 
domain that are linked by a flexible hinge. We have mapped a sixteen amino acid 
region in the hinge that, when linked to the DNA binding domain, is crucial and 
sufficient for chromosomal association. Further we have identified two residues in 
  
this region, arginine 250 (R250) and serine 253 (S253) within a highly conserved 
RXXS motif that are required for HPV8 E2 chromosome binding. Additionally, we 
have shown that the S253 residue is phosphorylated. To gain insight into the 
regulation of the E2 chromosome binding function, we investigated the role of 
phosphorylation of S253. We have shown that S253 is phosphorylated by PKA in S-
phase, which increases the half-life of E2 protein and modulates its interaction with 
host chromatin. Since E2 is also involved in transcriptional regulation and viral 
genome replication, we examined if mutating residues R250 or S253 affected the 
transcriptional activation or replication functions of the HPV8 E2 protein. 
Furthermore using a domain swapping approach, we also explored the role of the C-
terminal domain in the HPV8 E2 chromosome binding function. Finally to establish 
the mode of interaction responsible for mediating HPV8 E2 chromosome binding, we 
employed both a proteomics approach and ribonuclease treatment techniques, to 
examine whether HPV8 E2 chromosomal association is mediated through protein-
protein or protein-RNA interactions, respectively. Collectively, these studies have 



















CHARACTERIZATION OF THE INTERACTION OF THE HPV8 E2 TETHERING 













Dissertation submitted to the Faculty of the Graduate School of the  
University of Maryland, College Park, in partial fulfillment 
of the requirements for the degree of 












Leslie Pick, Ph.D, Chair 
Alison A McBride, Ph.D, Co-chair 
Jeffrey DeStefano, Ph.D 
Osnat Herzberg, Ph.D 
Zvi Kelman, Ph.D 
Brenda Fredericksen, Ph.D 















































This dissertation is dedicated to my spiritual guru, Mata Amritanandamayi and to my 





First and foremost, I would like to express my sincere and deepest gratitude to 
Dr. Alison A McBride, my research advisor, for her guidance and support throughout 
the course of my graduate studies. I have learned immensely from her scientific 
intellect, patience, perseverance and drive for perfection. Her ‘never give up’ attitude 
has really inspired me and was the very reason that made it possible for foreign 
students like me to pursue dissertation research at NIH.  
My sincere thanks to my advisory committee members: Dr. Leslie Pick, Dr. 
Jeffrey DeStefano, Dr. Osnat Herzberg, Dr. Zvi Kelman and Dr. Brenda Fredericksen 
for their guidance, valuable ideas and support.  
Thanks to members of Alison’s lab: Moon Kyoo Jang, Nozomi Sakakibara, 
Jameela Khan, Koenraad (Vanni), Wesley Stepp and Raymond Fernalld for all your 
help and your friendships. You are all talented, hard-working and most importantly 
fun people. It has been a great experience working with all of you. Moon Kyoo, thank 
you for teaching me your perfect molecular biology techniques and for introducing 
me to Korean cuisine. Vanni and Jameela thanks for being the best PV consultants on 
board. Wesley and Raymond, you guys are the best stress busters I could ask for. 
Nozomi, I can never thank you enough for being such a great friend and of course for 
always extending your help whenever I needed it. Thanks to you all, I have many 
cherished memories of my experience in lab. Good luck to all of you in all your 
future endeavors.  
Most importantly, I want to thank my family and feel really blessed to have 




expressed in words, for all the sacrifices they have made and always provided me 
with the best in life. Mom and Dad thank you for being such great parents and for 
inculcating the right values in me. You are my role models and I hope I can be a great 
parent to Govind just like you are. I owe everything I am today to you. I can also 
never thank my husband, Gireesh enough for always believing in me and encouraging 
me in all my endeavors. You are the pillar of my life. I am also blessed to have my 
son, Govind who has brought so much joy and happiness in our lives. Finally, I would 
like to thank God for showering grace on me in the form of all the different 









Table of Contents .......................................................................................................... v 
Table of Tables ............................................................................................................. v 
List of Figures ............................................................................................................ viii 
 
Chapter 1 ..................................................................................................................... 1 
Introduction ................................................................................................................... 1 
Chapter 1: Introduction ................................................................................................. 2 
Classification of Papillomaviruses ................................................................................ 2 
Diseases associated with papillomaviruses ................................................................... 5 
Benign lesions .............................................................................................................................. 5 
Cancers ........................................................................................................................................... 5 
HPV vaccine and prevention ........................................................................................ 6 
Genome organization of Beta Papillomaviruses ........................................................... 7 






Genome maintenance and viral persistence ................................................................ 20 
Plasmid segregation in Prokaryotes and Eukaryotes .................................................. 24 
Cellular targets of PV E2 proteins .............................................................................. 25 
Brd4 .............................................................................................................................................. 26 
Ribosomal DNA (rDNA) ...................................................................................................... 26 
Mitotic spindle, TopBP1, ChlR1 and MKlp2 ................................................................. 27 
Rationale for the Dissertation ..................................................................................... 28 
 




Establishment of stable pMEP-E2 cell lines ............................................................... 34 
Immunoblotting........................................................................................................... 34 
Immunoprecipitation and Immunoblotting ................................................................. 34 
In vivo phosphorylation assay ..................................................................................... 35 
PKA inhibitor and enhancer treatments ...................................................................... 36 
Indirect immunofluorescence ...................................................................................... 36 
Protein complex purification for the proteomics study: ............................................. 37 
RNAse A treatment followed by Immunofluorescence .............................................. 39 




Luciferase assay for E2 transactivation: ..................................................................... 43 
Dimerization assay ...................................................................................................... 44 
Identification of Putative E2 binding sites (E2BS) ..................................................... 45 
Calculation of percent similarity among different PV E2 CTDs: ............................... 45 
 
Chapter 3 ................................................................................................................... 46 




Regions in the hinge of the HPV8 E2 protein required for Mitotic Chromosomal 
Interaction ................................................................................................................................... 50 
The HPV8 E2 Proteins Localize to Nuclear Speckles, but this does not correlate 
with Mitotic Chromosome Binding ................................................................................... 57 
The Chromosome Binding Region is functional in other BetaPapillomavirus E2 
Proteins ........................................................................................................................................ 61 
The Chromosome Binding Region of the Beta Papillomaviruses is highly 
conserved .................................................................................................................................... 63 
An RXXS motif in the hinge is crucial for mitotic chromosome binding ............ 65 
HPV8 E2 Serine 253 is a Phosphorylation Site ............................................................. 72 
Discussion ................................................................................................................... 75 
 
Chapter 4 ................................................................................................................... 82 
Chapter 4: PKA phosphorylation regulates the chromosome binding function of the 
HPV8 E2 protein ......................................................................................................... 83 
Introduction ................................................................................................................. 83 
Results ......................................................................................................................... 87 
HPV8 E2 protein is phosphorylated at S253 residue by Protein Kinase A (PKA)
 ........................................................................................................................................................ 91 
Modulation of cellular PKA activity affects the mitotic localization of the HPV8 
E2 protein ................................................................................................................................... 96 
Enhanced E2 phosphorylation results in an increase in number of interphase 
cells with E2 associated with pericentromeric foci ...................................................... 98 
S253 phosphorylation of HPV8 E2 increases during S–phase and mitosis ...... 100 
Increase in phosphorylation of the E2 protein in S-phase correlates with an 
increase in association of E2 protein with pericentomeric foci ............................. 102 
HPV8 E2 proteins phosphorylated at S253 have a longer half-life ..................... 104 
Discussion ................................................................................................................. 108 
 
Chapter 5: Role of the C-terminal DNA binding and dimerization domain in the 
chromosomal association function of the HPV8 E2 protein ............................... 114 
Introduction ............................................................................................................... 114 
Results ....................................................................................................................... 118 
The DNA binding defective E2 protein R431K/R433K is capable of 
dimerization ............................................................................................................................ 118 




Discussion ................................................................................................................. 128 
 
Chapter 6 ................................................................................................................. 136 
Chapter 6: Role of protein-protein and protein-RNA interactions in the chromosomal 
association function of the HPV8 E2 protein ........................................................... 137 
Introduction ............................................................................................................... 137 
Results ....................................................................................................................... 141 
Validation of interactions of the HPV8 E2 protein with candidate proteins 
identified from the TAP/mass spectrometry study .................................................... 141 
RNAse treatment of E2 expressing cells did not affect the chromosome binding 
function of the HPV8 E2 protein ..................................................................................... 151 
Discussion ................................................................................................................. 155 
 
Chapter 7:  The effect of the chromosome binding motif on the transactivation 
and replication functions of the HPV8 E2 protein ............................................... 160 
Introduction ............................................................................................................... 160 
Results ....................................................................................................................... 161 
Alanine substitutions of residues R250 and S253 within the HPV8 E2 hinge 
region had no effect on the transactivation function of the HPV8 E2 protein . 161 
Alanine substitutions of residues R250 and S253 within the HPV8 E2 hinge 
region have no effect on the replication function of the HPV8 E2 protein in 
U2OS cells .............................................................................................................................. 163 
Discussion ................................................................................................................. 167 
 
















List of Tables 
 
 
Table 1:   List of all the primers used in cloning…………………………………….32 
 
Table 2:   List of antibodies used for the proteomics study………………………….39 
 
Table 3.1: Percentage of truncated E2 expressing mitotic cells with foci pattern 
on chromosomes……………………………………………………………………..56 
 
Table 3.2: Percentage of mutated E2 expressing mitotic cells with foci pattern on 
chromosomes (set of mutations in the background of 216-255-CTD)..…....………..67 
 
Table 3.3: Percentage of mutated E2 expressing mitotic cells with foci pattern on 













List of Figures 
Figure 1.1 Genomic organization of HPV8………………………………………….8 
 
Figure 1.2 Schematic diagram of the full length HPV8 E2 protein ………… .……11 
. 
Figure 1.3 Diagram of the viral life cycle in a stratified host epithelium………...…18 
 
Figure 1.4 Model illustrating the tethering of viral genome to host chromosomes....22 
 
Figure 3.1 Amino acid sequence of the HPV8 E2 protein hinge……………………51 
 
Figure 3.2 Truncated E2 proteins with deletions in the hinge examined for mitotic 
localizations……………………………………………………………………...…..53 
 
Figure 3.3 Chromosome Binding Phenotype of E2 proteins with deletions  
in the hinge……………………………………………………………..…………….55 
 
Figure 3.4 Colocalization of E2 and SC35 in interphase cells………………………59 
 
Figure 3.5 Summary of the intracellular localization of the HPV8 E2 Proteins…….60 
 
Figure 3.6 HPV5 E2 protein shows a similar mitotic binding pattern to  
HPV8 E2 protein……………………………………………………………………..62 
 
Figure 3.7 Sequence analysis of the Chromosome Binding Region………………...64 
 
Figure 3.8 Mutational Analysis and Mitotic Chromosome Binding Phenotype of  
216-255-C E2 Proteins ………………………………………………………………66 
 
Figure 3.9 Arginine 250 and serine 253 are critical residues mediating 
 chromosomal association function of HPV8 E2 protein …………………………...70 
 
Figure 3.10 Phosphorylation analysis of the HPV8 E2 proteins…………..………..74 
 
Figure 3.11 Similarities among the chromosome binding regions of HPV8 E2,  
EBNA1 and LANA........................…………………………………………………80 
 
Figure 4.1 Residues arginine 250 and serine 253 are critical for the full length HPV8 





Figure 4.2 Phospho-RXXS motif specific antibodies can detect HPV8 E2  
protein phosphorylated at residue serine 253………………………………..…...…90 
 
Figure 4.3 Effect of kinase inhibitors on S253 phosphorylation…………………..92 
 
Figure 4.4 Prediction of the PKA phosphorylation sites within the HPV8  
E2 protein………………………………………………………………………..….94 
 
Figure 4.5 PKA phosphorylates HPV8 E2 protein at serine 253 residue………….95 
 
Figure 4.6 Mitotic localization of the HPV8 E2 protein is affected by modulators  
of cellular PKA activity………………………………………………………..…...97 
 
Figure 4.7 Modulation of PKA activity alters the association of E2 
with pericentromeric foci in interphase cells……………………………………….99 
 
Figure 4.8 HPV8 E2 phosphorylation at serine 253 residue increases in the S- 
phase and remains high in mitosis………………………………………………….101 
 
Figure 4.9 Increased S253 phosphorylation in S-phase correlates with increase in  
the number of S-phase interphase cells with E2 associated pericentromeric foci…103 
 
Figure 4.10 Phosphorylated E2 protein is more stable than phosphorylation  
defective E2 protein……………………………………………………………......105 
 
Figure 4.11 Chromatin bound E2 protein has a longer half-life…………………...109 
 
Figure 5.1 Both dimerization defective and DNA binding defective HPV8  
E2 proteins show loss of mitotic binding phenotype………………………………117 
 
Figure 5.2 DNA binding defective E2 protein R431K/R433K is capable  
of dimerization in the in vitro dimerization assay………………………………….119 
 
Figure 5.3 Substitution of the HPV8 E2 CTD with CTDs from other PVs……….121 
 




substitute the HPV8 E2 CTD when fused to the 240-255 hinge peptide…………..123 
 
Figure 5.5 CTDs from alpha, gamma, kappa or delta PVs cannot  
 substitute the HPV8 E2 CTD when fused to the 240-255 hinge peptide………….125 
 
Figure 5.6 Interphase localization of HPV5, HPV8 and HPV4 CTDs and  
the respective fusion proteins…………………………………………………….....127 
 
Figure 5.7 Consensus E2 binding sites varies among each genus  
of PVs......……………………………………………………….......……………...129 
 
Figure 5.8 Alignment of the CTDs of HPV11, HPV4, HPV5, HPV8, HPV107,  
BPV1 and SfPV1………………………………………………………………..….133 
 
Figure 6.1 Schematic representation of the different HPV8 E2 proteins used for the 
immunoprecipitation assay…………………………………………..……………..143 
 
Figure 6.2 Validation of the protein interactions in the immunoprecipitated  
HPV8 E2 protein complexes……………………………………………………….150 
 
Figure 6.3 RNAse A treatment of E2 expressing CV-1 cells does not affect 
 HPV8 E2 chromosome binding…………………………………………………....154 
 
Figure 6.4 HPV8 E2 chromosomal association is not mediated through RNA 
Binding……………………………………………………………………………...156 
 
Figure 7.1 R250A and S253A mutations within the HPV8 E2 hinge do not affect 
transactivation function of the HPV8 E2 protein…………………………………...164 
 
Figure 7.2 HPV8 ori plasmid can replicate in the presence of both R250A or 
 S253A mutated E2 in U2OS cells………………………………………………….166 
 









ACA         Anti centromere antibodies 
ATP          Adenosine triphosphate 
bp              base pair 
BCA         Bicinchoninic acid 
BPV1        Bovine papillomavirus type1 
CBP          CREB binding protein 
CBS          Chromosome binding sequence 
CENP        Centromere protein  
CIN           Cervical intraepithelial neoplasia 
CREB        cAMP response element-binding 
CTD          C-terminal domain 
CTX          Cholera toxin 
DAPI         4', 6'-diamidino-2-phenylindole 
DBD       DNA binding and dimerization domain 
DNA        Deoxyribonucleic acid 
DTT         Dithiothreitol 
EBNA1    Epstein Barr nuclear antigen 1 
EBV         Epstein Barr virus 
EDTA      Ethylene diamine tetraacteic acid 
ER            Endoplasmic reticulum 




FITC         Fluorescein isothiocyanate 
HC            Hinge and C-terminal domain 
HEPES      4-2-hydroxyethyl-1-piperazineethanesulfonic acid 
HMG        High mobility group 
HPV         Human papillomaviruses 
h               hour      
Kb            Kilobase  
KAP1       Krab-associated protein-1 
KSHV      Kaposi Sarcoma herpesvirus 
LANA      Latency associated nuclear antigen 
LCR          Long control region 
LDS          Lithium dodecyl sulfate 
MARS      Matrix attachment regions 
MCB         Mitotic chromosome binding  
MEME      Multiple EM Motif Elicitation 
MHC         Major histocompatibility complex 
NH            N-terminal domain and hinge 
NLS          Nuclear localization sequence 
NMR        Nuclear magnetic resonance 
NP40        Nonidet P40 
NRIP        Nuclear receptor interaction protein 
ORF         Open reading frame 




PBS          Phosphate buffer saline 
PCNA       Proliferating Cell Nuclear Antigen 
PCR          Polymerase chain reaction 
PCV          Packed cell volume 
PKA          Protein kinase A 
PML         Promyelotic leukemia 
PP2A        Protein serine/threonine phosphatases 2A 
PRMT5    Protein arginine methyltransferases 5 
PV            Papillomaviruses 
RFC         Replication factor C 
RG           Arginine glycine 
RIPA       Radio-Immunoprecipitation Assay 
RLU        Relative light units 
RNA       Ribonucleic acid 
RNAse    Ribonuclease 
RNAi      RNA interference 
RPA     Replication protein A 
RS           Arginine serine 
SAFA      Scaffold attachment factor A 
SDS         Sodium dodecyl sulfate 
SR            Serine arginine 
SRPK1    Serine-arginine protein kinase 1 




TAD        Transactivation domain 
TAP         Tandem affinity purification 
TBP         TATA box binding protein 
TE           Tris EDTA 
UBF        Upstream binding factor 
URR        Upstream Regulatory region 
UV          Ultra violet 
VLP        Virus like particles 
WDR5    WD repeat containing protein 
WSTF     Williams syndrome transcription factor 












Portions of the section ‘cellular targets of PV E2 proteins’ were adapted from sections 
that I had written for a book chapter to be published in March 2012. 
Koenraad Van Doorslaer, Vandana Sekhar, Jameela Khan, and Alison A. McBride 
(2012) - Replication and Maintenance of Viral Genomes by Association with Host 














Chapter 1: Introduction  
Classification of Papillomaviruses 
Papillomaviruses (PVs) are a group of small, ubiquitous, double stranded, 
non-enveloped DNA viruses that are the causative agents of cutaneous and mucosal 
infections of both humans and animals [24]. Currently over 214 different types of PVs 
have been characterized (http://pave.niaid.nih.gov/#home). They are classified into 
different genera based on their nucleotide identity across the conserved L1 gene [24]. 
All sequenced papillomaviruses have been classified into various categories in the 
following order: genus, species, type and variant [58]. Based on the sequence of the 
L1 genes, PV types are classified into a genus if they show at least 60% sequence 
identity. If they show less than 60% sequence identity, they are grouped into another 
genus. Within a genus, if the L1 gene sequence shares identity between 71-89 %, the 
viral genome is labeled as a type and if the sequence shares identity between 60-70% 
it is classified as a species.  Further, if the L1 gene sequence differs less than 2%, the 
genome is labeled as a variant [58,24].  
Papillomaviruses are thought to have co-evolved along with their natural 
hosts. To date there are 29 different genera of papillomaviruses that have been 
characterized, of which five are human papillomaviruses (HPVs) [24]. There are 
twenty genera of non-human mammalian PVs, three of avian and one genus of 
reptiles [24]. The five different genera of HPVs include the Alpha, Beta, Gamma, Mu 
and Nu papillomaviruses [58]. 
Alpha PVs- Members of the alpha-PV genus has been studied quite extensively 




that fall into two categories: high-risk and low-risk, depending on their propensity to 
cause infections that can progress into malignant carcinomas. High-risk viruses are 
associated with the development of anogenital cancers like cervical cancer, while the 
low-risk types rarely cause malignancies and are mainly associated with benign 
genital warts (reviewed in [30]). In addition, high-risk viruses are also associated with 
approximately 20% of the human oral cancers [289]. High-risk types include HPV16, 
HPV18, HPV31, HPV33 and HPV45. Examples of low-risk types are HPV6 and 
HPV11 [289].  
 
Beta PVs- Members of the beta PV genus infect the skin and hence, are cutaneous 
papillomaviruses. The most widely studied members of this genus are HPV5 and 
HPV8. Studies described in this dissertation are focused mainly on HPV8. Beta PVs 
are usually associated with asymptomatic infections in healthy individuals; but in 
immuno-compromised individuals these viruses cause lesions on the skin that can 
progress to squamous cell carcinomas after decades of infection [143]. Clinical 
manifestations of beta PV infections are most commonly seen in patients with a rare 
form of inherited autosomal recessive immune disorder called epidermodysplasia 
verruciformis (EV) [86]. HPV5 and HPV8 have been detected in 90% of squamous 
cell carcinomas in EV patients (reviewed in [185]). Most of these patients harbor 
mutations in two genes namely, EVER1 and EVER2 that are part of the EV1 locus on 
human chromosome 17. These genes belong to the transmembrane channel-like gene 
family [208]. However, since not all EV patients have been found to carry these 




[6]. Members of the beta genus have also been implicated in certain types of non-
melanoma skin cancers [80]. However, the mechanistic contribution of beta PVs in 
the development of skin cancers is still not clearly established [58]. One of main 
reasons for this disparity is that infections with beta PVs are extremely common in 
general populations such that they are thought to be a part of the normal ‘viral flora’ 
of the skin. Thus, the presence of beta PVs in the skin surrounding the skin biopsies 
confounds the analysis of distinguishing between beta PVs resulting in malignant 
conditions from those that are part of normal viral flora of the skin [85].  
Unlike the genome of high-risk alpha HPVs, the genome of beta PVs is not 
integrated into the host genome; rather, it is maintained as an extrachromosomal 
element during infection [78]. The focus of this dissertation is to elucidate the 
mechanism by which beta PVs maintain their genome as extrachromosomal elements 
in infected cells. This process is believed to be essential to establish persistent PV 
infection of hosts. Moreover, some studies indicate that HPV5 and HPV8 are 
oncogenic [60,192]. The oncogenic potential of HPV8 was first identified with the 
development of skin tumors in transgenic mice while expressing HPV8 early proteins 
from a keratin promoter [221]. More specifically, expression of HPV8 E2 protein has 
been shown to induce formation of skin tumors in transgenic mice [203]. Thus, the 
beta PV genus constitutes a group of viruses that share many unique characteristics. 
Gamma, Mu and Nu PVs- Apart from the alpha and beta PVs, members of the rest of 
the genera of HPVs including gamma, mu and nu PVs infect the cutaneous epithelia 





Diseases associated with papillomaviruses 
Papillomaviruses are the etiological agents of a broad spectrum of diseases.  
They cause infections that range from asymptomatic infections, benign lesions like 
common warts and anogenital warts to malignant carcinomas.  
Benign lesions 
Benign lesions include proliferative epithelial lesions that are referred to as 
‘warts’ when appearing on the skin and ‘condylomas’ when occurring on genital 
epithelia. Many low-risk PV types such as HPV6 and HPV11 are associated with 
benign lesions [99]. These lesions may either regress spontaneously due to 
immunological response or persist indefinitely. HPV1 is responsible for causing 
plantar warts on the feet of infected individuals [74]. However, some 
papillomaviruses like HPV2 can target both cutaneous and mucosal epithelia [44]. 
Cancers  
Among the different factors that can trigger development of cancer, 
approximately 15% of human cancers are associated with viruses [89]. Dr. Zur 
Hausen won the 2008 Nobel Prize in Physiology or Medicine for his pioneering 
efforts in discovering the connection between HPV and cervical cancer. Cervical 
cancer is the second most common cause of cancer death in women [197]. In the 
absence of HPV infection, development of cervical cancer is extremely rare. 
However, only small fractions of high-risk HPV infections that are not cleared by the 
immune system progress into carcinomas. Although HPV infection is essential, it is 




factors that contribute to HPV induced malignancies. These include hereditary 
factors, immune suppression and various environmental cofactors. Progression to 
cervical cancer can be categorized into different stages of cervical intraepithelial 
neoplasia (CIN). It begins with a low grade lesion (CIN1), which progresses over 
time into CIN2 and then to a severe dysplasia (CIN3), and finally into a carcinoma 
that may metastasize [67]. High-risk types HPV16 and 18 together with the types 
HPV31, 33, 39, 45, and 58 are detected in about 97% of cervical cancer cases [268].  
Cervical cancer is not the only cancer associated with HPV infections.  HPVs 
have also been shown to exist in cancers of the oral cavity such as tonsils, base of 
tongue and the soft palate and the larynx [59,225,231]. As mentioned in the beta PV 
section, some cutaneous HPVs such as  HPV5, 8, 12, and 23 cause lesions that further 
develop into squamous cell carcinomas, primarily in EV patients [193]. It is believed 
that, given its potential links to cervical, vulvar, penile, anal, oral, laryngeal and non-
melanoma skin cancers, HPVs may contribute to about 10% of cancer cases 
worldwide [197,287].  
 
HPV vaccine and prevention   
Two prophylactic vaccines have been introduced to block initial infection with 
some of the high and low risk HPV types in young girls and boys. One is a 
quadravalent vaccine called Gardasil® (Merck) for protection against high-risk 
HPV16, 18 and low-risk HPV6 and 11. The second is a bivalent vaccine, CervarixTM 
(Glaxo SmithKline) that protects against HPV16 and HPV18. Both vaccines consist 




however, the adjuvants in which the VLPs are carried and the VLP expression 
systems differ (269). Since the two available vaccines are not effective in preventing 
cancer progression in already infected individuals and do not target infections with 
other high-risk HPVs, it is important for women to continue undergoing regular Pap 
smear screenings as a means for early detection of HPV associated infections.  
 
Genome organization of Beta Papillomaviruses 
The HPV8 genome is a circular double-stranded DNA that is 7654 base pairs long 
(Figure1.1). It encodes four early proteins (E1, E2, E6 and E7) and three late  
proteins (E4, L1, L2). The genome contains two promoters. The early promoter, p175 
located within the long control region (LCR) regulates the transcription of early genes 
E1, E2, E6 and E7 [113,237]. The second differentiation-dependent promoter, p7535 
is located at the 5’ end of the LCR and transcribes the late genes E4, L1 and L2 upon 
late epithelial differentiation [98,213]. There is a short non coding region of 500 bp 
known as the LCR or upstream regulatory region (URR) located upstream from the 
coding region. This contains the viral replication origin [78]. In addition, this region 
also contains viral transcriptional enhancers such as specific conserved motifs called 







Genomic organization of HPV8. The genome is 7654 bp long coding for early 
proteins E1, E2, E6, E7 and late proteins E4, L1 and L2. The long control region 
(LCR) is shown and the early promoter, P175 and late promoter, P7535 are indicated. 















Proteins expressed by Papillomaviruses 
 Although the PV genome is small and encodes a limited number of viral 
proteins, these proteins interact with a multitude of cellular proteins to initiate an 
efficient, persistent infection that eventually results in the production of progeny 
viruses. The functions of the different papillomaviral proteins are described in detail 
below: 
E1 protein 
The PV E1 protein is an ATP-dependent helicase, approximately 70 kDa in 
size that binds to the viral origin of replication to initiate viral replication [280]. E1 
consists of an N-terminal domain, a sequence specific DNA binding domain (DBD), 
an oligomerization domain and a helicase domain. During initiation of viral 
replication, both viral E1 and E2 proteins bind cooperatively to their respective 
binding sites within the replication origin [261]. The N terminal domain contains 
nuclear import and export signals that are important for shuttling the protein from the 
cytoplasm to the nucleus and vice-versa [62,118,149,158]. The helicase domain of E1 
interacts with the N-terminal domain of E2 during the process of loading the E1 
protein to the origin [218,234]. The E1 protein can bind to DNA either specifically 
via its DBD, which binds to E1 binding sites in the replication origin, or non-
specifically via the helicase domain [46,218,234]. During initial binding, the presence 
of E2 in the complex prevents the non-specific binding of E1 by masking the DNA 
binding function of the helicase domain. But once the E2 protein dissociates, E1 
converts to a double hexameric helicase ring encircling the DNA and can bind to 




the 3’-5’ direction to unwind the DNA. The role of the oligomerization domain is to 
stabilize the interaction between the helicase domains by providing a rigid collar 
around the DNA [76]. E1 protein interacts with many cellular replication proteins 
such as replication protein A (RPA), DNA topoisomerase I, DNA polymerase α 
primase, proliferating cell nuclear antigen (PCNA), and polymerase δ and recruits 




  E2 is a multifunctional protein that is required for viral DNA replication, 
regulation of viral transcription and is involved in viral genome maintenance. E2 
protein consists of a conserved N-terminal transactivation domain linked by a highly 
flexible hinge region to a conserved C-terminal DNA binding and dimerization 
domain (CTD) [165][69,90,96]. 
 
N-terminal transactivation domain 
The N-terminal domain is approximately 200 amino acids long and is a key 
regulator of viral transcription through its interaction with different cellular factors 
such as transcriptional factors and co-activators (reviewed in [167]). As mentioned 
previously, this domain is also involved in interaction with the E1 helicase domain to 
initiate viral DNA replication. The transactivation domain forms a cashew shaped 
structure consisting of three alpha helices in the N-terminal half linked by a fulcrum 






Schematic diagram of the full length HPV8 E2 protein 
Schematic diagram representing the full length HPV8 E2 protein that consists of an 
N-terminal transactivation domain linked to the C-terminal DNA binding and 
dimerization domain by the flexible hinge region. The structures of the N-terminal 
and the C-terminal domains were reconstructed using PyMol (The PyMOL Molecular 
Graphics System, Version 1.3, Schrödinger, LLC) [PDB ID-1R6K (HPV11 N-
terminal domain) (105) and 2AYG (HPV6 CTD) [116,270]]. The N-terminal residues 
important for transcriptional regulation are highlighted in red. The dimer of the CTD 
















Different residues in the N-terminal domain are required for transcriptional regulation 
and replication. For instance, residues arginine 37 and isoleucine 73, located on the 
adjacent helices are important for transcriptional regulation in BPV1 E2 (Figure 1.2) 
[11] whereas, residue glutamate 39 of the E2 protein interacts with arginine 454 in the 
helicase domain of E1 for viral DNA replication [1]. 
 
C-terminal DNA binding and dimerization domain (CTD) 
The CTD is approximately 100 amino acids long and is important for 
dimerization of the protein and binding to a 12bp palindromic consensus motif of 
ACCN6GGT in the viral genome [10]. It forms a dimeric beta barrel structure with 
each half of the barrel consisting of four beta strands and two alpha helices [110]. One 
of the alpha helices forms the recognition helix that recognizes specific DNA 
sequences in the viral genome [110]. This sequence specific interaction between the 
recognition helix and the DNA is mediated by both the backbone and the side chains 
of the alpha helix [110]. The E2 protein directly binds to the conserved sequences by 
inserting the recognition helix into the major groove of the DNA while the variable 
spacer regions in the minor groove are not contacted. Although the spacer sequence is 
variable, its conformation affects the relative affinity of the E2 proteins for the 
binding sites present on the viral genome [28,114] 
 
Hinge region  
The flexible hinge region of the E2 protein that links the N and the C-terminal 




genera of PVs. However, within each genus the hinge contains certain functional 
elements that are conserved only among the related viruses. For example, the hinge of 
HPV11 E2 carries the nuclear localization signals [286], the HPV8 hinge carries 
elements required for mitotic chromosome binding and transcriptional regulation 
[235,248] and the BPV1 E2 hinge contains residues that contribute to E2 stability 
[201].  
Interaction of the E2 protein with the E1 protein for initiation of viral DNA 
replication has been already described in the ‘E1 protein’ section. During 
transcriptional regulation of viral genes, binding of the E2 protein to binding sites of 
critical transcription factors such as Sp1 and TATA box within the LCR, results in 
transcriptional repression  [97]. At high E2 levels, E2 protein occupies all the E2 
binding sites and results in displacement of the TATA box binding protein (TBP) and 
Sp1 from their binding sites in the LCR.  Thus, the E2 protein and the essential 
transcription factors, Sp1 and TBP, compete for their respective binding sites that are 
in close proximity to one another within the LCR and determine the fate of HPV 
transcription [23,54,255]. However, in addition to E2 occupying these binding sites, 
E2 repression also requires interaction with cellular proteins like Brd4 and other 
repressor complexes to repress transcription via its N-terminal transactivation domain 
[229].  Additionally, the E2 protein plays an important role in genome maintenance 
during persistent infection of hosts by linking the viral DNA to host chromosomes. 
Much of the initial studies understanding genome maintenance were carried out in 
BPV1. BPV1 E2 mediated mitotic tethering is carried out in association with a 




domain of BPV1 E2 protein (R37A and I73A) that abrogate Brd4 interaction also 
compromise E2’s mitotic chromosome binding ability [19]. The C-terminal DNA 
binding domain of E2 is not absolutely required for the interaction with Brd4, but the 
dimerization function of this domain greatly increases the affinity of Brd4 for 
chromatin, most likely by enabling the assembly of higher order E2-Brd4 complexes 
[41].  
Studies described in this dissertation aim to understand the mechanism by 
which HPV8 E2 protein interacts with mitotic chromosomes.  
 
E6 protein 
 The E6 protein of high risk PVs is a small 18KDa viral oncoprotein 
containing two zinc finger domains [16]. Unlike E6 proteins of high-risk HPVs that 
consist of an additional PDZ (post synaptic density protein (PSD95), Drosophila disc 
large tumor suppressor (Dlg1), and zonula occludens-1 protein (zo-1)) domain, which 
is involved in protein-protein interactions [182], beta E6 lacks a PDZ domain. One of 
the most important functions of E6 proteins is the induction of cellular proliferation 
and delayed differentiation of host cells. This is achieved through E6 binding and 
inactivation of the tumor suppressor protein p53 via its interaction with the cellular 
ubiquitin ligase E6-associated protein (E6AP) [222]. This interaction leads to the 
ubiquitination and subsequent proteosomal degradation of p53 [223]. Although E6 
proteins from both high-risk and low-risk alpha HPVs bind p53, only high-risk E6 is 
capable of p53 degradation. However, the E6 protein of beta PVs such as HPV5 and 




p53 inactivation by beta E6 proteins. Instead, E6 proteins from multiple beta PVs 
have been shown to target the Bak protein for proteosomal degradation and in the 
process protect keratinocytes from UVB induced apoptosis [260]. Thus, this process 
is believed to contribute towards the progression of non-melanoma skin cancer. 
Additionally, HPV5 E6 expressing cells have been shown to be defective in repairing 
UV induced thymidine dimers [126]. Moreover, association of histone acetyl 
transferase p300 with E6 proteins from HPV5 and HPV8 results in its  proteolytic 
degradation[117]. Further, the reduced levels of p300 in cells affect many 
downstream signaling events such as expression of differentiation markers. Thus, this 
process could delay the differentiation of cells [117]. Another speculated effect of 
p300 degradation is believed to be the inhibition of p53 transactivation [117]. This 
could be a mechanism by which beta E6 proteins affect p53 function. More recently, 
the HPV5 and HPV8 E6 proteins have been shown to downregulate the expression of 
interleukin-8 (IL-8), which can aid in progression of UV induced tumorigenesis [4]. 
In addition E6 proteins of these viruses can also immortalize rodent fibroblasts [75]. 
Studies of the beta E6 proteins indicate that they have different mechanisms that 
contribute to tumor progression compared to alpha E6 proteins.  
 
E7 protein 
 In addition to the E6 protein, E7 is the other viral oncoprotein that is involved 
in cellular immortalization [20,179]. E7 is a small 11 kDa, acidic phosphoprotein 
containing a zinc finger domain and an LXCXE motif, which is necessary for binding 




in conjunction with the E6 oncoprotein to delay host cell differentiation and induce 
immortalization by sustaining cells in an S-phase like state. The E7 protein of high-
risk HPVs accomplishes this by binding to pRB and mediating its proteosomal 
degradation through the ubiquitin-dependent pathway. This results in the expression 
of S-phase genes and hence, maintains cells in a prolonged pseudo-S phase during 
which viral replication can take place [72]. The E7 protein from a beta PV type, 
HPV38 is capable of inactivating pRB and result in loss of regulation of cell cycle 
progression [40]. However, the E7 proteins of HPV8 and HPV5 weakly bind pRB 
proteins but do not degrade them and furthermore, cannot immortalize primary 
human keratinocytes [227,277]. Since, HPV5 and HPV8 are thought to be oncogenic; 
this suggests that beta E7 proteins might contribute to tumorigenicity via a different 
mechanism compared to the alpha PV E7 proteins. Additionally, the HPV8 E7 protein 
is speculated to play a direct or indirect role in viral DNA replication because of its 
ability to complement a E7 mutated BPV1 genome, which was observed to be 
deficient in viral DNA maintenance [122]. Thus, the above described studies indicate 
that the properties of beta E7 are different from that of the alpha E7 proteins. 
 
L1 and L2 proteins 
 L1 and L2 are the major and minor capsid proteins, respectively, of PVs. PV 
capsids consist of 360 copies of L1, which are arranged as 72 pentameric capsomeres 
(pentamers) [47]. Each pentamer is made up of five monomers of the 55 kDa L1 
major capsid protein [83]. These pentamers arrange to form an icosahedral lattice. The 




kD minor capsid protein [38]. The L2 protein is multifunctional and involved in a 
number of functions such as genome encapsidation [190,224], interaction with L1 
protein and capsid stabilization [83,125], and nuclear import of the HPV genome 




Initial stage of infection 
PVs have evolved to infect distinct niches in the cutaneous and mucosal 
epithelia of their host, thus strictly limiting the cellular targets available for infection. 
The life cycle of papillomaviruses is tightly coupled to the epithelial differentiation of 
the infected host keratinocytes (Figure 1.3). In uninfected epithelium, the basal layer 
contains cells that replicate continuously giving rise to transit amplifying cells [25]. 
These cells divide a limited number of times and then undergo differentiation as they 
move upwards through the epithelial layers following emergence of new cells from 
the basal layer. As the cells move upwards, the keratinocytes lose their nuclei and 
other cellular compartments and finally, cells are sloughed off the superficial 
cornified layers. During viral infection however, viruses infect the dividing basal cells 
of the epithelium through microabrasions or wounds by binding to the heparan sulfate 
proteoglycans on the exposed basement membrane [226]. This process is followed by 
a conformational change in the viral capsid proteins L1 and L2, which finally results 
in the internalization of the virus through an as yet unknown secondary receptor on 






Diagram of the viral life cycle in a stratified host epithelium. The viral genome is 
maintained and partitioned in the lowermost dividing basal cells. Vegetative viral 
DNA replication occurs in the more differentiated layers and eventually cells from the 























the late endosomes [130], the minor capsid protein L2, together with the viral 
genome, moves to the nucleus along the microtubule network [84]. It has been 
suggested that either the viral genome enters during nuclear membrane breakdown in 
mitosis [207] or is actively imported into the nucleus in complex with the L2 protein. 
Once inside the nucleus, it localizes close to the promyelotic leukemia oncogenic 
domains (PODs), possibly utilizing them for successful viral establishment [32]. 
 
Modes of replication  
Upon infection, there is an initial establishment phase, wherein the incoming 
viral genome is translocated to the nucleus and replicated to a limited copy number to 
establish the infection. Following establishment, viral genomes are maintained as 
extrachromosomal elements that replicate in synchrony with host cellular 
chromosomes in the mitotically active basal cells. This stage of replication is 
classified as maintenance replication. For some papillomaviruses, it has been shown 
that the viral E2 protein maintains and partitions the viral genome by tethering it to 
the host chromosomes [123]. In addition to segregating the viral genome to daughter 
cells after each cell division, this process also ensures that the viral genome is 
retained within the nucleus of the infected cell. During the process of differentiation, 
the dividing cells of the basal layer migrate up to replenish the overlying, virus 
producing, differentiated cells. During the productive phase of infection called the 
amplification stage, in the upper layers of the stratified epithelium, replication 
switches to a vegetative mode. To ensure high amounts of viral DNA amplification 




disrupt the normal process of cell differentiation and sustain cells in an S-phase like 
state as described previously [271]. Hence, these viral proteins delay the cell cycle 
exit of differentiating cells thereby, providing a cellular environment conducive to 
viral genome amplification. However, recent work indicates that viral DNA 
amplification occurs in the G2-phase of cell cycle [269] and the host DNA damage 
response is required for vegetative amplification [176]. Additionally during this 
phase, expression of E1 and E2 proteins result in a cellular DNA damage response 
that is believed to recruit the host DNA repair and replication machinery to viral 
DNA so that they can be utilized by the virus to replicate its genome [215]. Thus, 
progeny genomes are packaged into new viral particles. 
 
 Release of mature virions 
Synthesis of the capsid proteins L1, L2 and assembly of virions occur in the 
terminally differentiated upper layers of the epithelium from where virus containing 
cells are shed. Thus being non-lytic viruses, papillomaviruses depend on the host 
epithelial cell differentiation program to release viral particles via the shedding of the 
upper epithelial squamous cells. The E4 protein is thought to play a role in viral 
egress by associating with keratin and resulting in collapse of the cytokeratin network 
[68]. 
 
Genome maintenance and viral persistence 
 
One of the hallmarks of papillomaviral infection is its ability to cause 




replicating their genome in dividing cells is to have a robust mechanism for viral 
genome maintenance. As described in the life cycle section, during the initial and 
maintenance stages of replication, the virus has to partition its genome in dividing 
cells to maintain them as low copy number episomes and retain them within the 
nucleus. In the case of PVs such as BPV1 the viral E2 protein acts as a molecular 
bridge and physically links their genomes to the host chromosomes, to ensure viral 
partitioning and nuclear retention following host cellular division. The earliest 
evidence of E2 protein’s involvement in genome maintenance and physical 
interaction with host chromosomes came from observations wherein the BPV1 E2  
protein and viral genomes were noted to be localized to discrete spots all over the 
arms of mitotic chromosomes [243]. Detailed studies in BPV1 established that the N-
terminal domain of BPV1 E2, in association with the cellular protein Brd4, bound 
host chromosomes whereas the CTD of the E2 protein tethered the viral genome by 
binding to the E2BS on the viral genome [18,123,147,171,281]. In studies conducted 
in our laboratory, E2 proteins from different PVs were observed to bind to mitotic 
chromosomes in varying patterns [191]. This suggested that E2 mediated linking of 
viral DNA to host chromosomes could possibly be a common theme of genome 
maintenance among PVs. Unlike BPV1 E2, which was observed as small punctate 
dots all over chromosomes; the HPV8 E2 protein was observed to bind as large 
distinct foci on mitotic chromosomes. However, observation of HPV8 E2 protein in 
infected cells has been challenging. This is partly due to the low expression levels of 






Model illustrating the tethering of viral genome to host chromosomes 
Tethering the viral genome to host chromosomes is a common strategy employed by 
persistent viruses. Similar to the E2 proteins of PV, LANA of KSHV and EBNA1 of 

















proteins. Efforts to co-transfect and observe the viral genome and the E2 proteins in 
cells have not yielded positive results so far (Atasi Poddar, personal communication). 
Nonetheless, tethering the viral genome to host chromosomes is a strategy 
employed by other persistent viruses such as the gamma herpesviruses EBV and  
KSHV. These viruses also express tethering proteins analogous to papillomavirus E2 
protein. EBV encodes the EBNA1 tethering protein and KSHV encodes the LANA 
protein. EBNA1 consists of N-terminal and C-terminal domains linked by a central 
repetitive region composed of glycine and alanine residues. The chromosome binding 
regions of EBNA1 have been mapped to two short regions rich in glycine-arginine 
repeats. The C-terminal DNA binding and dimerization domain of EBNA1 is 
structurally similar to the CTD of E2 proteins [29]. Similarly, the CTD of LANA is 
also thought to have a structure similar to the E2 and EBNA1 CTDs [101,105]. The 
chromosome binding motifs of LANA are present in the N-terminal domain whereas 
the central domain consists of a non-conserved and long repetitive region. In addition, 
the LANA CTD by itself also binds to pericentromeric and telomeric regions on 
mitotic chromosomes [132].  
Thus, utilization of similar strategies for genome partitioning and maintenance 
by different persistent viruses clearly highlights the essential role of this process in 







Plasmid segregation in Prokaryotes and Eukaryotes 
The process of segregation of genomic material is not limited to viruses. 
Segregation of low copy number plasmids can be observed in both prokaryotes and 
eukaryotes. To ensure efficient and faithful segregation of bacterial plasmids, a 
partitioning complex consisting of proteins called Par proteins is employed by 
bacteria [252]. ParA and ParB work in conjunction with the centromere like locus 
ParC to partition bacterial plasmids. The partitioning complex spatially localizes 
plasmids within the bacterial cell for proper segregation [252]. However, for 
partitioning of the yeast 2 micron plasmid that is present in almost all Saccharomyces 
yeast strains, the partitioning system consists of two encoded plasmid proteins, Rep1p 
and Rep2p and a cis-acting partitioning locus STB [94]. With respect to utilizing two 
proteins and a centromere like locus for segregation, both the bacterial and yeast 
partitioning system appear to be similar. However, there are no functional similarities 
between the two systems. Notably, one of the models to explain the segregation of 
yeast 2 micron plasmid proposes hitchhiking of the plasmid cluster, by means of 
tethering the duplicated cluster to the chromosomes via the cohesin complex [94]. 
Cohesin ensures attachment of duplicated plasmid clusters to the chromosomes by 
binding to STB locus, until the cell is ready to divide. During division, cohesin 
disassociates and the plasmids are segregated to daughter cells on the sister 
chromosomes [94]. This theme of hitchhiking on chromosomes is very close to the 
tethering mechanism of viral genomes to host chromosomes observed with 
papillomaviruses and gamma herpesviruses. There is also a second chromosome 




pairing plasmids, probably uses the mitotic spindle for the movement of the plasmids 
during division [94]. The features of chromosome segregation in higher eukaryotes 
vary slightly from those of yeast. In the eukaryotic system, cohesin is important for 
maintaining the sister chromatid pairing and unpairing mechanism and also helps 
differentiate sister chromatids from homologues during segregation. In addition to 
cohesin complex, another essential component of eukaryotic chromosome segregation 
is the condensin complex. Condensin complex is essential for preventing 
entanglement of chromosomes during segregation by maintaining the intramolecular 
compaction of DNA [115]. Finally cohesin undergoes proteolytic cleavage by 
enzymes such as separase, which results in chromosome sisters being separated and 
pulled away towards opposite cell poles by the mitotic spindle apparatus [183]. 
 Although prokaryotes and eukaryotes employ distinct partitioning strategies 
for genome segregation, it is clear that the basic theme of transferring genetic 
information to progeny cells is evolutionarily conserved.  
 
Cellular targets of PV E2 proteins 
Although the E2 proteins from different PVs associate with host mitotic 
chromosomes to efficiently partition the viral genome to daughter cells, they interact 
with distinct chromosomal targets. This is mainly reflected by the fact that the E2 
proteins from different PVs show different patterns of binding on the mitotic 
chromosomes [170,191,205,262]. The interaction of different viral tethering proteins 
with host chromatin could be direct, through binding to specific sequences on the host 




Identifying different cellular protein partners that mediate the chromosomal binding 
functions of the various tethering proteins has been an area of intense research 
interest, especially because of their potential to be used as targets for novel antiviral 
therapeutics. The known targets of PV E2 proteins are described below. 
Brd4 
As described previously, BPV1 E2 mediated mitotic tethering is carried out in 
association with a cellular partner identified as the Brd4 protein [281]. Brd4 is a 
double bromodomain protein that binds to acetylated lysine residues on histones H3 
and H4 [64]. Brd4 normally forms a diffuse coat around the mitotic chromosomes, but 
in the presence of E2 both proteins colocalize on mitotic chromosomes in punctate 
dots all over the mitotic chromosomes [19,124,170,171,282]. Brd4 is critical for E2 
mediated transcription of all PVs [170,245,273], but is clearly not an essential cellular 
partner for genome partitioning in all the different PVs [124,170]. This is further 
supported by observations that R37A and I73A mutations that abrogate E2-Brd4 
interactions, do not affect the mitotic localization of E2 proteins belonging to the 
alpha or the beta genus [170,205]. Notably, the EBNA1 and LANA proteins have also 
been shown to interact with Brd4 [152,283].  
Ribosomal DNA (rDNA) 
The HPV8 and HPV5 E2 proteins bind to the pericentromeric region of 
chromosomes as large distinct foci [191]. HPV8 E2 protein has been shown to 
associate with the ribosomal DNA loci present on the short arms of the acrocentric 




[205]. UBF is a transcription factor required for rDNA transcription by RNA 
polymerase I that remains bound to chromosomes during mitosis when transcription 
ceases [127,212]. During interphase, the HPV8 and HPV5 E2 proteins are seen 
localized both in a granular nuclear pattern and colocalized with SC35 speckles 
[141,235]. However, as cells transition from interphase to mitosis, there is 
disassembly of the nuclear membrane and nucleolus and the E2 protein is free to 
localize to rDNA. This spatial segregation during the different stages of the cell cycle 
would allow the E2 protein to actively participate in viral DNA replication and 
transcription during interphase and tether to host chromosomes for genome 
partitioning during mitosis. This separation might be essential considering the 
multitude of functions the E2 protein has to perform during these distinct phases of 
the cell cycle.  
In the case of the alpha-PVs, under normal fixation conditions the alpha E2s 
are only observed on mitotic chromosomes during prophase and telophase. However, 
following a brief pre-extraction step that removes all the weakly bound nuclear 
proteins prior to fixation, the E2 proteins from alpha-PVs such as HPV11, HPV16 
and HPV31 show a mitotic localization pattern similar to HPV8 E2. This suggests 
that the interaction of alpha E2s could be unstable and dynamic [191]. These E2 
proteins might require a specialized cellular environment or additional cellular or 
viral factors to stabilize the binding of the E2 proteins to mitotic chromosomes.  
 Mitotic spindle, TopBP1, ChlR1 and MKlp2  
 
Although HPV11, HPV16 and HPV18 E2 proteins have been reported to 




these associations would result in the maintenance of the viral genomes within the 
host nucleus. In addition to being a transcriptional coactivator of HPV16 E2 [31], 
topoisomerase II-binding protein1 (TopBP1) also interacts and colocalizes with 
HPV16 E2 on mitotic chromosomes during late telophase [66]. The E2 proteins of 
BPV1, HPV11 and HPV16 interact with two proteins required for cellular 
chromosome segregation: ChlR1 (an ATP-dependent DNA helicase important for 
sister chromatid cohesion) [196] and mitotic kinesin like protein, MKlp2 (a motor 
protein required for cytokinesis) [284]. Although E2 and ChlR1 do not colocalize on 
mitotic chromosomes, it is believed that ChlR1 could load the E2 protein onto 
chromosomes [196]. On the other hand, the colocalization of MKlp2 and E2 has been 
observed in the mid-body during late mitosis [284]. 
It is clear that the interaction of E2 proteins with mitotic chromosomes is 
complex and may involve multiple different interacting partners to aid in viral 
genome maintenance. 
 
Rationale for the Dissertation 
 
As described previously, several studies have shown that the viral E2 protein 
acts as a molecular bridge to tether the viral genome to host chromosomes in different 
papillomaviruses. However, the exact molecular mechanism of this interaction has yet 
to be elucidated for E2 proteins of beta-papillomaviruses. The main objective of this 
dissertation was to characterize the interaction of the E2 protein of the HPV8, a 




detailed understanding of this interaction, we have addressed the following questions 
in this dissertation: 
1. What domains of the HPV8 E2 protein are required for interaction with 
mitotic chromosomes?  As described previously, several studies have shown 
that different PV E2 proteins interact with mitotic chromosomes in varied 
patterns. Previous work from our laboratory has shown that the requirements 
for HPV8 E2 chromosomal interaction are different from the well 
characterized BPV1 E2. The initial objective of my study was to map the 
regions required for chromosomal interaction in the HPV8 E2 protein using 
deletion analysis. Further, using a mutagenesis approach I identified residues 
essential for chromosome binding. In addition, I have also investigated the 
role of the C-terminal domain in the chromosomal association function. 
2. How is the E2 chromosome binding function regulated? To gain further 
insight into how the HPV8 E2 mitotic chromosome binding function is 
regulated, I have examined the role of HPV8 E2 phosphorylation. I have also 
identified the protein kinase responsible for E2 phosphorylation. 
3. Is the HPV8 E2 chromosomal association mediated through protein-protein or 
protein-RNA interactions? To obtain a clearer understanding of how E2 
associates with host chromosomes, proteomics and RNAse treatment 
techniques were employed. Using these approaches, I have examined whether 





Understanding the mechanism of interaction of the HPV8 E2 protein with mitotic 
chromosomes will enable us to devise strategies that can interfere with the process of 
E2 tethering the viral genome to host chromosomes and thus, disrupt HPV genome 




















Chapter 2: Materials and Methods  
Plasmids  
DNA fragments encoding domains or sub-domain regions of the HPV8 or 
HPV5 E2 proteins were amplified from plasmids expressing either full length HPV8 
or HPV5 E2 proteins using PCR primers listed in the table below (Table 1). The PCR 
amplified products were first cloned into the pTZ19U in vitro expression plasmid 
with the appropriate restriction enzymes. The pTZ19U plasmid contains the T7 
promoter. Using restriction enzymes HindIII and BamHI, the inserts from pTZ19U 
were cloned in the pMEP4 expression vector that contains an inducible 
metallothionein promoter. The fragments encoding the C-terminal domains (CTD) of 
E2 proteins from HPV107, SfPV1 (CRPV), LANA-CTD and mutated LANA-CTD 
(LANA-SHP) were PCR amplified with the appropriate restriction sites using the 
primers listed in table 1. The PCR amplified products were first cloned into the 
pTZ19U in vitro plasmid with the appropriate restriction enzymes followed by 
cloning in the pMEP4 expression vector. The HPV8 C-terminal domain was 
expressed either with a FLAG tag fused upstream of residues 404 (C) or with an 
additional CBP (Calmodulin binding protein) and SBP (Streptavidin binding protein) 
tag cloned between the FLAG tag and CTD (Tag-C). The fragments encoding the 
CTDs of BPV1 E2 and HPV11 E2 were sub-cloned from the respective pTZ19U 
plasmids encoding respective full length E2 proteins using ClaI and BamHI sites. The 
HPV4 CTD was sub-cloned into pMEP4 vector from the pTZ19U plasmid using 
BamHI and EcoRI sites. The CTD fusion proteins of different PVs were generated by 




a pTZ19U plasmid carrying the fragment encoding the HPV8 240-255 hinge peptide. 
From the pTZ19U plasmid, the inserts were cloned in the HindIII and BamHI sites of 
the pMEP4 expression vector.  All E2 proteins were expressed with an N-terminal 
flag epitope tag from an inducible metallothionein promoter in the pMEP4 expression 
vector.  
Table 1 – List of primers used for cloning 
Name Sequence (5’-3’) Restriction Sites Purpose
AM1383 TATAAGCTTCCACCATGGCTACAGCCACCTCTAGGCGA HindIII,NcoI Forward primer; amplifies  aa 313 to 498 of HPV8 E2
AM1384 CCTTTGGATCCTTATAGACTGTCCAGGTTACCATAAGATGTATC BamHI Reverse primer; amplifies  aa 313 to 498 of HPV8 E2
AM1502 TATAAGCTTCCACCATGGCCGCCGCCAAGACCCCCACC HindIII,NcoI Forward primer; amplifies  aa 216‐498 of HPV8E2
AM1503 TATAAGCTTCCACCATGGGCTCCACCACCGTATCCAGGTC HindIII,NcoI Forward primer; amplifies  aa 286 to 498 of HPV8E2.
AM1504 TATAAGCTTCCACCATGGGCAGAACAAGACCGCAAAAAGAGCAGAG HindIII,NcoI Forward primer; amplifies  aa 255 to 498 of HPV8 E2. 
AM1505 TTATTATCGATTCTGCTGGACGGCCGTCTCC ClaI Reverse primer; apmlifies  aa 216 to 255 of HPV8E2.
AM1506 TATAAGCTTCCACCATGGGTCAAACCGAAACCAAAGGACGAAGGTA HindIII,NcoI Forward primer; amplifies  aa  240 to 498 of HPV8E2.
AM1507 TTATTATCGATTTTGTTGTGGCTGTTTTGCAGGGGACC ClaI Reverse primer; amplifies  aa 216 to 240 of HPV8E2
AM1508 TTATTATCGATCCTGGTGCGGTGTCGCGACCTT ClaI Reverse primer; amplifies  aa 216 to 272 of HPV8E2.
AM1509 TTATTATCGATGGATACGGTGGTGGAGCCAACG ClaI Reverse primer; amplifies  aa 216 to 290 of HPV8E2.
AM1591 TTATTATCGATCGACTTGGAAGATTACTGGAA ClaI C‐terminal  domain of HPV‐5 E2. 
AM1592 CCTTTGGATCCTTAAAGACTGTCCAGGTTGCCAT BamHI C‐terminal  domain of HPV‐5 E2. 
AM1593 TTATTCCATGGCCACCCCCGCGACCCCCACCACC NcoI 216‐255 of HPV‐5 E2 hinge. 
AM1594 TTATTATCGATGGAGGGCCTCCGTCCGTACCT ClaI 216‐255 of HPV‐5 E2 hinge.
AM1675 CATGGGTCAAACCGAAACCAAAGGACGAAGGTACGGGAGACGGCCGGACAGCAGAAT NcoI,ClaI 240‐255 region of HPV‐8 E2 hinge S253D
AM1676 CCAGTTTGGCTTTGGTTTCCTGCTTCCATGCCCTCTGCCGGCCTGTCGTCTTAGC NcoI,ClaI 240‐255 region of HPV‐8 E2 hinge S253D
AM1677 CATGGGTCAAACCGAAACCAAAGGACGAAGGTACGGGAGACGGCCGTCCGACAGAAT NcoI,ClaI 240‐255 region of HPV‐8 E2 hinge S254D
AM1678 CCAGTTTGGCTTTGGTTTCCTGCTTCCATGCCCTCTGCCGGCAGGCTGTCTTAGC NcoI,ClaI 240‐255 region of HPV‐8 E2 hinge S254D
AM1679 CATGGGTCAAACCGAAACCAAAGGACGAAGGTACGGGAGACGGCCGGCAAGCAGAAT NcoI,ClaI 240‐255 region of HPV‐8 E2 hinge S253A
AM1680 CCAGTTTGGCTTTGGTTTCCTGCTTCCATGCCCTCTGCCGGCCGTTCGTCTTAGC NcoI,ClaI 240‐255 region of HPV‐8 E2 hinge S253A
AM1682 CCAGTTTGGCTTTGGTTTCCTGCTTCCATGCCCTCTGCCGGCAGGCGTTCTTAGC NcoI,ClaI 240‐255 region of HPV‐8 E2 hinge S254A
AM1683 CATGGGTCAAACCGAAACCAAAGGACGAAGGTACGGGGCACGGCCGTCCAGCAGAAT NcoI,ClaI 240‐255 region of HPV‐8 E2 hinge R250A
AM1684 CCAGTTTGGCTTTGGTTTCCTGCTTCCATGCCCCGTGCCGGCAGGTCGTCTTAGC NcoI,ClaI 240‐255 region of HPV‐8 E2 hinge R250A
AM1685 CATGGGTCAAACCGAAACCAAAGGACGAAGGTACGGGAGAGCACCGTCCAGCAGAAT NcoI,ClaI 240‐255 region of HPV‐8 E2 hinge R251A
AM1686 CCAGTTTGGCTTTGGTTTCCTGCTTCCATGCCCTCTCGTGGCAGGTCGTCTTAGC NcoI,ClaI 240‐255 region of HPV‐8 E2 hinge R251A
AM1687 CATGGGTCAAACCGAAACCAAAGGAGCAGCATACGGGAGACGGCCGTCCAGCAGAAT NcoI,ClaI 240‐255 region of HPV‐8 E2 hinge RR246,247AA
AM1688 CCAGTTTGGCTTTGGTTTCCTCGTCGTATGCCCTCTGCCGGCAGGTCGTCTTAGC NcoI,ClaI 240‐255 region of HPV‐8 E2 hinge RR246,247AA
AM1689 CATGGGTCAAGCAGAAGCAAAAGGACGAAGGGCAGGGAGACGGCCGGCAGCAAGAAT NcoI,ClaI 240‐255 region of HPV‐8 E2 hinge with all  the possible 
phosphorylation sites  replaced by Alanines.
AM1690 CCAGTTCGTCTTCGTTTTCCTGCTTC CGTCCCTCTGCCGGCCGTCGTTCTTAGC NcoI,ClaI 240‐255 region of HPV‐8 E2 hinge with all  the possible 
phosphorylation sites  replaced by Alanines.
AM1691 CATGGGTCAAACCCAAACCAAAGGACGAAGGTACGGGAGACGGCCGTCCAGCAGAAT NcoI,ClaI 240‐255 region of HPV‐8 E2 hinge E242Q
AM1692 CCAGTTTGGGTTTGGTTTCCTGCTTCCATGCCCTCTGCCGGCAGGTCGTCTTAGC NcoI,ClaI 240‐255 region of HPV‐8 E2 hinge E242Q
AM1693 CATGGGTCAAACCGAAACCGCAGGACGAAGGTACGGGAGACGGCCGTCCAGCAGAAT NcoI,ClaI 240‐255 region of HPV‐8 E2 hinge K244R
AM1694 CCAGTTTGGCTTTGGCGTCCTGCTTCCATGCCCTCTGCCGGCAGGTCGTCTTAGC NcoI,ClaI 240‐255 region of HPV‐8 E2 hinge K244R
AM1977 TTATTATCGATCGGCTTCGCGAGCTTATAACA ClaI CTD of CRPV E2 protein
AM1978 CCTTTGGATCCCTAAAGCCCATAAAAATTCCC BamHI CTD of CRPV E2 protein
AM1979 TTATTATCGATCGACTTGGAAGGTTACTGGAT ClaI CTD of HPV107 E2 protein
AM1981 TTATTATCGATGTGGAAGAGCCCATAATCTTG ClaI CTD of LANA from aa 933 to 1162




Plasmids used for transactivation and replication assays: Fragment encoding the 
HPV8 origin from 7626-188 bp of the HPV8 genome is cloned between HindIII and 
EcoRI of pUC18 plasmid. HPV8 E2 proteins including the full length wild-type, 
S253A, R250A, R250A/S253A and R431K/R433K mutated E2 proteins were 
expressed from pMEP4 plasmids. HPV8 E1 protein was expressed from a pMEP9 
expression plasmid. BPV1 E2 was expressed from a pMEP4 expression plasmid. 
Mutagenesis 
Two sets of E2 point mutations were generated. One set was designed in the 
background of a 40 amino acid region from the HPV8 E2 hinge (residues 216-255)  
fused to the C-terminal DNA binding domain (CTD). The second set was designed in 
the background of a 16 amino acid region from the hinge (residues 240-255) fused to 
the CTD. DNA fragments encoding the respective amino acid substitutions were 
chemically synthesized (GenScript Corporation) and cloned in frame with the CTD 
into the pTZ19U plasmid and the pMEP-4 expression plasmid. All E2 plasmids were 
sequenced to confirm the mutations. 
Cells 
 
The following cells were used for experiments described in this dissertation: 
Parental Cells Description Culture Media 
CV-1 African green monkey kidney cells  
DMEM +10% fetal bovine serum+ 
penicillin(100U/ml)+ streptomycin 
(100μg/ml)+ 2mM glutamine 
C33A HPV negative human 
cervical carcinoma cells 
DMEM +10% fetal bovine serum+ 
penicillin(100U/ml)+ streptomycin 
(100μg/ml)+ 2mM glutamine 
U2OS Human  osteosarcoma cells 
DMEM +10% fetal bovine serum+ 
penicillin(100U/ml)+ streptomycin 




Establishment of stable pMEP-E2 cell lines 
CV-1 and C33A cell lines stably expressing E2 were generated by transfection of 
pMEP-E2 plasmids with Fugene 6 (Roche) according to manufacturer’s instructions 
and selection with 200µg/ml or 80µg/ml hygromycin B (Roche), respectively. After 2 
weeks, drug-resistant colonies were pooled and cultures were expanded. 
Immunoblotting  
Cellular proteins were extracted in 2% SDS, 50mM Tris-HCl pH6.8, 10% 
glycerol and Complete® protease inhibitor (Roche). Protein concentration was 
determined using the BCA (bicinchoninic acid) protein assay kit (Pierce) according to 
manufacturer’s instructions. For each sample, 12µg-20µg protein was separated by 
SDS-polyacrylamide gel electrophoresis (PAGE) and electro-transferred onto 
Immobilon-P membranes (Millipore). E2 proteins were detected with M2 anti-flag 
monoclonal antibody (Sigma) followed by horseradish peroxidase-conjugated goat 
anti-mouse immunoglobulin G (Pierce). Immune complexes were detected on the 
membrane with the chemiluminescent reagent SuperSignal West Dura 
(ThermoScientific). Images were captured using the Kodak Image station system and 
quantitation was performed using Kodak MI software.  
Immunoprecipitation and Immunoblotting  
 
Cells extracts were prepared in modified RIPA buffer (20mM HEPES pH 7.0, 
150mM NaCl, 1mM EDTA, 1% NP-40, 1% deoxycholate, 0.1% SDS) containing 
Complete® protease inhibitor cocktail (Roche) and PhosSTOP® (Roche). Protein 




(Pierce). Equal amounts of total protein were immunoprecipitated using M2 anti-
FLAG antibody beads (Sigma) at 4ºC for 1h. Immune complexes were washed five 
times with RIPA buffer and E2 proteins were eluted in 50µl of Lithium dodecyl 
sulfate (LDS) sample buffer and separated on a 4-12% gradient polyacrylamide gel 
electrophoresis gel (Invitrogen). Proteins were electro-transferred onto Immobilon-P 
membranes (Millipore). E2 proteins were detected with M2 anti-FLAG monoclonal 
antibody (Sigma), phosphorylated E2 proteins with rabbit anti-RXXS motif antibody 
(Cell Signaling) followed by horseradish peroxidase-conjugated goat anti-mouse 
immunoglobulin G (Pierce). Proteins were detected on the membrane with the 
chemiluminescent reagent SuperSignal Extended West Dura (Pierce).   
In vivo phosphorylation assay 
E2 protein expression was induced for 3h with 3µM CdSO4 in medium 
containing 0.42mCi/ml [32P]-orthophosphate or a combination of 0.2mCi/ml [35S]-
methionine and [35S]-cysteine. Cells extracts were prepared in modified RIPA buffer 
(20mM HEPES pH 7.0, 150mM NaCl, 1mM EDTA, 1% NP-40, 1% deoxycholate, 
0.1% SDS) containing Complete® protease inhibitor cocktail (Roche) and 
PhosSTOP® (Roche). E2 proteins were immunoprecipitated using M2 anti-flag 
antibody beads (Sigma). Immune complexes were washed five times with RIPA 
buffer and E2 proteins were eluted in 2% SDS-PAGE sample buffer and separated by 
SDS-PAGE. Gels were fixed, dried and autoradiographed. Quantitation was 
performed using PhosphorImager (Typhoon, Molecular Dynamics) and ImageQuant 




PKA inhibitor and enhancer treatments  
CV-1 cell lines expressing E2 proteins were plated onto 10 cm plates so as to 
achieve 80-85% confluence at harvest. The following day cells were pretreated for 2h 
with PKA inhibitors, 10µM H89 (Calbiochem 371962) or 6µM KT-5720 (Tocris 
1288) or PKA enhancers, 10µM forskolin (Calbiochem 344270) or 100ng/ml cholera 
toxin (Calbiochem 227036). Following pretreatment, E2 expression was induced with 
3µM CdSO4 for 3h in the presence and absence of the inhibitors or enhancers. 
Samples were prepared for immunoprecipitation and immunoblotting as described 
below. 
Indirect immunofluorescence  
CV-1 cell lines expressing E2 proteins were grown on Superfrost Plus slides. 
For cell cycle experiments, cells were synchronized in 2mM thymidine for 16h. The 
thymidine was removed to allow progression of the cell cycle and the cells were fixed 
at indicated time points in 4% paraformaldehyde for 20 mins at room temperature. E2 
expression was induced with 3µM CdSO4 for 3h before fixation. For mitotic 
synchronization, thymidine was removed and cells were cultured for an additional 9h, 
with E2 expression induced by the addition of 3µM CdSO4 during the last 3h. Cells 
were fixed in 4% paraformaldehyde for 20 mins at room temperature and 
permeabilized with 0.1% Triton X-100 in phosphate-buffered saline (PBS) for 15 
mins at room temperature. The E2 proteins were detected with monoclonal anti-
FLAG M2 antibody (1:500; Sigma, F3165), UBF with rabbit anti-UBF antiserum 
(1:100; Santa Cruz Biotechnologies, sc-9131) and ACA with human anti-ACA 




secondary antibodies (Jackson ImmunoResearch). Slides were mounted in Prolong 
Gold (Invitrogen) containing 1µg/ml DAPI (4', 6'-diamidino-2-phenylindole). Images 
were collected with a Leica TCS-SP5 laser scanning confocal imaging system.  
Protein complex purification for the proteomics study:  
 
Preparation of Nuclear Extracts 
  Each of the E2 expressing C33A cell lines were plated on four, 15 cm dishes 
at a concentration of 8X106 cells per dish and harvested after 48h following E2 
induction with 3μM cadmium sulfate for 4 h. Cells were harvested using the protocol 
described below: 
Buffer A (hypotonic 
buffer) 2X Buffer C Buffer D 
10 mM Hepes, pH 7.9 
10 mM M KCl 
1.5 mM MgCl2 
Complete protease 
inhibitor  (Roche) 
20 mM Hepes, pH 7.9 
0.42 M NaCl 
1.5 mM MgCl2 
0.2 mM EDTA 
Complete protease 
inhibitor  (Roche) 
20 mM Hepes, pH 7.9 
100 mM KCl 
1.5 mM MgCl2 
0.2 mM EDTA 
 
Inhibitors used: 
1 mM PMSF  
1 mM Na3VO4 
0.1 mM Na2MoO4 
10M NaF 
 
Cells on plate were washed with PBS twice and scraped into 10ml PBS. Cells 
were pelleted at 1,200 rpm, 4ºC for 5 minutes. Pellets were resuspended in 5-10 PCV 
(packed cell volume) of ice cold Buffer A and incubated on ice for 10 minutes 
followed by centrifugation at 1,200 rpm, 4ºC for 5 minutes. Pellets were again 




homogenized by passing them through the homogenizer by 10-20 strokes. Contents of 
the homogenizer were transferred to centrifuge tubes. Suspensions were again 
centrifuged at 2000 rpm, 4ºC for 5minutes. Pellets were resuspended in 1-2 volume 
ice cold 2X Buffer C and passed through the dounce homogenizer by 6 strokes. The 
suspensions were kept on a stir plate that was placed on ice for 30-45 minutes. The 
homogenized suspensions were then transferred to centrifuge tubes and centrifuged at 
15000 rpm, 4ºC for 30 minutes. Supernatants were collected into chilled tubes and 
dialyzed against Buffer D for 3h. The extracts were again centrifuged for 10 minutes 
at 4ºC.  
The nuclear extracts (1.6ml total volume) were divided into two fractions: one 
fraction was the input fraction and rest of the extracts was used for 
immunoprecipitation. For input fraction, 112µl of the nuclear extracts + 40µl LDS 
loading buffer + 8µl DTT were mixed together. For the immunoprecipitation assay 
the M2 anti-flag coated antibody agarose beads were used as described under the 
section immunoprecipitation and immunnoblotting. Following immunoprecipitation, 
the samples were eluted twice; once with flag peptide elution (150µl) and second time 
with sarcosyl elution (150µl). 12.5µl of each of the eluates were mixed and loaded on 
a NuPage 4-12% gradient polyacrylamide gel. 5µl of the input lysate for each of the 
sample was run on a separate NuPage 4-12% gradient polyacrylamide gel. The rest of 







Table 2- List of antibodies used for the proteomics study 
 
Antibody Company Dilution Species
UBF Santa Cruz Biotechnologies, sc-9131 1:1000 Rabbit 
WSTF Sigma, W3641 1:1000 Rabbit 
WDR5 Abcam, ab22512 1:1000 Rabbit 
PRMT5 Bethyl laboratories, A300-850A 1:1000 Rabbit 
Matrin 3 Abcam, ab51081 1:1000 Rabbit 
SAF-A Abcam, ab10297 1:1000 Mouse 
SRPK1 BD Biosciences, 611072 1:1000 Mouse 
TRIM28 Abcam, ab22553 1:1000 Mouse 
U5 116 Proteintech group, 10208-1-AP 1:1000 Rabbit 
Nucleophosmin Abcam, ab24412 1:1000 Rabbit 
PP2A Cell Signaling technology, 2038 1:1000 Rabbit 
Flag Sigma, F3165 1:10000 Rabbit 
 
RNAse A treatment followed by Immunofluorescence 
 
Preparation of RNAse A: 
RNAse A powder (Roche, 109169) was dissolved at a concentration of 
10mg/ml in 0.01M sodium acetate pH 5.2. The solution was then boiled at 100ºC for 
15 minutes, followed by slow cooling to room temperature. pH was adjusted with 





RNAse A treatment of E2 expressing cells: CV-1 cell lines expressing E2 proteins 
were grown on Superfrost Plus slides so as to achieve 80-85% confluence. For mitotic 
synchronization, thymidine was removed and cells were cultured for an additional 9h, 
with E2 expression induced by the addition of 3µM CdSO4 during the last 3h. Cells 
were permeabilized with 0.1% Triton X 100 and 0.1% Tween 20 for 15 minutes. 
RNAse A treatment was carried out with the addition of 1mg/ml RNAse A in PBS 
onto slides for 10 minutes at room temperature. Following RNAse A treatment, cells 
were washed twice with PBS for 3 minutes at room temperature. Cells were then 
fixed in 4% paraformaldehyde in PBS for 20 minutes at room temperature. Following 
fixation, slides were immunostained with M2 anti-flag (1:500) and rabbit anti-
fibrillarin (1:500) antibodies as described in the protocol in the immunofluorescence 
section. For E2 expressing cells that were to be stained with SYTO RNASelect stain, 
cells were permeabilized with 0.1% Triton X 100 and 0.1% Tween 20, treated with 
RNAse A for 10 minutes at room temperature followed by fixation with chilled 
methanol at -20ºC for 10 minutes and chilled acetone at -20ºC for 2 minutes. 
Following fixation, slides were immunostained with M2 anti-flag (1:500) and SYTO 
RNASelect stain according to the protocol described in the indirect 
immunofluorescence section. Slides were mounted in Prolong Gold (Invitrogen) 
containing 1µg/ml DAPI (4', 6'-diamidino-2-phenylindole). Images were collected 
with a Leica TCS-SP5 laser scanning confocal imaging system.  
Replication assays 
 
Transfection of U2OS cells and extraction of DNA: Using the Amaxa Nucleofector 




manufacturer’s instructions. Three days post transfection cells were harvested and 
low molecular weight DNA was extracted using the following protocol: 
Extraction of the low-molecular weight DNA by HIRT extraction: 


















Three days post transfection, cells were trypsinized and resuspended in 200µl 
of Solution I and then lysed by adding 400µl of Solution II made fresh before each 
extraction. Samples were incubated on ice for 5 minutes. Lysed samples were 
neutralized by addition of 300µl of Solution III, followed by incubation on ice for 10 
minutes. Following neutralization, samples were centrifuged at 4ºC for 10 minutes. 
The nucleic acids were collected and precipitated with 0.6 volumes of isopropanol 
and incubated at -20ºC overnight. Precipitated DNA was centrifuged and resuspended 
in 200µl of HIRT digestion buffer. The resuspended solution was incubated at 37ºC 
for 30 minutes followed by incubation at 50ºC for 30 minutes. Samples were purified 
by a phenol\chloroform extraction, followed by a chloroform\isoamyl alcohol 
extraction using Phase Lock Gel tubes (Eppendorf).  Pelleted DNA was resuspended 
in 200µl of TE and reprecipitated with 0.3M sodium acetate and 2.5 volumes ethanol.  
Finally, DNA was washed in 70% ethanol, resuspended in 50µl TE containing 




The Hirt extracted DNA (25µl) was digested with the appropriate restriction enzymes 
including DpnI. DNA samples were digested overnight at 37ºC. DNA samples were 









































DNA samples were transferred onto Nytran SPC membranes (Whatman) 
using the TurboBlotter system, according to manufacturer’s instructions. Following 
transfer for 4h at room temperature, the membrane was cross-linked with a 
Stratalinker UV Crosslinker (Stratagene) at 1200µJ/cm2.  The probe was prepared by 
digesting either the full length HPV8 genome with the appropriate enzymes (BamHI) 
to release the complete HPV8 genome from the pUC9 cloning vector or by digesting 
HPV8 ori plasmid (EcoRI) to linearize it. The digested DNA was purified using 
QIAquick Gel Extraction Kit. The purified DNA was then radiolabeled with 32P 
dCTP (3000 Ci/mmol) using the Random Primed DNA labeling Kit (Roche). 
Unincorporated nucleotides were removed by passing the samples through the Illustra 
ProbeQuant G-50 Micro Columns (GE Healthcare).  Meanwhile, membranes were 
incubated in pre-hybridization buffer at 68ºC for at least 1 hour before hybridization.  
1x106 counts/ml of either the HPV8 radiolabeled genomic DNA or the radiolabeled 




hybridization oven at 68ºC overnight.  The next day, the membranes were washed 
until no background signal was detected and exposed to MS film (Kodak) or a 
Phospho imager screen and analyzed using Typhoon (Molecular Dynamics). 
Luciferase assay for E2 transactivation: 
 
Transfection and preparation of cell lysates: 
CV-1 cells were plated onto 60mm dishes in triplicate at a density of 2.5 x 105 
cells per dish. The following day different amounts of the E2 expression plasmids 
ranging from 0ng, 25ng, 100ng, 250ng and 1000ng were co-transfected with 1000ng 
of luciferase reporter plasmid pBS1073 using 6µl of Fugene 6 reagent, according to 
manufacturer’s protocol. Cells were harvested at 48h post transfection. After washing 
once with 1X PBS, the cells were extracted in 500µl of 1X luciferase cell culture lysis 
buffer. Samples were centrifuged at 12,000g for 2 minutes at 4ºC. Supernatants were 
transferred to new tubes that could either be stored at -70ºC or could be used for 
assaying using a luminometer. 
Luciferase assay: 
10ml of the luciferase assay buffer was added to the lyophilized luciferase 
assay substrate and equilibrated to room temperature before use. 100µl of the 
luciferase assay reagent was dispensed into luminometer tubes, one tube per sample. 
A Zylux Femtomaster FB12 luminometer was used to measure luminescence. 
Samples were read in triplicate and the readings were recorded as relative light units 








E2 proteins were either translated independently or co-translated in vitro in 
the presence of [35S] methionine, PerkinElmer Easy Tag L- [35S] methionine, using 
the TnT coupled reticulocyte lysate systems (Promega). The incorporation of [35S] for 
the different in vitro translated products was determined using the ImageQuant 
software. For the immunoprecipitation step, equivalent counts of single translated and 
co-translated proteins were used in a total volume of 24µl. From the 24µl of the mix, 
2µl of each mix was kept for input lane. To the remaining 22µl of the mix, 78µl of 
NET-200 buffer was added to make up the final volume to 100µl. For 
immunoprecipitation, 40µl of M2 bead slurry per protein sample was aliquoted into a 
microfuge tube (total 400µl for 10 reactions), followed by centrifugation at 8500g for 
30 seconds. The pelleted beads were washed twice with 1ml of NET-200 buffer and 
made up to original volume of 400µl with NET-200 buffer. 40µl of the resin was 
aliquoted into a new microfuge tube for each of the protein samples to be tested. The 
lysate mix was added to each of the tubes and incubated at 4ºC for 1 hour on a rotator. 
Following incubation, the resin was washed three times with 1ml NET-200 buffer, 
spinning at 8500xg for 30 seconds each time. The samples were eluted in 50µl of 2X 
SDS sample buffer without DTT by heating at 100ºC for 3 minutes. After adding 






Identification of Putative E2 binding sites (E2BS) 
 
The URR sequences of all the members of the alpha (75 types), beta (44 
types), gamma (25 types) and delta (10 types) genera of PVs were obtained from the 
Papillomavirus Episteme (PaVE) database website (http://pave.niaid.nih.gov/#home). 
The sequences were loaded into the Multiple EM Motif Elicitation (MEME) software 
to create a consensus motif sequence for E2 binding site within each genus based on 
the criteria of looking for palindromic sequences with a minimum motif width of 6 
residues and maximum motif width of 15 residues. Identified putative E2BSs were 
displayed as a sequence logo for each of the genus to compare the differences 
between the E2 binding consensuses between each of the PV genus. The sequence 
logo indicates the conservation of the nucleotides within the binding site. 
Calculation of percent similarity among different PV E2 CTDs: 
 
A fasta file containing the amino acid sequences of the HPV11, BPV1, 
SfPV1, HPV4, HPV107, HPV5 and HPV8 E2 CTDs was loaded into the BioEdit 
program (http://www.mbio.ncsu.edu/bioedit/bioedit.html). The sequences were 
aligned using ClustalW. To calculate the percent similarity, each pair of sequences 
was aligned using the pairwise alignment option. Within the pairwise alignment 
option, the percent of similarity between the selected sequences was calculated using 
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Chapter 3: Interaction of the Betapapillomavirus E2 Tethering 
Protein with Mitotic Chromosomes  
Introduction  
The life cycle of papillomaviruses is coupled to the epithelial differentiation 
of the host keratinocytes. Infection is initiated when viruses enter the basal cells of 
the epithelium, through microabrasions or wounds. Upon infection, the viral genome 
replicates to a low copy number and is maintained as an extrachromosomal element 
that replicates in synchrony with the host cellular DNA. For some papillomaviruses, 
the viral E2 protein maintains and partitions the viral genomes by tethering them to 
the host chromosomes [18,123,147,243]. This mechanism ensures that the virus 
retains its genome within the nucleus of the infected cell and partitions its DNA to 
daughter cells after each cell division. This process helps maintain a persistent 
infection of the host; the dividing basal cells provide a reservoir of infected cells that 
migrate up to replenish the overlying, virus producing, differentiated layers. In the 
productive phase of infection, genome amplification, synthesis of the capsid proteins 
and assembly of virions occurs in the differentiated upper layers of the epithelium 
from where virus containing cells are shed. 
Human Papillomavirus type 8 (HPV8) and type 5 (HPV5) belong to the 
betapapillomavirus genus. They infect the cutaneous epithelium of humans and cause 
asymptomatic infections in healthy individuals [108]. However, in individuals with  
epidermodysplasia verruciformis (EV), a rare, inherited immune disorder, infection 




infection [86]. The betapapillomaviruses have also been implicated in non-melanoma 
skin cancers [81]. 
The HPV E2 protein is multi-functional; it is involved in initiating viral DNA 
replication and regulating viral transcription, in addition to maintaining the genome as 
an extrachromosomal replicating element. The full length E2 protein consists of an N-
terminal domain (approximately 200 amino acids) linked by a flexible hinge region to 
a CTD (approximately 100 amino acids) [168]. The E2 protein regulates viral 
transcription by binding to a 12bp palindromic sequence with a consensus motif of 
ACCN6GGT that is present in the LCR of the viral genome [10]. The N-terminal 
domain is important for the transcriptional regulation function of E2, interaction with 
the E1 replication protein, as well as interaction with many cellular proteins that are 
required for the transcriptional regulation of viral genes [177,209,233]. In BPV1 E2, 
the N-terminal domain associates with mitotic chromosomes in complex with the 
Brd4 protein [19,171,281]. 
 A study from our laboratory analyzed the mitotic binding phenotype of the 
E2 proteins from thirteen different papillomaviruses, belonging to six different genera 
[191]. Most of the E2 proteins associated with mitotic chromosomes, but it was 
observed that the mitotic binding pattern varied among the E2 proteins from different 
genera. BPV1 E2 was detected as small speckles over the arms of all mitotic 
chromosomes. In contrast, the HPV8 E2 protein showed a distinct pattern of large 
foci bound to the pericentromeric region of chromosomes [191]. Our laboratory has 
shown that the HPV8 E2 protein associates with the rDNA loci present on the short 




factor (UBF) [205]. UBF is a transcription factor required for rDNA transcription by 
RNA polymerase I [127]; it remains bound to chromosomes during mitosis even 
though transcription is silenced [188,212]. Studies in our laboratory have shown that 
the domains required for mitotic chromosomal association of HPV8 E2 are different 
from those required for BPV1 E2 binding; the hinge and CTD are sufficient and 
essential for chromosomal association [205]. Unlike BPV1 E2, the HPV8 N-terminal 
transactivation domain is not required for binding. Substitution of residues R37 and 
I73 in the transactivation domain abrogates Brd4 binding and mitotic chromosome 
binding of BPV1 E2 but an identical mutation does not abrogate chromosome 
association of HPV 8 E2 [205].  
Other persistent DNA viruses have developed a similar strategy for genome 
maintenance and partitioning to enable them to persist in the host. 
Gammaherpesviruses KSHV and EBV encode DNA binding proteins LANA and 
EBNA1, respectively, which bind to specific sites in the viral DNA and tether the 
genome to host chromosomes. In addition to sharing the common function of genome 
tethering, these proteins also play an important role in viral genome replication and 
transcriptional regulation [88,148]. Structurally, all three proteins form, or are 
predicted to form, a similar dimeric beta-barrel C-terminal DNA binding structure, 
despite having no sequence homology ([101] and (reviewed in [56]). Short peptide 
sequences have been identified in LANA and EBNA1 that mediate binding to mitotic 
chromosomes [15,43,132,160]. In this study we have defined specific residues within 
the HPV8 E2 hinge region that mediate the characteristic HPV8 E2 mitotic 




required for this association, and that the serine within this motif is phosphorylated in 
vivo. Furthermore, this sequence has similarities to the chromosome binding regions 
of the herpesvirus EBNA1 and LANA proteins. 
Results 
Regions in the hinge of the HPV8 E2 protein required for Mitotic Chromosomal 
Interaction 
 
Both the hinge and the CTD are essential and sufficient for HPV8 E2 mitotic 
chromosome binding [205]. The hinge region of the betapapillomavirus E2 proteins is 
unusual in composition compared to the E2 proteins from other genera of 
papillomaviruses. The hinge is not well conserved with other papillomaviruses but 
within the beta genus, the hinge regions have similar length and sequence 
composition. The beta PV E2 hinge regions are longer than those of most 
papillomavirus E2 proteins and are rich in RG and RS dipeptide motifs. The amino 
acid sequence is shown in Figure 3.1. The E2 hinge regions are thought to be 
unstructured, and this has been experimentally shown for HPV16 E2 [91]. The 
regions of the EBV EBNA1 protein required for mitotic chromosome binding contain 
A-T hooks [232]. The amino acid sequence of the HPV8 E2 hinge region has 
stretches of sequence with similarities to A-T hook motifs but there is no exact match 
with the A-T hook consensus motif (PRGRP). In this study we have defined the 











Amino acid sequence of the HPV8 E2 protein hinge. Amino acids 206 to 403 from 
the hinge region of HPV8 E2 are shown. SR and RS dipeptides are shown in red and 




















We have previously shown that HPV8 E2 is observed in distinct foci in the 
pericentromeric region of mitotic chromosomes in both African Green monkey CV-1 
and human C33A cells [191]. We have mapped this localization in human C33A cells 
to the rDNA loci on the short arm of acrocentric chromosomes [205]. In CV-1 cells 
approximately three UBF foci are observed and the HPV8 E2 protein associates with 
these regions (data not shown). However, there are additional pericentromeric foci in 
CV-1 cells that do not overlap with UBF and we are currently characterizing these 
additional pericentromeric regions. All of the HPV8 E2 proteins used in this study 
associated with mitotic chromosomes in a similar pattern; they completely co-
localized with UBF and rDNA foci in C33 cells and they associated with both UBF 
positive and negative foci in CV-1 cells.  
To identify regions within the E2 hinge required for mitotic chromosome 
association, E2 proteins were expressed in CV-1 cells  The localization of each 
protein was analyzed by indirect immunofluorescence using an antibody against an 
N-terminal FLAG epitope tag. A series of E2 proteins were expressed that contained 
an intact C-terminal domain (404 to 498) fused to various sequence segments from 








Truncated E2 proteins with deletions in the hinge examined for mitotic localizations.  
A. Schematic representation of E2 proteins truncated in the hinge region and their 
chromosome binding phenotype. Truncated E2 proteins were generated as fusion 
proteins with the indicated hinge sequence fused to the CTD. The FLAG epitope is 
shown at the N-terminus as a black box. B. Immunoblot analysis of the E2 proteins, 







examined for their ability to bind to mitotic chromosomes in the distinct foci 
characteristic of HPV8 [191]. The N-terminal region of the hinge was truncated at 
amino acid positions 216, 240, 255, 286 and 313. Deletions up to position 240 had no 
effect on chromosomal association but further deletion abrogated the characteristic 
HPV8 E2 binding foci. Deletions were also generated to remove C-terminal portions 
of the hinge with endpoints at residues 385, 366, 338, 312, 290, 272, 255, and 240. In 
this case, deletion up to residue 255 had no effect on chromosome association but 
further deletion to 240 eliminated binding. Correspondingly, a small region from the 
hinge consisting of residues 240-255 fused to the C-terminal domain (240-255-C) 
was able to associate with mitotic chromosomes (see Figure 3.2 A and 3.3). The 
percentage of positive E2 expressing mitotic cells showing the foci binding pattern is 
shown in table 3.1. Furthermore, the 240-255-C mitotic foci co-localized with UBF in 
a similar fashion to the full-length E2 protein. Thus, a 16 amino acid region, when 












Chromosome binding phenotype of E2 proteins with deletions in the hinge.  
Immunolocalization of truncated HPV8 E2 proteins in mitotic CV-1 cells. E2 
proteins, as detected with a FITC-labeled antibody, are shown in green. Cellular DNA 
was stained with DAPI (blue). For mitotic localization of HPV8 E2 CTD alone, refer 
to figure 5.4 in chapter 5. The percentage of E2 expressing mitotic cells and the 
percentage of positive E2 expressing mitotic cells showing the foci binding pattern 











N (# mitotic 
cells 
examined) 
% cells expressing 
E2 
% E2 positive cells with E2 foci 
on mitotic chromosomes 
E2 41 46.3 89.5 
E2HC 40 55.0 95.5 
216-404-C 29 75.9 100 
240-404-C 41 56.1 82.6 
255-404-C 54 38.9 0 
286-404-C 42 40.5 0 
313-404-C 30 36.7 0 
216-240-C 35 34.3 0 
216-255-C 35 82.9 93.1 
216-272-C 27 85.2 73.9 
216-290-C 40 72.5 100 
240-255-C 37 43.2 81.3 
207-312-C 36 69.4 100 
207-338-C 34 79.4 100 
207-366-C 44 75.0 100 









The HPV8 E2 Proteins Localize to Nuclear Speckles, but this does not correlate 
with Mitotic Chromosome Binding 
 
Proteins from the SR family of splicing factors contain multiple RS motifs and 
localize to nuclear speckles, where they are intimately involved in transcription and 
splicing (reviewed in [154]). The E2 protein from the betapapillomavirus HPV5 
localizes to these speckles [141] and this localization is dependent on the hinge 
region. We found that the HPV8 E2 protein is also localized to the nuclear speckles in 
interphase cells, as shown by colocalization with SC35, a marker for nuclear speckles 
(see Figure 3.4). To determine which domains of the HPV8 E2 protein are required 
for this colocalization, FLAG-tagged E2 proteins containing various combinations of 
the N-terminal (N), hinge (H) and C-terminal domain (C) were expressed and 
analyzed for colocalization with the SC35 protein. As shown in Figure 3.4, the hinge 
region was required for this localization but it was not sufficient. The hinge region 
alone (H) did not associate with nuclear speckles and a combination of the N- 
terminal domain and hinge region (NH) resulted in only weak colocalization with 
SC35. In fact, the absence of the C-terminal domain resulted in nucleolar localization 
of these E2 proteins. However, a protein consisting only of the hinge and C-terminal 
domain (HC) gave strong nuclear speckle localization. Therefore, a function of the C-
terminal domain, such as DNA binding or dimerization, might be important to 
augment this localization. Notably, the same two domains are required for mitotic 
chromosome association.  
 The E2 proteins with truncations in the hinge region were also analyzed for 




on the multiple SR dipeptide motifs and to determine whether this association 
correlated with mitotic chromosome localization. The sequence of amino acids that 
was found to be important for mitotic chromosomal association (residues 240 to 255) 
contains one SR dipeptide motif (see Figure 3.1). Deletion of the C-terminal half of 
the hinge in the background of the full-length E2 protein resulted in only a minimal 
decrease in nuclear speckle localization (N-206-312-C; see Figure 3.5). However, a 
dramatic decrease was observed when the N-terminal half of the hinge was deleted 
(N-313-403-C and 313-403-C). Progressive truncation of the N-terminal half of the 
hinge resulted in decreased nuclear speckle binding. In the absence of the N-terminal 
transactivation domain this resulted in a progressive increase in nucleolar 
localization. However, neither half of the hinge was sufficient to localize the proteins 
to nuclear speckles, despite the presence of multiple SR sequences. We postulate that 
either a minimal number of SR motifs are required for this localization, that specific 
sequences from both halves of the hinge are required or that the deletion endpoint at 
residues 312/313 interrupts a crucial element. In interphase, the minimal 
chromosomal binding E2 protein, 240-255-C, was localized throughout the nucleus 
and nucleolus in a diffuse staining pattern and did not localize specifically to nuclear 







Figure 3.4.  
Colocalization of E2 and SC35 in interphase cells. CV-1 cells expressing full length 
E2 (WT), or the N, NH, H or HC E2 domains were assayed for E2 and SC35 
localization by indirect immunofluorescence. The E2 protein, as detected by a FITC-
labeled antibody, is shown in green; the SC35 protein, as detected by a Texas Red 
antibody, is shown in red; colocalization of these proteins appears as yellow in the 
merged images. Cellular DNA was stained with DAPI (blue). The interphase 













Summary of the intracellular localization of the HPV8 E2 Proteins.   
All E2 proteins used in this study are shown with their intranuclear localization 
indicated to the right. Nuclear speckles were determined by colocalization with SC35: 
-, no apparent colocalization with SC35; +/-, minimal; +, low; ++, moderate; and 
+++, high colocalization with nuclear speckles (all of the E2 proteins colocalized with 
SC35). Nucleolar localization was determined by colocalization with UBF: -, minimal 
nucleolar localization; +, equal detection in nucleus and nucleolus; ++, moderate and 
+++, high amounts of protein accumulated in the nucleolus relative to nucleus. The 





The Chromosome Binding Region is functional in other BetaPapillomavirus E2 
Proteins 
To confirm whether the pattern of chromosome binding seen with HPV8 E2 is 
common to other beta-papillomavirus E2 proteins, we examined the association of   
HPV5 E2 with mitotic chromosomes. As shown in Figure 3.6, the mitotic localization 
of HPV5 E2 was similar to HPV8 E2, with E2 detected as large distinct foci on the 
chromosomes. These foci also overlapped with the Pol I transcription factor, UBF 
(data not shown). To test that the chromosome binding region mapped in HPV8 E2 
was also functional in HPV5 E2, we expressed an HPV5 E2 protein carrying a forty 
amino acid region similar to the mapped chromosome binding region of HPV8 (216-
255) fused to the C-terminal DNA binding domain. The HPV5 216-255 C protein was 
also observed to associate with mitotic chromosomes (see Figure 3.6D) and to 
colocalize with UBF (data not shown). We also carried out experiments in which the 
C-terminal domains and 40 residue hinge chromosome binding regions from each E2 
protein were exchanged (see Figure 3.6B). The pattern of mitotic binding was the 
same for each of the E2 fusion proteins (see Figure 3.6D). Hence, from this study we 
can conclude that the mitotic binding pattern observed with the HPV8 E2 protein is 
also observed in other beta-virus E2 proteins and involves a similar region of the 
hinge region along with the DNA binding domain. Figure 3.6A shows a comparison 
of the 216 to 255 regions of HPV5 and 8. Notably, the smaller 16 amino acid 
chromosome binding region (240-255; underlined in HPV8) is the largest invariant 








HPV5 E2 protein shows a similar mitotic binding pattern to HPV8 E2 protein.  
A. Homology between the HPV8 and HPV5 216-255 hinge regions. Underlined 
region indicates the chromosome binding region in HPV8 E2. 
B. Schematic representation of the HPV8 and HPV5 E2 fusion proteins. The black 
box represents the flag-tag. 
C. Immunoblot analysis showing the expression levels of the full length, truncated 
and fusion E2 proteins of HPV8 and HPV5. E2 was detected using an anti-FLAG 
antibody.  
D. Immunolocalization of the HPV8 and HPV5 full length, truncated and fusion E2 
proteins in mitotic CV-1 cells. E2 proteins, as detected with a FITC-labeled antibody, 




The Chromosome Binding Region of the Beta Papillomaviruses is highly 
conserved 
 
Elements sufficient for mitotic binding of HPV8 and HPV5 E2 map to the 
same hinge region of the proteins. To assess whether this region is also conserved 
among the  five different species of beta-papillomaviruses, the predicted E2 
sequences from 29 different beta-viruses, belonging to species 1, 2, 3, 4 and 5, were 
analyzed using the Clustal W alignment program (see Figure 3.7). The alignment 
showed that the 16 amino acid chromosome binding region contains a small stretch of 
the most highly conserved residues in the E2 hinges of all beta-papillomaviruses. 
Hence, we have mapped the region of E2 required for mitotic chromosomal 
association to a short peptide that is highly conserved in all beta HPVs. The fact that 
this region has been conserved throughout evolution in an otherwise divergent region 






Sequence analysis of the Chromosome Binding Region 
Clustal W alignment of 29 papillomaviruses E2 proteins belonging to the five 
different species of the beta genus. The numbers represent the amino acid residue 
numbers of the HPV8 E2 protein. Residues arginine 250, serine 253 and tyrosine 248 
are 100% conserved in these 29 sequences. The 16 amino acid chromosome binding 
sequence (CBS) is underlined. The transactivation domain and DNA binding 














An RXXS motif in the hinge is crucial for mitotic chromosome binding 
 
To further map specific residues in the hinge important for mitotic 
chromosomal interaction of the HPV8 E2 protein, we generated specific amino acid 
substitutions. These studies were initiated at the point when we had mapped the 
chromosomal binding region to the forty residues between amino acids 216-255 of 
the hinge.  The point mutations were generated in a background of these forty 
residues fused to the C-terminal domain. This region contains a few residues that are 
highly conserved among all beta-papillomavirus E2 proteins and also contains 
number of putative consensus sites for different modification enzymes such as CK2, 
Aurora kinases and protein arginine methyl transferases (PRMTs). Key residues were 
substituted with alanine to eliminate sites of possible post-translational modifications, 
such as arginine methylation (R250/251) and serine/threonine phosphorylation (T219, 
SP233/234 SS253/254), and to change conserved residues (P220A, D225, 
QQ239/240, Y248, GG245/249 and P252). The sequences of these mutations and 
expression level of the mutated E2 proteins are shown in Figures 3.8A and B, 
respectively. 
The mutated 216-255-C E2 proteins were tested for their ability to bind 
mitotic chromosomes by immunofluorescence (Figure 3.8C). Only two of the mutated 
E2 proteins, RR250/251AA and SS253/254AA, showed a loss of the chromosome 
binding phenotype. Neither protein was observed in the characteristic, distinct HPV8 
chromosomal foci. All of the other mutated E2 proteins exhibited the wild-type 





Figure 3.8  
Mutational analysis and mitotic chromosome binding phenotype of 216-255-C E2 
proteins  
A. Amino acid substitutions in the background of E2 proteins with a 40 amino acid 
region from the hinge (216-255) fused to the CTD. MCB: mitotic chromosome 
binding phenotype. 
B. Immunoblot analysis showing the expression levels of the mutated E2 proteins. E2 
was detected using an anti-FLAG antibody.  
C. Immunolocalization of the mutated 216-255-C E2 proteins in mitotic cells. 
Negative (-) represents cells transfected with empty vector. E2 proteins were detected 
using anti-FLAG antibody (green) and cellular DNA was stained with DAPI (blue). 
The percentage of E2 expressing mitotic cells and the percentage of positive E2 






Table 3.2 - Percentage of positive E2 expressing mitotic cells showing the foci 
binding pattern (Mutations in 216-255-CTD hinge background) 
 
E2 Protein 





% E2 positive cells with E2 foci on 
mitotic chromosomes 
WT(216-255-C) 33 69.7 91.3 
D225Q 49 81.6 85.0 
QQ239/240AA 50 92.0 95.7 
Y248A 46 50.0 87.0 
RR250/251AA 53 30.2 0 
SS253/254AA 48 31.3 0 
GG245/249AA 52 63.5 84.8 
T219A 50 68.0 79.4 
P220A 54 70.4 89.5 
SP233/243AA 51 60.8 90.3 

















on mitotic chromosomes [205], these mutated E2 proteins were also tested for their 
colocalization with UBF. All mutated E2 proteins, except RR250/251AA and 
SS253/254AA showed overlapping localization with UBF on mitotic chromosomes 
(data not shown). The percentage of positive E2 expressing mitotic cells showing the 
foci binding pattern is shown in table 3.2. Thus, the region between position 250 and 
254 in the HPV8 E2 hinge region is important for HPV8 mitotic chromosomal 
binding. 
Further examination of the RR250/251AA and SS253/254AA amino acid 
sequences determined that both mutations disrupted two overlapping ‘RXXS’ kinase 
motifs. This RXXS motif is a common consensus for several different kinases such as 
the aurora kinases, protein kinase A and C, calmodulin dependent kinases and the 
Rho-kinase (ROCK) [174,251,279]. Furthermore, these four residues map to the 
region of sixteen amino acids (240-255) identified in parallel by deletion analyses. To 
further analyze which of the two serine and arginine residues were actually 
contributing to the mitotic binding phenotype, we designed another set of mutations. 
In this case, they were generated in the background of the sixteen amino acid residues 
240-255, fused to the C-terminal DNA binding domain (240-255-C). The residues 
arginine 250 and 251 and serine 253 and 254 were individually substituted with 
alanine residues. Each serine residue was also substituted with aspartic acid to mimic 
the effect of constitutive phosphorylation. To identify additional residues required for 
chromosomal association, the remaining E2 proteins in this set also contained 
substitutions of conserved residues that had not been previously mutated in this 




five potential phosphorylation sites in the 240 to 255 region were substituted with 
alanine (A5). The sequences of these mutations and the expression level of the 
mutated proteins are shown in Figure 3.9A and 3.9B respectively. 
Figure 3.9C shows the intracellular mitotic localization of the mutated 240-
255-C proteins. This analysis revealed that arginine 250 and serine 253 were crucial 
for mitotic localization of the HPV8 E2 protein; R250A and S253A, as well as 
S253D, were deficient in mitotic binding function and did not form mitotic 
chromosomal foci (Figure 3.9C). These residues lie within the R250XXS253 motif. As 
mentioned above, this is a motif common to a number of protein kinases. However, 
the phosphor-mimetic S253D was not able to substitute for phosphorylated S253 as 
this protein was excluded from mitotic chromosomes. The overlapping R251XXS254 
motif was not required as R251A and S254A E2 proteins could bind mitotic 
chromosomes. Chromosome binding was also abolished in the A5 protein, which had 
alanine substitutions in all potential phosphorylation sites within the 240-255 region. 
All other mutated E2 proteins exhibited a binding pattern similar to that of the wild-
type protein. The E2 proteins that bound to mitotic chromosomes also colocalized 
with UBF (data not shown). The percentage of positive E2 expressing mitotic cells 
showing the foci binding pattern is shown in table 3.3.  Therefore, the motif 
R250XXS253 in the hinge region is essential for the mitotic binding function. Notably, 
arginine 250 and serine 253 and the consensus motif ‘RXXS’ are absolutely 








Figure 3.9  
Arginine 250 and serine 253 are critical residues mediating chromosomal association 
function of HPV8 E2 protein  
A. Amino acid substitutions in the background of E2 proteins with a 16 amino acid 
hinge region (240-255) fused to the CTD. MCB: mitotic chromosome binding 
phenotype. 
B. Immunoblot analysis showing the expression levels of the mutated E2 proteins. E2 
was detected using an anti-FLAG antibody.  
C. Immunolocalization of the mutated 240-255-C E2 proteins on mitotic 
chromosomes. Negative (-) represents cells transfected with empty vector. E2 
proteins were detected using anti-FLAG antibody (green) and cellular DNA was 
stained with DAPI (blue). The percentage of E2 expressing mitotic cells and the 
percentage of positive E2 expressing mitotic cells showing the foci binding pattern 





Table 3.3 - Percentage of positive E2 expressing mitotic cells showing the foci 
binding pattern (mutations in the 240-255-CTD background) 
 




% E2 positive cells with E2 
foci on mitotic chromosomes 
WT(240-255-C) 181 24.9 93.3 
S253D 160 25 0 
S254D 210 29 95.1 
S253A 142 16.9 0 
S254A 196 25 98.0 
R250A 158 26.6 0 
R251A 149 29.5 100 
RR246/247AA 172 25.6 100 
A5 180 23.9 0 
E242Q 164 25.6 95.2 














HPV8 E2 Serine 253 is a Phosphorylation Site 
 
To investigate the phosphorylation status of the E2 proteins, we expressed the 
E2 proteins in CV-1 cells in the presence of [32P]-orthophosphate or a combination of 
[35S]-methionine and [35S]-cysteine. E2 proteins were immunoprecipitated from 
equivalent counts of total protein and analyzed by gel electrophoresis, 
autoradiography and phosphor-imaging (see Figure 3.10). An initial study included 
the full length E2 protein, the HC protein (206-403-C) and the series of mutated 
proteins shown in Figure 3.8A in the 216-255-C background. Figure 3.10A shows 
that the wild-type, HC and 216-255-C were all labeled with 32P, indicating that they 
were phosphorylated. Notably, the full-length E2 and HC proteins were highly 
phosphorylated, as determined by the ratio of 32P to 35S incorporation, compared to 
the smaller 216-255-C protein. However, all 216-255-C proteins containing the amino 
acid substitutions shown in Figure 3.8A were also phosphorylated. There was a slight 
reduction in 32P incorporation in the RR251/252AA and SS253/254AA proteins, but 
it was difficult to conclude whether this was due to the elimination of 
phosphorylation in one of the overlapping RXXS motifs because of the potential 
background phosphorylation due to the additional 12 potential sites of 
phosphorylation in the 216 to 255 region (data not shown). 
To further determine whether the R250XXS253 motif is phosphorylated, the 
experiment was repeated with the series of mutated proteins in the 240-255-C 
background. As shown in Figure 3.10B, the 240-255-C protein was phosphorylated 
and minimal, if any, phosphorylation was detected with C alone. Mutation of all five 




Furthermore, both S253A and S253D proteins have no detectable phosphorylation, 
confirming that residue 253, in the R250XXS253 motif, is a phosphorylation site. The 
240-255-C proteins with substitutions in residue 254 (S254A and S254D) were 
phosphorylated and so S254, in the overlapping R251XXS254 motif, is not a major 
phosphorylation site. However, substitution of either R250 or R251 resulted in a 
substantial decrease in phosphorylation. Therefore, the optimal motif for 
phosphorylation is RRXS. However, although the R251A 240-255-C protein showed 
greatly reduced phosphorylation, it was able to bind to mitotic chromosomes in the 
characteristic HPV8 E2 binding foci. Therefore, even though R251 and S253 are 
essential for association with mitotic chromosomes, phosphorylation of the 
R250XXS253 motif may not be absolutely required. Alternatively, the minimal 
phosphorylation observed may be sufficient for the observed chromosome binding. 
The in vivo labeling experiments were carried out in asynchronous cells and, if the 
observed phosphorylation is cell cycle regulated, the residual phosphorylation might 









Phosphorylation analysis of the HPV8 E2 proteins 
A. CV-1 cells expressing full-length, HC (206-404-CTD) and 216-255-CTD E2 
proteins were metabolically labeled with either [32P]-orthophosphate or [35S]-
methionine and cysteine. Equivalent amounts of total protein were 
immunoprecipitated using anti-FLAG beads and the samples were analyzed by 15% 
SDS-PAGE. Incorporation of labeled isotopes was determined using a 
Phosphorimager.  E2 proteins are indicated by arrows.  
B. CV-1 cells expressing the series of mutated proteins shown in Figure 7A were 
metabolically labeled with [32P]-orthophosphate or [35S]-methionine and cysteine, as 















Several studies have shown that the papillomavirus E2 proteins link the viral 
genome to the host chromosomes to support maintenance, stability and partitioning of 
the viral genome. For BPV1, both the N-terminal transactivation domain and C-
terminal DNA binding domain of E2 are required for efficient mitotic chromosome 
interaction and genome partitioning [18,123,243]. The N-terminal domain is required 
for interaction with cellular factors bound to mitotic chromosomes, such as the Brd4 
protein [19,281], and the C-terminal domain is required for binding to DNA sites in 
the viral genome [123,243]. Specific residues within the transactivation domain of E2 
are required for interaction with Brd4 [19,124,236,281] and the C-terminal 
dimerization function of E2 augments the E2-Brd4-mitotic chromosome interaction 
[41]. We have previously shown that the domains required for chromosomal 
association of HPV8 E2 protein are different from those required for BPV1 E2 [205]. 
Unlike BPV-1 E2, the N-terminal domain of HPV8 E2 is not required for 
chromosomal association; instead, the C-terminal DNA binding and dimerization 
domain and the hinge region are essential. In this study we have identified a 16 amino 
acid chromosome binding region in the hinge that, when fused to CTD, is sufficient 
for E2 chromosomal association. Further analyses identified two specific residues 
within the mapped region, arginine 250 and serine 253, which are critical for the E2 
mitotic chromosome binding function. Notably, the identified R250XXS253 motif, 
along with the arginine 250 and the serine 253 residues, is completely conserved 
among the 29 beta-papillomaviruses that have been sequenced to date. We have also 




confers an identical chromosomal binding phenotype. Thus, evolutionary 
conservation of this region, in an otherwise divergent part of the E2 protein, 
highlights its functional significance in the viral life cycle.  
The hinge region of the beta-papillomavirus E2 proteins is also responsible for 
a unique intracellular localization in interphase cells. The beta E2 proteins are 
localized in nuclear speckles; these speckles are enriched in splicing factors and are 
adjacent to sites of active transcription ([120] and this study).  Lai et al. have shown 
that the HPV5 E2 protein can also associate with splicing factors and can augment 
splicing [141]. In HPV8 E2, the hinge region is essential for nuclear speckle 
localization but it is not sufficient; the C-terminal domain of E2 is also required for 
efficient nuclear speckle association. Progressive removal of SR dipeptide motifs in 
the hinge region results in loss of nuclear speckle localization. However, expression 
of the hinge region alone results in nucleolar localization. In addition, proteins 
containing truncated regions of the hinge region fused to the C-terminal domain, 
which no longer associate with nuclear speckles, also localize to the nucleolus. Thus, 
in the presence of the DNA binding domain, nuclear speckle localization is dominant 
but in the absence of this domain, E2 proteins derived from hinge and CTD are often 
observed in the nucleolus. It is not clear whether the nucleolar localization is of 
physiological significance. The hinge region contains many GR-rich regions that may 
function as RNA binding regions that could associate with the high amounts of RNA 
found in the nucleolus. We have shown that the hinge region is important for the 
colocalization of HPV8 E2 with UBF and the ribosomal DNA loci on mitotic 




unexpected. However, the mitotic chromosome binding region of the hinge (240 to 
255) does not localize E2 specifically to the nucleolus. Furthermore, E2 proteins that 
do localize to the nucleoli are usually found diffusely throughout the nucleolus and 
are not located specifically in the fibrillar centers or dense fibrillar components that 
contain the rDNA genes and UBF factor.  
Within the 16 amino acid chromosome binding region of the E2 hinge we 
have identified two, highly conserved residues that are crucial for mitotic 
chromosome association. Arginine 250 and serine 253 lie within a consensus kinase 
motif, R250XXS253 and we have demonstrated that serine 253 is phosphorylated and 
that mutation of arginine 250 greatly decreases this modification. An overlapping 
R251XXS254 motif is not required for mitotic chromosomal foci and serine 254 is not a 
major phosphorylation site. However, mutation of arginine 251 also results in greatly 
reduced phosphorylation although the resulting protein is not defective for 
chromosome binding. Therefore, an RRXS motif is required for phosphorylation but 
only RXXS is required for localization to mitotic chromosomal foci. Thus, 
phosphorylation does not seem to be directly required for the chromosome binding of 
the 240-255-C E2 protein, unless it is cell cycle regulated and the residual 
phosphorylation observed is found primarily in mitotic cells. We propose that 
phosphorylation may instead regulate another property of the E2 protein that is 
related to but not directly required for mitotic chromosome association. For example, 
the BPV1 E2 proteins are phosphorylated in the hinge region by CK2 and this 
modification triggers a conformational switch that targets the E2 protein for 




regulates genome copy number [166,200,201]. 
The RXXS motif is a consensus for many protein kinases including protein 
kinase A and C, calcium-calmodulin dependent kinase, aurora kinase B and the 
ROCK kinases. Notably, some of these, such as aurora kinase B, play an important 
role during mitosis in regulating host chromosomal segregation and cytokinesis. 
Phosphorylation of the E2 chromosome binding region requires more than the 
minimal R250XXS253 motif since R251A results in decreased phosphorylation and the 
S254 in the overlapping R251XXS254 motif is not phosphorylated. The requirements 
for S253 phosphorylation indicate that the kinase recognition motif might be RRXS, a 
protein kinase A site.  
Notably, the chromosome binding regions of LANA and EBNA1 have been 
mapped to short peptide sequences that have sequence similarities to the chromosome 
binding region of HPV8 E2 that we have mapped in this study. As shown in Figure 
3.11, the identified RXXS kinase motif is also present in the chromosome binding 
region of the LANA and EBNA1 tethering proteins. In EBNA1 several of the RXXS 
motifs overlap with AT hook regions that are required for chromosome binding and 
partitioning [232]. In LANA, substitution of residues overlapping the RXXS motif 
also disrupts episomal persistence, chromosome binding and interaction with histones 
H2A and H2B [14]. In addition, the chromosome binding regions all contain GR 
motifs. In EBNA1 these arginine residues are methylated [240] and the serine 
residues are phosphorylated and substitution of the serines disrupts the EBNA1 
partitioning function [71,240]. EBNA1 is thought to associate with mitotic 




hook DNA binding regions [232] and\or or by interacting with a host nucleolar 
protein hEBP2 [239]. LANA interacts with a number of cellular chromosomal 
proteins and the N-terminal chromosome binding region of LANA interacts with the 
nucleosomal surface of histones H2A and B [14]. These observations suggest that, 
although these proteins may have different chromosomal targets, phosphorylation by 
certain cell cycle dependent kinases could be a common mechanism of regulation of 
chromosome binding function. 
Future studies will address the molecular interactions of the chromosome 
binding region of the betapapillomavirus E2 proteins. Several functions and protein 
interactions have already been assigned to the PV E2 hinge region. For example, the 
HPV8 E2 hinge region can activate transcription by recruitment of Sp1 to cellular 
promoters [248]. The studies presented here show that the full-length HPV8 E2 
protein interacts with several different complexes that direct its intracellular 
localization. One of the strongest associations is with nuclear speckles. As mentioned 
previously, the hinge of HPV5 E2 interacts with splicing factors and enhances 
splicing. The N-terminal domain of HPV8 E2 binds the Brd4 protein and this 
interaction strengthens the association of Brd4 with cellular chromatin [170]. 
However, Brd4 is not required for the prominent foci observed bound to the rDNA 
loci on mitotic chromosomes [205].  In the absence of the N-terminal domain and the 
RS regions of the hinge, the E2 protein was observed in the nucleolus. As discussed 
above, this localization might be due to putative RNA binding regions of the hinge 








Similarities among the chromosome binding regions of HPV8 E2, EBNA1 and 
LANA. AT hook regions are underlined and RXXS motifs are shown in red. The E2 
serine 253 residue, shown to be phosphorylated in this study, is indicated by a P. The 




















The betapapillomavirus E2 proteins have distinct properties compared to the 
E2 proteins from other papillomavirus genera. To date, the interphase localization to 
nuclear speckles and mitotic association with rDNA loci has only been characterized 
for the beta PV E2 proteins. HPV8 E2 can give rise to tumors in transgenic mice 
[203] and it will be of interest to see if any of these unique properties are connected 
and relate to the unique pathogenesis of beta PV infection. The experiments described 
here have characterized sequences required for the interaction of the HPV8 E2 protein 
with mitotic chromosomes. By analogy with other papillomaviruses, we assume that 
this interaction is crucial for the virus to tether its genome to host chromosomes 
during persistent infection. Understanding the mechanism by which the E2 protein 
tethers the viral genome to host chromosomes during persistent infection will assist in 
the development of anti-viral therapies to inhibit E2 interaction with mitotic 
chromosomes and thus eliminate viral genomes from infected cells.  
Following mapping of the chromosome binding elements in the HPV8 E2 
protein, we next wanted to elucidate the mechanism of regulation of E2-chromosomal 
association. In the following chapter (Chapter 4), studies were conducted to 
understand the regulation of the HPV8 E2 chromosome binding function by 












The following chapter is based on a manuscript ready for submission. 
Phosphorylation by PKA regulates the chromosome binding function of the HPV8 E2 
protein-Sekhar,V and McBride A.A 
 
Contributions: I wrote the manuscript and performed all the experiments presented in 




















Chapter 4: Phosphorylation regulates the chromosome binding 
function of the HPV8 E2 protein 
Introduction 
 
Papillomaviruses (PV) are small, ubiquitous, double stranded DNA viruses 
that infect either the mucosal or the cutaneous epithelia of their natural hosts. They 
are the etiological agents of a wide spectrum of diseases that range from mild 
asymptomatic infections to malignant carcinomas. HPV8 belongs to the 
betapapillomavirus genus which contains viruses that infect the cutaneous epithelium. 
In healthy individuals these viruses are associated with asymptomatic infections, but 
in individuals with immune disorders such as EV they cause lesions that can become 
cancerous after decades of infection [86]. Members of this genus have also been 
implicated in certain types of non-melanoma skin cancer [80].  
One of the hallmarks of papillomavirus infection is the ability of the virus to 
establish persistent infection of the host. An essential feature of persistent infection is 
the ability of the viral E2 protein to tether the viral genomes to the host chromosomes 
during mitosis as a means to ensure their partitioning and nuclear retention at the end 
of cell division. The E2 protein consists of two conserved domains; the carboxy-
terminal DNA binding and dimerization domain (CTD) that binds to a palindromic 
12bp target sequence on the viral genome and the amino-terminal transactivation 
domain that along with the CTD is involved in viral replication and transcription. The 
two domains are separated by a highly flexible and non-conserved hinge region [165]. 




many diverse functions have now been mapped to hinges of different E2 proteins. 
Regions that regulate nuclear localization in HPV11 E2 [286], proteasomal 
degradation in BPV1 E2 [201] and transcriptional regulation and chromosome 
binding functions have been mapped to the HPV8 E2 hinge [235,248].   
E2 proteins from different papillomaviruses have been shown to associate 
with distinct chromosomal targets [191]. BPV1 E2 binds as small speckles over the 
arms of all mitotic chromosomes in association with the cellular protein Brd4, but 
HPV8 E2 is observed as large pericentromeric foci on mitotic chromosomes 
[171,205]. BPV1 E2 interacts with host chromosomes through the amino-terminal 
transactivation domain but HPV8 E2 does not require either the N-terminal 
transactivation domain or the Brd4 interaction to bind to mitotic chromosomes [205]. 
The HPV8 E2 protein has been shown to associate with the repetitive rDNA loci on 
the short arms of human acrocentric chromosomes and colocalize with the rDNA 
transcription factor, upstream binding factor (UBF) on mitotic chromosomes [205].  
We have previously identified a 16 amino acid region of the HPV8 E2 hinge that, 
when fused to the C-terminal DNA binding domain, is both essential and sufficient to 
bind pericentromeric foci on mitotic chromosomes. Furthermore, two residues within 
this hinge region, arginine 250 (R250) and serine 253 (S253), are critical for E2 
mediated chromosomal interaction [235].   
The regulatory mechanisms governing E2 mediated papillomavirus 
chromosome tethering and genome partitioning have not yet been completely 
elucidated. Many viruses have evolved to rely on post-translational modifications to 




For example, post-translational modifications have been implicated in regulating 
the chromatin binding function of the herpesvirus tethering protein EBNA1. The 
325-376 GR-rich chromosome binding region of EBNA1 is both phosphorylated, 
likely by calmodulin-dependent kinase II, and methylated by protein arginine 
methyl transferases (PRMT), PRMT1 and PRMT5 [240]. Phosphorylation of 
multiple serine residues within the GR-rich region is important for the partitioning 
function of EBNA1 [240]. EBNA1 is a nuclear protein with small amounts of 
protein observed in the nucleolus. Inhibition of EBNA1 arginine methylation alters 
its localization within the nucleolus from a diffuse pattern to a peri-nucleolar ring. 
This suggests that methylation affects the EBNA1 interaction with either nucleolar 
proteins or RNA [240]. 
The PV E2 proteins are also subjected to such post-translational 
modifications that regulate their various functions and properties. In the case of 
BPV1 E2 protein, phosphorylation of serine residue 301 within the hinge region by 
casein kinase 2 (CK2) triggers a conformational switch that targets the E2 protein 
for proteosomal degradation [201]. Mutating the serine 301 residue in the BPV1 
viral genome resulted in expression of a highly stable E2 protein and very high 
levels of viral DNA [166], indicating that E2 phosphorylation regulates viral 
genome copy number. The observation that when the half-life of E2 protein was 
increased, significantly higher number of viral genomes were found to be tethered 
to the mitotic chromosomes further supported the role of phosphorylation in 
regulating E2 function [243]. In the case of HPV16, phosphorylation of E2 results 




the functional significance of this E2 modification in the viral life cycle is not 
completely known. Conversely, recent work has also shown that nuclear receptor 
interaction protein (NRIP), a novel calmodulin binding protein, activates the 
phosphatase calcineurin that promotes dephosphorylation of HPV16 E2 protein, 
which in turn increases E2 stability and E2 mediated transcription [45]. In addition, 
studies have also reported a role for sumoylation in influencing E2 stability [274].  
Similarly, the HPV8 E2 protein is highly phosphorylated [235]. The two 
residues crucial for chromosomal association, R250 and S253, lie within a common 
kinase motif, RXXS that is highly conserved in the E2 proteins of all members of 
the beta genus. We have also shown that S253 within this motif is phosphorylated 
[235]. The fact that the residues required for HPV8 E2 chromosomal association 
and phosphorylation are the same, raises the possibility that S253 phosphorylation 
plays a role in regulating the chromosome association function of the HPV8 E2 
protein. Additionally, a comparison of the chromosome binding regions of the 
gamma herpesvirus proteins, EBNA1 and LANA with HPV8 E2 reveals that all 
three tethering proteins contain RXXS motifs within their respective chromosome 
binding regions [235]. This suggests that the chromosome binding function of these 
proteins might be regulated by a common mechanism. To gain further insight into 
regulation of the chromosome binding function of the HPV8 E2 protein, we 
investigated the role of phosphorylation of S253. Here, we show that 
phosphorylation of S253 by protein kinase A (PKA) regulates the interaction of the 







Residues arginine 250 and serine 253 are essential for the chromosome binding 
function of the full length HPV8 E2 protein  
We have previously shown that residues R250 and S253 within the hinge of 
the HPV8 E2 protein along with the C-terminal DNA binding and dimerization 
domain, are essential to bind to mitotic chromosomes [235]. In the current study, we 
wanted to ensure that mutating these residues in the background of the full-length 
protein abrogated the chromosome binding phenotype of the mutated proteins. We 
individually mutated each of these residues in the background of the full length HPV8 
E2 protein and examined the localization of the E2 proteins on the mitotic 
chromosomes by indirect immunofluorescence.  As shown in figure 4.1, alanine 
substitutions of residues R250 and S253 abrogated the chromosome binding function 
of the mutated E2 proteins. These residues lie within a common kinase motif, RXXS 
that is highly conserved among all betapapillomaviruses. We have previously 
reported that S253, within this motif, is phosphorylated [235]. 
 
Detection of HPV8 E2 protein phosphorylated at residue serine 253 
To further investigate the role of S253 phosphorylation on the chromosome 
binding function of the E2 protein, we screened two phospho-specific antibodies that 
could detect proteins phosphorylated at the serine residue within the RXXS motif. 
One of these antibodies detects phosphorylated serine within an RRXS motif (Cell 
Signaling, 9624) while the other recognizes phosphorylated serine with an RXXS 




specifically detect S253 phosphorylated E2 proteins, cell extracts prepared from CV-
1 cell lines expressing inducible wild-type E2 protein and the S253 mutated E2 
protein, were immunoprecipitated using the flag epitope tag and analyzed for 
phosphorylation by immunoblotting. Both phospho-RXXS and phospho-RRXS motif 
specific antibodies could detect the S253 phosphorylated E2 protein (Figure 4.2). 
Furthermore, phosphorylated E2 proteins were not detected in the S253A mutated E2 
protein samples. For all further studies we used the phospho-RRXS motif specific 
antibody (Cell Signaling, 9624).  
We also tested a number of other phospho substrate antibodies directed 
against phospho-MAPK/CDK substrate, phospho-Akt substrate and phospho-(Ser) 
PKC substrate, to determine whether they could detect S253 phosphorylation. None 
of these antibodies recognized the phosphorylated E2 proteins. Thus, the phospho- 
RXXS motif specific antibodies provide a valuable tool to detect HPV8 E2 proteins 










Residues arginine 250 and serine 253 are critical for the full length HPV8 E2 
chromosomal association. CV-1 cell lines carrying control vector plasmid (-) or 
plasmids expressing wild-type HPV8 E2 protein (WT), R250 mutated E2 protein 
(R250A) or S253 mutated E2 (S253A) protein were visualized by indirect 
immunofluorescence to determine the location of E2 proteins on the mitotic 
chromosomes. E2 proteins were detected using anti-flag antibody (green) and cellular 





















Figure 4.2  
Phospho-RXXS motif specific antibodies can detect HPV8 E2 proteins 
phosphorylated at S253. Proteins extracted from CV-1 cell lines carrying control 
vector plasmid or plasmids expressing truncated E2 proteins were 
immunoprecipitated with M2 anti-flag antibody beads. Two versions of WT and 
mutated E2 proteins were used; one contained a 16 amino-acid region of the hinge 
fused to the C-terminal domain (240-255-CTD) and the other a 40 amino-acid region 
of the hinge fused to the CTD (216-255-CTD). The mutated E2 protein in the 240-
255-CTD background has an alanine substitution at residue 253 (S253A). The 
mutated E2 protein in the 216-255-CTD background has alanine substitutions at 
residues S253 and S254 (S253A/S254A). Phosphorylated E2 proteins were detected 
by phospho-RXXS and phospho-RRXS motif specific antibodies. Total E2 protein 









HPV8 E2 protein is phosphorylated at S253 residue by Protein Kinase A (PKA) 
The RXXS motif is a common kinase motif that is shared by a number of 
different cellular kinases including protein kinase A and aurora kinases. To 
understand the role of S253 phosphorylation in regulating the chromosome binding 
function of the HPV8 E2 protein, we proceeded to first identify the cellular kinase 
responsible for S253 phosphorylation. We used inhibitors against various cellular 
kinases such protein kinase G, CaM kinase II and Rho-kinase and examined their 
effects on E2 phosphorylation (Figure 4.3A). Treatment with the inhibitors did not 
affect the levels of S253 phosphorylation. In addition, we also treated cells with 
different concentrations of inhibitors against PKA and aurora kinases (Figure 4.3B). 
Treatment with PKA inhibitor H89 resulted in reduction in S253 phosphorylation 
levels whereas; treatment with aurora kinase inhibitor ZM447439 did not affect the 
levels of S253 phosphorylation (Figure 4.3B). The decrease in the levels of E2 
phosphorylation observed with 2µM ZM447439 was not reproducible. Moreover, 
treatment with a PKA enhancer forskolin resulted in enhanced E2 phosphorylation 
(Figure 4.3B). Additionally, using a program called pkaPS predictor that predicts the 
PKA phosphorylation sites based on a simplified kinase substrate binding model 
[184], S253 was predicted to be a strong PKA substrate site (Figure 4.4). Thus, the 
above findings indicated that PKA might be responsible for S253 phosphorylation. 
PKA is a cAMP dependent protein kinase that is involved in phosphorylation of many 
different cellular proteins involved in regulating signal transduction pathways, 






Effect of kinase inhibitors on S253 phosphorylation. (A) CV-1 cell lines carrying 
plasmids expressing 216-255-CTD E2 (WT) or mutated E2 (S253A) were either 
untreated or pretreated for 2h with PKG inhibitor (1µM), CaM kinase II inhibitor, 
KN-93 (5µM) or Rho-kinase inhibitor, Y-27632 (10µM). Following pretreatment, E2 
was induced for an additional 3h. RIPA cell extracts were prepared and equivalent 
amounts of total proteins were immunoprecipitated with M2 anti-flag antibody beads. 
Phosphorylated E2 protein was detected using phospho-RRXS motif specific 
antibody, followed by re-blotting for total E2 protein using rabbit anti-flag antibody. 
(B) CV-1 cell lines carrying pMEP plasmid, plasmid expressing wild-type (216-255-
CTD or 240-255-CTD) or mutated E2 (S253A/S254A or S253A) were either 
untreated (-) or pretreated for 2h with different concentrations of PKA inhibitor, H-89 
(10µM, 20µM) or PKA enhancer 10µM forskolin (F) or aurora kinase inhibitor, 
ZM447439 (100nM, 1µM, 2µM). Following pretreatment, E2 was induced for an 










To further confirm the role of cellular PKA in S253 phosphorylation, we used 
different PKA modulators to either activate or inhibit PKA activity and examined 
their effects on the phosphorylation status of the E2 protein. CV-1 cells expressing  
240-255-CTD E2 and S253A mutated E2 were pretreated for 2h with the PKA 
inhibitors H89 and KT- 5720 or PKA enhancers, forskolin and cholera toxin (CTX). 
Treatment was followed by induction of E2 expression for 3h in the presence of the 
PKA modulators. H89 and KT-5720 are competitive antagonists that bind to the ATP 
site on the catalytic subunit of PKA and prevent phosphorylation of target proteins. 
On the contrary, the PKA enhancers, forskolin and CTX act by increasing the levels 
of cAMP in the cells, which results in increased cellular PKA activity. Treatment of 
E2 expressing CV-1 cells with 10μM H89 resulted in reduced levels of S253 
phosphorylation compared to untreated cells (Figure 4.5). Treatment with KT-5720 
twice resulted in lower lewels of E2 phosphorylation, whereas the third time no 
reduction was observed. There is some residual amount of phosphorylated E2 protein 
observed even after the inhibitor treatment. This could either be due to incomplete 
inhibition of PKA at the concentrations used or due to redundancy with a secondary 
protein kinase that can phosphorylate E2 in the absence of PKA. Reciprocally, 
treatment of E2 expressing cells with enhancers of PKA activity (10μM forskolin or 
100ng/ml CTX) greatly increased the levels of S253 phosphorylation compared to 
that in untreated cells (Figure 4.5). Thus, modulation of cellular PKA activity alters 
the level of HPV8 E2 phosphorylation at S253 confirming that PKA can 









Prediction of the PKA phosphorylation sites within the HPV8 E2 protein using the 
pkaPS predictor program (174). Residue S253 within the HPV8 E2 hinge has a high 












PKA phosphorylates HPV8 E2 protein at serine 253 residue. CV-1 cell lines carrying 
control vector plasmid or plasmid expressing 240-255-CTD E2 protein were either 
untreated or pretreated for 2 h with PKA inhibitors, 10µM H-89 and 6µM KT-5720 
or PKA enhancers, 10µM forskolin or 100ng/ml cholera toxin (CTX) followed by E2 
induction for 3h. (A) RIPA cell extracts were prepared and equivalent amounts of 
total proteins were immunoprecipitated with M2 anti-flag antibody beads. 
Phosphorylated E2 protein was detected using phospho-RRXS motif specific 
antibody, followed by re-blotting for total E2 protein using rabbit anti-flag antibody. 
(B) Quantitative representation of the proportion of phosphorylated E2 protein at 
indicated times relative to phosphorylated E2 in asynchronous cells observed by 
immunoblotting in different experimental repeats. The repeat 1 (blue bar) for 












Modulation of cellular PKA activity affects the mitotic localization of the HPV8 
E2 protein 
Since the two residues, R250 and S253, which are critical for the 
chromosomal association function of the HPV8 E2 protein are also important for E2 
phosphorylation [235], we wanted to examine whether modulating the activity of 
cellular PKA affected mitotic localization of the E2 protein. CV-1 cell lines 
expressing 240-255-CTD E2 proteins were treated with the different PKA modulators 
as described above and E2 localization in mitotic cells were examined by indirect 
immunofluorescence. Cells were also stained for UBF to detect the ribosomal DNA 
loci on mitotic chromosomes. Following treatment with the PKA inhibitor H89, there 
was a reduction observed in the number of mitotic cells with E2 foci on mitotic 
chromosomes compared to the untreated cells (Figure 4.6A and 4.6B). The cells 
without E2 foci on mitotic chromosomes had undetectable levels of E2 expression 
and there were almost no mitotic cells observed with E2 protein excluded from the 
chromosomes. These observations raise the possibility that E2 protein that is not 
bound to chromosomes is unstable and undetectable by immunofluorescence. The 
percentage of cells expressing E2 in untreated and treated interphase cells was 
similar, ranging from 54% of E2 expressing cells in untreated cells to 46% in treated 
cells. Also no change in the level of total E2 protein was observed following 
treatment with the different PKA modulators, as seen in the immunoblot in figure 
4.5A. In contrast, treatment with PKA enhancers, forskolin and CTX, resulted in an 






Figure 4.6  
Mitotic localization of the HPV8 E2 protein is affected by modulators of cellular 
PKA activity. (A) CV-1 cell lines carrying control vector plasmid or plasmid 
expressing 240-255-CTD E2 protein were either untreated or pretreated for 2h with 
10μM H-89 or 10μM forskolin or 100ng/ml CTX followed by E2 induction for 3h. 
Cells were visualized by indirect immunofluorescence to determine the location of E2 
proteins on the mitotic chromosomes. E2 proteins were detected using anti-flag 
antibody (green), UBF with anti-UBF antibody (red) and cellular DNA was stained 
with DAPI (blue). (B) Quantitative representation of the percentage of mitotic cells 
with E2 foci on the mitotic chromosomes in the untreated, H-89, forskolin or CTX 








compared to the untreated cells (Figure 4.6). However, there was no significant 
difference observed in the number of E2 foci per mitotic cell. Thus, modulating the 
activity of cellular PKA affects the mitotic localization of the HPV8 E2 protein, 
indicating that cellular PKA regulates the chromosomal association function of the 
HPV8 E2 protein. 
We have previously shown that both the full length HPV8 E2 protein and the 
truncated 240-255-CTD E2 protein localize as distinct pericentromeric E2 foci on the 
mitotic chromosomes of both African green monkey CV-1 cells and human C33A 
cells [205,235].  In case of the C33A cells, these pericentromeric E2 foci localize to 
the rDNA loci on the acrocentric chromosomes and colocalize completely with the 
RNA polymerase I transcription factor UBF [205]. However, in CV-1 cells there are 
two populations of E2 associated pericentromeric foci, one is UBF positive and one is 
UBF negative (Figure 4.6). Thus in CV-1 cells, there are additional UBF negative E2 
binding sites located adjacent to the centromere. Notably, PKA affects the association 
of E2 with both UBF positive and UBF negative E2 regions. 
Enhanced E2 phosphorylation results in an increase in the number of interphase 
cells with E2 associated pericentromeric foci 
In CV-1 cells during interphase, the 240-255-CTD E2 protein appears in a 
diffuse nuclear pattern with some nucleolar staining. However, in a subset of cells 
240-255-CTD E2 also localizes in distinct, bright foci that are adjacent to the 






Modulation of PKA activity alters the association of E2 with pericentromeric foci in 
interphase cells. (A) CV-1 cell lines carrying control vector plasmid (pMEP) or 
plasmid expressing E2 protein 240-255-CTD were either untreated or pretreated for 
2h with PKA inhibitor 10μM H-89 or PKA enhancers, 10μM forskolin or 100ng/ml 
CTX followed by E2 induction for 3h. Cells were visualized by indirect 
immunofluorescence to determine the location of E2 proteins in interphase cells. E2 
proteins were detected using anti-flag antibody (green), centromere with anti-ACA 
antibody (red) and cellular DNA was stained with DAPI (blue). (B) Quantitative 
representation of the percentage of E2 expressing interphase cells with E2 associated 
pericentromeric foci in untreated, H-89, forskolin and CTX treated samples. Error 













these pericentromeric interphase foci are completely absent in C33A cells, and in 
cells expressing the S253A mutated 240-255 CTD E2 protein. We believe that these 
foci represent the UBF negative foci observed in mitotic CV-1 cells. To examine 
whether the appearance of the E2 associated pericentromeric foci in interphase cells 
correlated with the phosphorylation status of the E2 protein, their localization was 
examined following treatment with the different PKA modulators. As shown in figure 
4.7A, treatment of wild-type 240-255-CTD E2 protein expressing cells with H89 
almost completely abrogated the appearance of E2 bound to pericentromeric foci in 
interphase cells. Most interphase cells showed only a diffuse nuclear E2 staining 
pattern, with some minor nucleolar localization. However, there was a dramatic 
increase in the number of interphase cells with E2 associated pericentromeric foci in 
cells treated with the PKA enhancers (Figure 4.7A and 4.7B). These results indicate 
that the localization of E2 adjacent to the centromere in CV-1 interphase cells is 
linked to the phosphorylation status of the E2 protein and these foci most likely 
represent the UBF negative pericentromeric E2 foci in CV-1 cells. Thus, enhanced 
levels of E2 phosphorylation result in an increase in the number of interphase cells 
with pericentromeric E2 foci, whereas in the presence of the PKA inhibitor, there is 
nearly a complete loss of these foci (Figure 4.7B). 
S253 phosphorylationa of HPV8 E2 increases during S–phase and mitosis 
To further understand the dynamics of regulation of the chromosomal 
association function of the HPV8 E2 protein, we examined the levels of E2 






HPV8 E2 phosphorylation at S253 increases in S-phase and remains high until 
mitosis. (A) CV-1 cell lines carrying control vector  plasmid or  plasmid expressing 
240-255-CTD E2 protein were synchronized with thymidine and proteins extracted at 
0h (G1/S), 3h (S), 6h (S/G2) and 9h (G2/M) post thymidine release in RIPA 
extraction buffer following E2 induction for 3h. Mitotic cells (M) were collected by 
mitotic shake off at 9h post thymidine release.  Equivalent amounts of total protein 
were immunoprecipitated with M2 anti-flag antibody beads. Phosphorylated E2 
protein was detected using phospho-RRXS motif specific antibody followed by re-
blotting for total E2 protein using rabbit anti-flag antibody. (B) Quantitative 
representation of the proportion of phosphorylated E2 protein at indicated times 
relative to phosphorylated E2 in asynchronous cells observed by immunoblotting in 
panel (A). The error bar shown is a representation of standard deviation of two 


















plasmid expressing the E2 protein or the control vector pMEP, were synchronized 
using 2mM thymidine for 16h, which arrests cells at G1/S boundary and in the S-
phase of the cell cycle. After releasing the E2 expressing cells from thymidine block, 
the cells were allowed to progress through the cell cycle. E2 expressing mitotic cells 
were collected by mitotic shake off at 9h post thymidine release. E2 proteins were 
extracted in modified RIPA buffer at the indicated times and analyzed for E2 
phosphorylated and total E2 levels by immunoprecipitation and immunoblotting. As 
shown in figure 4.8A, there is a significant increase in the level of E2 phosphorylation 
during S-phase, compared to the G1-phase or in an asynchronous population of cells. 
The levels of phosphorylated E2 remain high during the late stages of S-phase, G2/M 
and mitosis. Thus, as shown in the quantitative data in 4.8B, during mitosis the level 
of E2 phosphorylation is high, further indicating that phosphorylated E2 is bound to 
host chromatin, since only chromosome bound E2 can be detected at this stage. 
Increase in phosphorylation of the E2 protein in S-phase correlates with an 
increase in association of E2 protein with pericentromeric foci  
Since, an increase in the number of interphase cells with E2 associated 
pericentromeric foci corresponds with an increase in E2 phosphorylation and the level 
of E2 phosphorylation increases in S-phase; we wanted to determine whether the 
interphase foci were S-phase specific. 240-255-CTD E2 protein expressing cells were 
synchronized with thymidine. Cells were released from thymidine block and allowed 
to progress through the cell cycle. The cells were then fixed with 4% 







E2 association with pericentromeric regions increases in S-phase. (A) CV-1 cells 
expressing 240-255-CTD E2 protein were synchronized with thymidine and fixed at 
0h (G1/S) and 3h (S) post thymidine release. In addition, S-phase samples were also 
treated with H89 (10μM) or CTX (100ng/ml) for 2h followed by E2 induction for 3h 
prior to fixing. Asynchronous cells were also fixed following E2 induction for 3h. 
Cells were visualized by indirect immunofluorescence to determine the localization of 
E2 proteins. E2 protein was detected using M2 anti-flag antibody (green) and 
centromeres with anti-ACA (red). (B) Quantitative representation of the percentage of 
E2 expressing interphase cells with E2 associated with pericentromeric foci in 







Asynchronous cells were also fixed with 4%paraformaldehyde. As shown in figure 
4.9A, there is an increase in the number of interphase cells with pericentromeric E2 
foci in the cells enriched for S-phase compared to the asynchronous population and 
the G1/S phase enriched cells. Notably, there is a marked reduction in the number of 
foci seen in G1/S phase cells. Modulation of PKA activity in S-phase cells resulted 
either in a modest increase in the number of cells with foci in the presence of CTX or 
reduction in the presence of H89 (Figure 4.9A and 4.9B). Thus, there is an increase in 
E2-pericentromeric foci in S-phase and this correlates with enhanced E2 
phosphorylation. 
HPV8 E2 proteins phosphorylated at S253 have a longer half-life 
While examining the mitotic localization of E2 protein following H89 
inhibitor treatment, we observed that there were almost no mitotic cells with E2 
protein excluding the chromosomes. It appeared that in mitotic cells without 
chromosome bound E2 the levels of E2 protein were undetectable. These 
observations lead us to hypothesize that E2 protein that is not bound to chromosomes 
is unstable and hence, is not observed by immunofluorescence. To investigate this 
possibility further, we carried out a pulse-chase experiment and compared the half-
life of the 240-255-CTD E2 with that of the S253A mutated E2 protein. As shown in 
figure 4.10A and 4.10B, 240-255-CTD E2 protein had a longer half-life than 
phosphorylation defective S253A E2 protein. However, with wild-type E2, there was 
a dramatic decrease in the levels of E2 protein in the first 20 minutes following 






Phosphorylated E2 protein has a longer half-life than phosphorylation defective E2 
protein. (A) CV-1 cell lines carrying control vector plasmid or plasmids expressing 
240-255-CTD E2 protein or S253 mutated E2 protein (S253A) were either untreated 
or treated with 100ng/ml CTX for 2h followed by E2 induction for 2h with 4μM 
CdSO4.  Thereafter, cells were treated with protein synthesis inhibitors 25μM 
cycloheximide (CHX) and emetine (25μM) for the indicated time periods. Cells were 
also treated with MG132 (20μM) for 3h post E2 induction as indicated. Cell extracts 
were prepared in SDS extraction buffer at the indicated time points and E2 protein 
was detected using M2 anti-flag antibody and α tubulin was detected using anti-α 
tubulin. (B) Quantitative representation of the blot in (A) showing the percentage of 








type protein remained stable. Thus, E2 decay was biphasic. In contrast, the S253A 
mutated E2 protein undergoes much more rapid degradation and by 40 minutes has 
almost disappeared. The proteosome inhibitor MG132 was also added to the cells for 
3h, following inhibition of protein synthesis to see if it could rescue degradation of 
the E2 proteins. MG132 was only able to rescue the levels of wild-type E2 to about 
20% of the initial protein amount and in the case of the S253A mutated E2 protein; 
there was minimal effect on protein recovery (Figure 4.10A). This suggests that the 
proteasome is not primarily responsible for the degradation of the labile population of 
E2. To determine whether enhancement of PKA phosphorylation would result in 
enhanced stability of the wild-type protein, E2 expressing cells were pretreated with 
CTX for 2h followed by induction of E2 expression, as described above. Following 
CTX treatment, the amount of wild-type E2 protein was higher at the zero time point 
compared to untreated E2. Pulse-chase analysis showed that the wild-type 240-255 
E2 protein had an increased half-life in CTX treated cells and 40% of E2 protein 
remained stable for at least 3h, while the stability of the S253A protein was 
unchanged (Figure 4.10A and 4.10B). Thus, PKA phosphorylation increased the half-
life of the wild-type E2 protein. 
Next, we wanted to investigate whether the observed increase in E2 
phosphorylation and stability were related to chromatin binding. To this end, we 
compared the half-life of the E2 protein in chromatin bound and unbound fractions. 
The unbound fraction was extracted using a standard lysis buffer (0.5% Triton, 0.1M 
NaCl, 2mM EDTA, 0.1M Tris pH 8) and the  chromatin bound fraction was extracted 




the insoluble pellet of the unbound fraction. As can be observed in figure 4.11, 
chromatin-bound wild-type 240-255 E2 protein is quite stable through the different 
time points following inhibition of protein synthesis irrespective of MG132 treatment. 
This indicates that the chromatin bound wild-type protein is resistant to proteosomal 
degradation.  It is possible that the wild-type E2 population that we observe in figure 
4.10A following MG132 treatment is the chromatin bound stable E2 that is resistant 
to degradation. On the contrary, almost no S253A mutated protein could be detected 
in the bound fraction. This further supports the finding that S253A is defective in 
chromatin binding. Furthermore, both E2 proteins were observed to be unstable in the 
unbound fraction, supporting our hypothesis that there is a correlation between 
chromatin binding and protein stability. Notably, MG132 treatment did not rescue 
either the wild-type or the S253A mutated E2 protein in the unbound fraction.  
We also analyzed the difference in chromatin binding of E2 protein extracted 
from cells treated with CTX to enhance E2 phosphorylation. Increasing PKA 
phosphorylation with CTX resulted in a dramatic increase in the amount of wild-type 
E2 protein in the chromatin bound fraction whereas there is no effect on the 
distribution of the S253A E2 protein (Figure 4.11). Therefore, the increase in E2 
protein half-life correlates perfectly with the increase in chromatin binding that we 
observe following enhanced E2 phosphorylation in mitotic cells. The E2 proteins in 
the non-chromatin bound fraction are unstable and do not show much difference in 
half-life following CTX treatment. Taken together, these observations indicate that 
enhanced E2 phosphorylation correlates with increased binding to host chromatin and 





We recently reported that residues R250 and S253, located within the 
chromosome binding region of the HPV8 E2 protein, are required for E2’s 
chromosome binding function. Furthermore, S253 located within the highly 
conserved RXXS motif is phosphorylated [235]. In the current study, we have shown 
that phosphorylation of S253 regulates the chromosome binding function of the 
HPV8 E2 protein. RXXS is a common kinase motif shared by various cellular 
kinases, including protein kinase A (PKA). Using modulators of cellular PKA activity 
we have demonstrated that S253 is most likely phosphorylated by PKA.  
PKA is a cAMP dependent protein kinase that regulates many biological 
processes [254]. PKA is involved in multiple functions during the different stages of 
the cell cycle, ranging from regulation of S-phase replication to mitotic progression 
[278]. We report here that the level of E2 phosphorylation at residue S253 increases 
in S-phase and remains high through mitosis. This finding is in line with previous 
studies that have shown that PKA is required for chromosomal DNA replication, and 
so is active during the S-phase of the cell cycle [53]. PKA is ubiquitous and hence, is 
under strict spatial and temporal regulation. The A kinase anchoring proteins 
(AKAPs) play an important role in directing PKA to specific cellular sites so that they 
are in close proximity to their substrates [244]. One such protein is AKAP95, which 
recruits the regulatory subunit of PKA to chromosomes during mitosis and plays a 










Chromatin bound E2 protein has a longer half-life than unbound E2. (A) Chromatin 
bound and chromatin unbound fractions were prepared from CV-1 cell lines carrying 
control vector plasmid or plasmids expressing 240-255-CTD E2 protein or S253 
mutated E2 protein (S253A) that were either untreated or treated as described in 
Figure 4.10A. E2 protein was detected using M2 anti-flag antibody and α tubulin was 
detected using anti-α tubulin. (B) Quantitative representation of the relative levels of 




Since E2 also binds host chromatin, it is possible that PKA anchored to chromatin by 
AKAP95 is readily available to phosphorylate E2 protein. 
Previous studies have also implicated PKA in the HPV life cycle. PKA has 
been shown to phosphorylate the Dlg/PDZ binding motif of high-risk HPV E6 [138] 
and regulates the E6 dependent degradation of the human discs large protein (Dlg). 
PKA also plays a role in HPV16 E7 mediated transformation by contributing to 
cellular alkalinization, a common characteristic of transformed cells [42]. More 
recently, the HPV16 E5 protein has been reported to utilize the PKA pathway to 
inhibit apoptosis of transformed cervical epithelial cells by stimulating proteosomal 
mediated degradation of the Bax protein [189]. Although the functional significance is 
not known, the HPV11 E1^E4 protein has also been reported to be phosphorylated in 
vitro by PKA and MAPK [37]. These findings, along with our study, highlight the 
importance of PKA in the HPV life cycle. 
The HPV8 E2 protein binds to mitotic chromosomes as large distinct 
pericentromeric foci in human cells. These foci colocalize with UBF and overlap with 
the rDNA loci found on the short arm of acrocentric chromosomes [205]. However, in 
CV-1 cells, two populations of E2 associated pericentromeric foci are observed on 
mitotic chromosomes. One population is the UBF positive E2 foci that colocalize 
with UBF at the rDNA loci. The other consists of UBF negative foci that are localized 
adjacent to the centromeres of non-acrocentric chromosomes [235]. We believe that 
the latter regions consist of pericentromeric satellite DNA. Similar heterochromatic 




tethering protein LANA has been shown to bind to these murine chromocenters [162]. 
The E2-associated UBF-negative pericentromeric foci are not observed in human 
cells and it is possible that in human cells similar repetitive regions are dispersed 
throughout the chromosomes and hence, are difficult to detect. Although, the HPV8 
E2 protein has been shown to colocalize with the rDNA genes in human cells, the 
exact target has not been identified. It is possible that E2 is interacting with repetitive 
DNA sequences that are interspersed among the copies of rDNA genes and that these 
regions are similar to the monkey pericentromeric satellite DNA.  
While the HPV8 E2 protein binds to different mitotic chromosomal locations 
in cell types from different species, the binding is regulated in a very similar manner. 
Mutation of the S253 phosphorylation site in E2 eliminates chromatin binding of both 
populations in human and monkey cells, as does the inhibition of PKA activity. There 
is no colocalization of E2 with UBF-positive foci in either monkey or human 
interphase cells, most likely because the rDNA loci are sequestered into the nucleoli. 
However, one advantage of monkey cells is that the 240-255-CTD E2 protein can be 
observed binding to the UBF-negative pericentromeric regions in interphase as well 
as in mitosis. This interphase localization provides a useful tool to elucidate the 
regulation of E2-chromatin association throughout the cell cycle. Our analysis shows 
that E2 is bound to the UBF-negative foci during S-phase and that this interaction is 
increased by PKA phosphorylation of E2.  
There is a strong correlation between E2 phosphorylation, protein half-life and 
chromatin binding. PKA phosphorylation of HPV8 E2 enhances both chromatin 




directly regulates protein half-life thus leaving stable, phosphorylated E2 to bind to 
host chromatin or whether phosphorylation regulates chromatin binding and 
chromatin bound E2 has a much longer half-life than unbound protein. A dramatic 
decrease in the amount of E2 protein is observed by both immunofluorescence and 
western blotting as cells enter mitosis and only chromosome bound E2 can be 
detected in mitosis. Presumably, the labile population of unbound E2 protein rapidly 
disappears as cells cease transcription and translation at the onset of mitosis. It has 
also been shown that HPV16 E2 has both increased phosphorylation and extended 
half-life in S-phase [129]. 
Our findings are in accordance with a recent study that showed that the 
chromosome binding Gly-Arg repeat regions of the EBV tethering protein, EBNA1, 
were shown to inhibit its proteasomal degradation and stabilize the protein [52]. 
These chromosomal tethering regions are thought to resemble A-T hook motifs that 
bind with high avidity to A-T rich sequences on cellular DNA [232]. Another study 
demonstrated that EBV replicons replicate while bound to host chromatin [181]. 
Furthermore, the daughter molecules remain paired at the site of DNA synthesis until 
they are partitioned in mitosis. HPV8 replication could follow a similar scenario in 
which viral genomes are tethered to host chromatin by the E2 protein in S-phase and 
the daughter molecules remain bound throughout mitosis. Additionally, the presence 
of RXXS motifs within the chromosome binding regions of EBNA1 and LANA 
further underscore the possibility of a common mechanism regulating the 




     In summary, we have shown that PKA phosphorylates the HPV8 E2 
protein at S253. E2 phosphorylated at S253 can bind to specific, UBF-negative 
regions of host chromatin in interphase and has a much greater half-life than 
unphosphorylated E2. We propose that E2 is phosphorylated primarily in S-phase and 
that phosphorylated, chromatin bound E2 remains stabilized at these sites through 
mitosis. However as cells transition from interphase to mitosis, additional 
phosphorylated E2 protein can also associate with UBF-positive regions of 
chromosomes that become available when the nucleolus disassembles. Both types of 
binding could be used to tether viral DNA to host chromosomes for viral genome 
partitioning. On the contrary, the population of E2 protein that is unphosphorylated, 
and not bound to chromatin, has a short half-life and disappears quickly as 
transcription and translation ceases at the onset of mitosis. Finally, when infected 
cells exit from mitosis and re-enter interphase, the E2 protein is likely 
dephosphorylated and degraded. Newly synthesized E2 protein would not be highly 
phosphorylated on serine 253 until the next S-phase.   
 The CTD of HPV8 E2 is required for mitotic chromosome association 
and localization to nuclear speckles. Primary functions of this domain include 
mediating dimer formation [165] and specifically binding to a DNA motif that is 
found at multiple positions in the viral genome [10].  In Chapter 5, studies were 
performed to understand the role of HPV8 E2 CTD in the chromosome binding 




Chapter 5: Role of the C-terminal DNA binding and dimerization 
domain in the chromosomal association function of the HPV8 E2 
protein 
Introduction  
As described in earlier chapters, our mapping studies in the HPV8 E2 protein 
have shown that in addition to the elements in the hinge region, the CTD is also 
essential for the chromosomal association function of the HPV8 E2 protein [235]. The 
CTD of the PV E2 proteins belong to a unique structural class of proteins that form a 
dimeric beta-barrel structure, with each half of the barrel consisting of four beta 
strands and two alpha helices [110]. One of the alpha helices, termed the ‘recognition 
helix’, recognizes and binds a specific 12bp palindromic DNA sequence on the viral 
genome. The 12bp consensus E2 binding sites on the viral genome consist of two 
conserved four base pair sequences separated by a variable spacer region. The 
sequence specific interaction between the recognition helix of the E2 protein and the 
viral DNA is mediated by both the backbone and the side chains of the alpha helix 
[110]. The E2 protein directly binds to the sequences by inserting the recognition 
helix into the major groove of the DNA while the variable spacer regions that lie in 
the minor groove are not contacted. Although the spacer sequences are variable, their 
conformation affects the relative affinity with which the E2 proteins bind to the E2 
binding sites [28,114]. For instance, HPV16 E2 has been observed to have a stronger 
preference for an ‘AATT’ spacer than a ‘TTAA’ spacer [114]. The conformational 
flexibility within the AT rich spacers allows for bending towards the major groove of 




among closely related types to approximately 30% among distant viral types [27]. The 
electrostatic interactions of the CTDs among the different papillomaviruses are 
conserved, which suggests that specific interactions of the E2 protein with DNA are 
also conserved [27]. E2 proteins are expressed as dimers in cells [165,175]. Over the 
years, several crystal structures have been solved such as those of high-risk HPV16 
and HPV31 and low-risk HPV6 and BPV1 CTDs [39,61,109,110] . Several NMR 
solution structures have also been solved and these include the CTDs from HPV16, 
HPV31 and BPV1 [151,180,263]. 
 Notably, the EBNA1 tethering protein of EBV also forms a dimeric beta-
barrel structure similar to the E2 protein [29]. Although, the structure of EBNA1 CTD 
also consists of two alpha helices positioned similar to those of the E2 protein, it 
carries an additional flanking domain consisting of an alpha helix and an extended 
chain that seems to interact with the viral DNA in the crystal structure. Additionally, 
the CTD of the tethering protein LANA of KSHV has been predicted to form a 
dimeric beta-barrel structure similar to EBNA1 [101,105]. This prediction is further 
supported by studies wherein identification of residues in the LANA protein 
important for DNA binding and chromosome association functions were found to 
correlate with analogous EBNA1 residues [133,136]. These observations thus, point 
to a partial functional homology between these proteins. 
As mentioned earlier, the CTD of E2 proteins is important for both 
dimerization and binding to specific DNA motifs on the viral genome. The critical 
amino acid residues of the E2 protein that mediate dimerization and DNA contact 




abrogate dimerization and DNA binding, respectively [206]. The residues that make 
crucial contact at the dimer interface for the HPV8 E2 proteins are residues W449 and 
W451 (Figure 5.1A). Similarly, residues R431 and R433 are important for binding to 
sequences on the viral DNA (Figure 5.1A). The dimerization function of the CTD is 
essential for efficient BPV1 E2 mediated mitotic chromosome binding [41]. 
Substitution of the BPV1 E2 CTD with the dimeric DNA binding domain of Gal4 
from Saccharomyces cerevisiae or EBNA1 could rescue both the mitotic 
chromosome binding phenotype and Brd4 binding function of the E2 protein [41].  
However, substitution with a monomeric red fluorescence protein did not rescue 
either function of the BPV1 E2 protein [41].  
Preliminary studies conducted in our laboratory showed that, in addition to the 
HPV8 E2 dimerization defective protein (W449A/W451A) expressed in the full 
length background, a DNA binding defective protein (R431K/R433K) was also 
deficient in chromosome binding. We examined the mitotic localization of both the 
dimerization and DNA binding defective proteins in the background of 240-255-CTD 
(Figure 5.1B). In all the W449A/W451A and R431K/R433K E2 expressing mitotic 
cells, E2 proteins were excluded from the mitotic chromosomes and did not show any 
colocalization with UBF.  
At first glance, these observations point towards a requirement for both 
dimerization and DNA binding functions of the CTD, for the chromosomal 
association function of E2. However in our tethering model, the DNA binding 
function of E2 is required to bind to motifs in the viral genome and would not be 










Dimerization defective and DNA binding defective HPV8 E2 proteins are unable to 
bind mitotic chromosomes.  (A) Structure of HPV6a E2 CTD with the residues 
required for DNA binding highlighted in red and dimerization residues highlighted in 
blue reconstructed using PyMol (The PyMOL Molecular Graphics System, Version 
1.3, Schrödinger, LLC) (2AYG (HPV6a CTD) Hooley, Fairweather et al., 2006) (B) 
CV-1 cell lines expressing the 240-255-CTD wild-type protein, dimerization 
defective (W449A/W451A) and DNA binding defective (R431K/R433K) proteins 
were visualized by indirect immunofluorescence to determine the localization of the 
E2 proteins and UBF on mitotic chromosomes. E2 proteins were detected by anti-flag 
antibody (green), UBF with anti-UBF antibody (red) and cellular DNA was stained 





concluding that the DNA binding function is required for E2 host chromosomal 
association, we wanted to assess whether other functions such as dimerizaton of the 
CTD was affected by the R431K/R433K mutation. In this chapter, we have designed 
experiments to further elucidate the role of the CTD in the chromosome binding 
function of the HPV8 E2 protein 
 
Results  
The DNA binding defective E2 protein R431K/R433K is capable of dimerization 
Firstly, it was important to rule out the possibility that the R431K/R433K E2 
protein’s inability to bind to chromosomes was due to a defect in dimerization. It is 
possible that the lysine substitutions disrupted the structure of the E2 protein such that 
it is unable to dimerize. An in vitro dimerization assay was performed to check for the 
ability of the R431K/R433K E2 protein to self-associate. The putative dimerization 
defective W449A/W451A HPV8 E2 protein was included as a negative control and 
the wild-type E2 protein as a positive control.  We expressed an N-terminal flag 
tagged version of the wild-type 240-255-CTD E2 protein along with the 
W449A/W451A and R431K/R433K proteins, also in the 240-255-CTD background 
(Figure 5.2A). In addition, we also expressed the untagged versions of all the proteins 
in the full length HPV8 E2 background (Figure 5.2A). The flag tagged and untagged 
versions of the proteins were generated by in vitro translation in rabbit reticulocyte 
lysates. For the dimerization assay, both untagged and flag tagged proteins were 










DNA binding defective E2 protein R431K/R433K can form dimers. (A) Untagged 
version of the full length (FL) HPV8 E2 WT (represented in the top panel as 8E2), 
DNA binding defective E2 protein R431K/R433K and dimerization defective 
W449A/W451A were generated by in vitro translation. Similarly, the flag tagged 
versions of the wild-type (represented in the top panel as 240-255-CTD with an N-
terminal flag tag shown in blue and an anti-flag antibody), R431K/R433K and 
W449A/W451A proteins, in the 240-255-CTD background were also translated in 
vitro. For the dimerization assay, both untagged and flag tagged proteins were 
generated by either in vitro translation independently and mixed together or co-
translated together. E2 proteins were immunoprecipitated using anti-flag antibody and 
co-immunoprecipitation of untagged proteins were detected by western blot analysis. 
(B) Graphical representation of the immunoprecipitation of the untagged proteins 





proteins to dimerize efficiently it has been shown that they need to be co-translated 
together [165]. E2 proteins were then immunoprecipitated with an anti-flag antibody 
and the co-immunoprecipitation of the untagged version was detected by western blot 
analysis. The presence of the untagged R431K/R433K E2 protein in the 
immunoprecipitated complex confirmed its ability to dimerize. As can be observed in 
figure 5.2, E2 proteins only dimerize when they are co-translated. 
Similarly, the untagged wild-type full length E2 protein was also immunoprecipitated 
with the tagged version. However, as expected the dimerization defective 
W449A/W451A HPV8 E2 protein did not immunoprecipitate with the flag tagged 
version, further confirming that it is clearly dimerization defective (Figure 5.2). Thus, 
the in vitro dimerization assay indicates that the DNA binding defective 
R431K/R433K protein is capable of dimerization showing that its inability to bind to 
mitotic chromosomes is not related to a defect in dimerization. 
Substitution of the HPV8 E2 CTD with CTDs from other PVs 
The in vitro dimerization experiment indicates that the inability of the 
R431K/R433K protein to bind to chromosomes was unlikely to be due to a defect in 
dimerization.  Therefore, the possibility that the DNA binding function is required for 
E2-host chromosomal association could still not be dismissed. To test this hypothesis 
further, we decided to substitute the HPV8 E2 CTD with E2 CTDs from PVs 
belonging to different genera. As mentioned above, the E2 CTDs of PVs belonging to 
different genera are conserved and capable of both dimerization and DNA binding. 
Our rationale behind the domain swap approach was that if the HPV8 E2 CTD’s 







Substitution of the HPV8 E2 CTD with CTDs from other PVs. Fusion proteins were 
generated by substituting the CTD of the HPV8 E2 with CTDs from different PVs 
fused to the 240-255 hinge peptide. These included the E2-CTDs from species 1 of 
beta PV (HPV5), species 2 of beta PV (HPV107), gamma PV (HPV4), kappa PV 
(SfPV1), alpha PV (HPV11) and delta PV (BPV1). The percent amino acid similarity 














DNA binding, then substitution of the HPV8 E2 CTD with CTDs from other PVs 
should be able to restore the chromosome binding function of fusion proteins. 
Various fusion proteins were generated by substituting the HPV8 E2 CTD, fused to 
the 240-255 hinge peptide. The HPV8 E2 hinge peptide was fused to the CTDs of 
HPV11 from alpha, HPV5 from beta species 1, HPV107 from beta species 2, HPV4 
from gamma, delta BPV1 and kappa SfPV1 (Figure 5.3). The percent amino acid 
similarity between the CTD of the E2 proteins from different genera relative to the 
HPV8 E2 CTD is shown in figure 5.3. The members belonging t beta species 2 are 
phylogenetically closest to HPV8, a member of the species 1 of beta 
papillomaviruses, followed by gamma HPV4, kappa SfPV1, alpha HPV11 and delta 
BPV1. We also included the DNA binding domain of a non-PV protein, LANA. As 
mentioned above, the predicted structure of the LANA CTD is similar to that of the 
E2 CTD [134]. Moreover, the LANA CTD has been shown to bind to pericentromeric 
and telomeric regions of mitotic chromosomes similar to E2 protein [132]. 
Additionally, Kelley-Clarke et. al have shown that a mutated LANA-CTD (LANA-
SHP) protein, although capable of dimerization and binding to viral DNA, is 
defective in the chromosome binding function. The LANA-SHP carries alanine 
substitutions at serine 1125, histidine 1126 and proline 1127 of the CTD. We 
generated a fusion protein by fusing the E2 hinge peptide to LANA-SHP. We wanted 
to examine whether fusing the 240-255 peptide from the HPV8 E2 hinge to the 
LANA-SHP could rescue the chromosome binding phenotype of this protein. We also 
generated E2 proteins lacking the 240-255 hinge peptide and consisting of only the 







E2 CTDs from species 1 and 2 of beta papillomaviruses can functionally substitute 
the HPV8 E2 CTD when fused to the 240-255 hinge peptide. The LANA CTD can 
bind mitotic chromosomes in the presence and absence of 240-255 hinge peptide. 
CV-1 cell lines expressing either PV CTDs alone or fusion proteins consisting of the 
240-255 hinge fused to the CTDs from species 1 and 2 of beta PVs (HPV8, HPV5, 
HPV107) or to the LANA CTD were visualized by indirect immunofluorescence to 
examine the location of E2 proteins and UBF on mitotic chromosomes. E2 was 
detected using anti-flag antibody (green) and UBF with anti-flag antibody (red). 










their localization on mitotic chromosomes was examined using indirect 
immunofluorescence. We also examined if the CTDs or the fusion proteins 
colocalized with UBF, as seen in the case of the HPV8 E2 protein. From our confocal 
microscopic analysis, it is clear that none of the E2 proteins carrying the CTD alone 
but lacking the hinge peptide could bind to mitotic chromosomes (Figure 5.4 and 5.5). 
The only exception was the LANA-CTD, which has already been shown to bind to 
mitotic chromosomes as pericentromeric and telomeric foci (Figure 5.4). However in 
the case of the fusion proteins, the CTDs from beta species 1 and 2 could substitute 
for the chromosomal association function of HPV8 E2 when fused to the 240-255 
hinge peptide (Figure 5.4). These fusion proteins bound to mitotic chromosomes in a 
focal pattern reminiscent of the wild-type HPV8 E2 protein. Similar to the wild-type 
protein, they also showed partial colocalization with UBF. Thus, both the HPV5 and 
HPV107 CTDs could functionally compensate for the CTD of HPV8 E2 protein.  
On the contrary, fusing the 240-255 peptide to the CTDs of BPV1, HPV11, 
HPV4 and SfPV1 did not result in mitotic chromosome binding (Figure 5.5). Each of 
these fusion proteins were excluded from the mitotic chromosomes. The fusion 
protein with the LANA CTD showed similar pattern of mitotic binding to that of the 
LANA CTD alone. There was no obvious difference in mitotic localization in the 
presence and absence of the peptide (Figure 5.4). Furthermore, fusing the 240-255 
peptide to the LANA-SHP did not rescue the chromosome binding phenotype. The 
resulting fusion protein was distributed around the mitotic chromosomes (Figure 5.5). 






E2 CTDs from alpha, gamma, kappa or delta PVs cannot functionally substitute for 
the HPV8 E2 CTD when fused to the 240-255 hinge peptide. The mutated LANA-
SHP is also deficient in chromosome binding when fused to hinge peptide. CV-1 cell 
lines expressing either PV CTDs alone or fusion proteins consisting of the 240-255 
hinge fused to the CTDs from alpha PV (HPV11), gamma (HPV4), kappa (SfPV1), 
delta (BPV1) or to the mutated LANA-SHP CTD were visualized by indirect 
immunofluorescence to examine the location of E2 proteins and UBF on mitotic 
chromosomes. E2 was detected using anti-flag antibody (green) and UBF with anti-









with the CTDs from the beta species 1 and 2, which are phylogenetically very close to 
one another, results in retention of the chromosome binding function of the HPV8 E2 
protein. However, CTDs from distantly related types are unable to compensate for 
HPV8 E2 chromosomal binding. 
Notably in the interphase cells, the CTDs from the species 1 of beta genera 
were localized to the cytoplasm. But when the hinge peptide was fused to the CTD, 
the resulting fusion protein almost exclusively localized to the nucleus (Figure 5.6).  
In the case of HPV4 E2 protein, both the CTD alone and the fusion proteins were 
observed to be mainly cytoplasmic (Figure 5.6). Fusing the hinge peptide to the 
HPV4 CTD did not alter its cytoplasmic localization. However, the interphase 
localizations of all the other fusion proteins (BPV1, HPV11, HPV107, SfPV1 and 
LANA) were strictly nuclear (data not shown). 
There is still the possibility that the differences in the DNA binding 
specificities of the different CTDs, could contribute to the inability of the CTDs from 
different PVs to functionally replace the HPV8 E2 CTD. To gain a clearer 
understanding of this possible scenario, we compared the consensus E2 binding sites 
within the URR of the different PV genus, using the Multiple EM Motif Elicitation 
(MEME) software. Comparison of the consensus E2 binding sites of the beta PVs 
with those of the gamma, alpha and delta PVs, indicates that they have different DNA 
binding specificities (Figure 5.7). The members of the beta PV genus have a stronger 
preference for a ‘TTAA’ spacer sequence compared to the alpha PVs, which show a 
preference for the ‘AATT’ rich spacer instead. In contrast, the members of the 






Interphase localization of HPV5, HPV8 and HPV4 CTDs and their respective fusion 
proteins. CTDs of HPV5, HPV8 and HPV4 localize to the cytoplasm in the absence 
of the peptide. Fusion of 240-255 peptide to HPV5 and HPV8 CTDs results in 
nuclear localization whereas fusion of 240-255 peptide to HPV4 CTD does not 
localizes the protein to the nucleus. CV-1 cell lines expressing either PV CTDs alone 
or fusion proteins consisting of the 240-255 hinge fused to the CTDs from HPV5, 
HPV4 and HPV8 were visualized by indirect immunofluorescence to examine the 
location of E2 proteins and UBF on mitotic chromosomes. E2 was detected using 
anti-flag antibody (green) and UBF with anti-flag antibody (red). Cellular DNA was 














when binding to DNA (Figure 5.7). This would suggest that the CTDs of the gamma 
and delta PVs because of their less stringent consensus sequence are more likely to 
bind to cellular DNA sequences. However in the domain swapping experiments, the 
fusion proteins with gamma and delta CTDs are excluded from the mitotic 
chromosomes. Thus, the CTD swapping experiments suggest that the beta CTDs have 
a specific role in chromosome binding that cannot be compensated by other PVs. 
Discussion  
Two known functions attributed to the CTD of PV E2 proteins are 
dimerization and DNA binding. The latter is mediated through its ability to bind to 
specific sequences on the viral genome. Additionally, we have shown that the CTD is 
required for the chromosomal association function of the HPV8 E2 protein [235]. 
Thus, this study was aimed towards understanding the role of the CTD in the 
chromosome binding function of the HPV8 E2 protein.  
Although earlier work with BPV1 E2 has shown that dimerization is essential 
for mitotic chromosome binding [41], the observation that the DNA binding defective 
R431K/R433K HPV8 E2 protein was also defective in chromosome binding was 
unexpected. In accordance with our tethering model, the DNA binding function of the 
E2 protein is required to bind to sequences in the viral genome. Mutating residues 
involved in contacting the viral DNA would not be predicted to affect the localization 







Consensus E2 binding sites varies among each genus of PVs. Sequence logo 
indicating the consensus E2 binding site motif for each of the PV genus obtained after 
comparing the URR sequences of all the members of the genera alpha (75 types), beta 
(44 types), gamma (25 types) and delta PVs (10 types) using the Multiple EM Motif 














the DNA binding residues did not affect the chromosome binding function of the E2 
protein [243]. Additionally, the in vitro dimerization assay ruled out the possibility 
that the DNA binding defective E2 protein’s inability to associate with mitotic 
chromosomes was due to a dimerization defect. Instead, these observations indicated 
that the DNA binding function of the CTD might be required to mediate E2 
chromosomal association. The CTDs from different PVs are capable of dimerization 
and DNA binding functions. We hypothesized that if the role of the CTD in the 
chromosome binding function of the HPV8 E2 protein was limited to dimerization 
and DNA binding, then substitution of the HPV8 E2 CTD with CTDs from other PVs 
should be able to restore the chromosome binding function of the resulting fusion 
protein. However, domain swapping experiments indicate that only CTDs belonging 
to the beta genera, of which HPV8 is a member, are capable of functionally 
compensating for the ability of CTD of the HPV8 E2 protein to associate with mitotic 
chromosomes. CTDs from different species of the beta genera such as the HPV5 E2 
from species 1 and the HPV107 E2 from species 2 could associate with mitotic 
chromosomes when fused to the peptide. In contrast, the CTDs from the E2 proteins 
of alpha (HPV11), gamma (HPV4) or kappa (SfPV1) genus could not functionally 
substitute for the HPV8 E2 CTD and restore the chromosome binding phenotype. 
However, the fact that those different PVs have slightly different DNA binding 
specificities make it difficult to determine if this could contribute to the lack of 
functional replacement of the HPV8 E2 CTD with CTDs from other PVs.  
Nonetheless, it is possible that the role of the beta CTDs in the chromosome 




specific role that cannot be substituted by the CTDs from others PVs. It is possible 
that the CTDs from the beta-papillomavirus genus are involved in specific protein-
protein interactions that are regulated by phosphorylation of the hinge peptide. PVs 
are highly species and tissue specific. It would not be surprising if different PVs show 
highly specific interactions that are essential for establishing infections in their 
respective niche tissues and hence, are not shared by members belonging to other PV 
genus.  
We observed that the HPV8 E2, HPV5 E2 and HPV4 E2 CTDs by themselves 
are localized to the cytoplasm compared to the CTDs from other PVs. The CTDs of 
all the other PVs were nuclear. Nonetheless, fusing the 240-255 peptide from the 
hinge region to the CTDs of the HPV5 and HPV8 E2 proteins changes the sub-
cellular localization of these proteins from the cytoplasm to the nucleus. This 
suggests that the peptide might carry a nuclear localization signals (NLS) that results 
in nuclear retention of these fusion proteins. There is precedence for the presence of 
NLS in the hinge region, as has been previously reported for the HPV11 E2 protein 
[286]. The NLS in the hinge region was shown to be important for targeting the E2 
protein to the nuclear matrix. In conducting the mapping studies described in chapter 
3, we observed that a number of truncated HPV8 E2 proteins lacking the 240-255 
peptide region of the hinge, although, deficient in chromosome binding were 
localized to the nucleus. It is possible that multiple NLSs are present within the HPV8 
E2 hinge region. An alternative explanation for the nuclear localization of the HPV5 
and HPV8 fusion proteins could be that the phosphorylation of the hinge peptide 




the case of BPV1 E2, an NLS has been reported in the CTD [242]. Likewise, an NLS 
has also been detected in the HPV16 E2 CTD [135]. The NLS overlaps with the alpha 
recognition helix in the CTD [135]. Nevertheless, as described above, different E2 
proteins use different NLS to efficiently localize the protein to the nucleus. The fact 
that fusing the 240-255 peptide to the HPV4 CTD did not alter the localization of the 
fusion protein of HPV4 from the cytoplasm to the nucleus, further underscores this 
point.  
Using the ‘Muscle’ algorithm as interpreted in Geneious software [73]; we 
aligned and compared the CTD sequences from the different PVs to examine unique 
characteristics within the HPV4 E2 CTD (Figure 5.8). As can be observed from the 
Geneious alignment of the CTDs, HPV4 CTD has some unique sequence features 
compared to CTDs of other PVs. For example, HPV4 has a valine in place of a 
conserved threonine at residue 43 in a stretch of conserved residues spanning residues 
41 to 47 in the alignment. It is possible that the conserved threonine undergoes a post-
translational modification that is lacking in HPV4 E2 CTD and thus, can be attributed 
to differences in its CTD properties. Likewise, conserved basic arginine/lysine 
residues at position 54 and glycine at position 56 are replaced by a serine and 
aspargine respectively, in HPV4. The replacement of a hydrophobic residue, glycine, 
with hydrophilic aspargine could also affect the structure of HPV4 CTD. 
Additionally, a conserved bulky histidine/tyrosine at residue 33 is replaced by 
aspargine in HPV4 (Figure 5.8). In order to better understand how these differences 
in the HPV4 E2 CTD sequences affect its function and cellular localization, detailed 








Alignment of the CTDs of HPV11, BPV1, SfPV1, HPV4, HPV107, HPV5 and HPV8 
using Muscle as interpreted in Geneious. Black bars represent 100% amino acid 
similarity, grey bars represent 90% and light grey bars represent 80% amino acid 
similarity. Green bars represent 100% amino acid identity, yellow bars represent 80-





















alignment comparison of the CTD sequences of the beta PVs with other PVs indicates 
that there are conserved residues in the beta CTDs that are absent in others. For 
example, beta CTDs have a negatively charged residue at position 5 that is absent in 
other PVs. Likewise, position 35, position 40 and position 57 have conserved glycine, 
phenylalanine and arginine, respectively, in beta PVs. Comparison of the sequences 
further downstream indicates that a basic residue occupies position 78 whereas 
positions 84 and 91 are occupied by negatively charged acidic residues in beta CTDs. 
Whether the basic residues are important for binding DNA or the acidic residues aid 
in protein interactions need to be examined in future studies.  Mutagenesis targeting 
these conserved residues in beta PVs will be useful in understanding the unique 
characteristics of beta CTDs. 
  The CTD swapping experiments indicate that CTDs from the closely related 
species of beta genera can functionally replace the HPV8 E2 CTD. However, it is still 
not clear why the DNA binding defective R431K/R433K protein is unable to bind 
chromosomes. One possibility is that the R431K/R433K mutation affects another 
function of the CTD that is unrelated to DNA binding. Similar observations have 
been made with the LANA CTD, whereby mutations in the DNA binding domain can 
affect both DNA binding and chromosome binding function of the LANA protein 
[133]. However, these functions can be separated, indicating that the CTD has 
multiple roles in chromosome binding. As mentioned above, this might indicate that 
the CTD could be involved in certain protein-protein interactions to mediate 




and E2 and the predicted structure of LANA, using homology between EBNA1 and 
E2, we can develop a computer model of the LANA DNA binding domain  
Future work would involve using this model to identify the position of 
residues shown to be important for chromosome binding in the LANA protein and 
correlate this with residues in the analogous position in the HPV8 E2 protein. Further, 
we could examine whether these residues are specifically conserved in the E2 
proteins of beta-papillomaviruses and then test, using a mutagenesis approach, if 
these mapped residues contribute to the chromosomal association function of the E2 
protein.  If we are able to identify regions of the CTD that are required for 
chromosomal interaction but not dimerization or DNA binding, this would indicate 
that they are required for other functions such as interaction with various cellular 
proteins that might mediate binding to mitotic chromosomes. This approach will 
further allow us to identify potential interacting cellular partners of the E2 protein. 
 
It is not clear whether the chromosomal association function of the HPV8 E2 
protein is mediated through direct DNA binding, RNA binding or protein-protein 
interactions. In order to address this question, we performed the studies that have 















Contributions: Protein complex purification was performed by Moon Kyoo Jang. I 

































Chapter 6: Role of protein-protein and protein-RNA interactions in 
the chromosomal association function of the HPV8 E2 protein 
Introduction 
In previous chapters we have described mapping of HPV8 E2 domains that 
are essential for its chromosomal association function. However, it is not yet clear 
whether the chromosomal association function of the HPV8 E2 protein is mediated 
through protein-protein, protein-RNA or protein-DNA interactions. The possibility of 
E2-chromosomal interaction through direct DNA binding was discussed in Chapter 5. 
However, it is possible that protein-protein or protein-RNA interactions could be 
involved in mediating HPV8 E2-chromosomal association. E2 proteins from different 
PVs show variable patterns of mitotic binding on chromosomes [171,205,262], 
suggesting that they interact with distinct chromosomal targets. One of the best 
characterized E2 binding partners is the cellular double bromodomain protein, Brd4 
that binds to acetylated lysine residues on histone H3 and H4 [64]. The N-terminal 
residues R37 and I73 of the BPV1 E2 protein interact with the C-terminal domain of 
Brd4 [281]. Notably in the presence of BPV1 E2, both Brd4 and E2 colocalize in 
punctate dots all over the mitotic chromosomes [243]. In addition, E2 protein 
stabilizes the interaction of Brd4 on chromosomes in interphase and mitosis [171]. 
Although E2 proteins of all PVs interact with Brd4 for E2 mediated transcriptional 
regulation, it is not a partner for chromosome binding in all PVs [124,170,273]. This 
is exemplified in the case of the beta and alpha PVs, where R37A and I73A mutations 




the E2 proteins from either genus [170,205]. Unlike the pattern of small E2 speckles 
observed in association with Brd4, all over the chromosomes with BPV1 E2, the 
HPV8 E2 protein binds as large distinct foci to the rDNA loci [205]. However, the 
chromosome tethering partner for HPV8 E2 still remains elusive. Additionally, 
various other cellular proteins such as TopBP1, MKlp2 and ChlR1 have been 
reported to interact with different E2s [66,196,284]. 
  Similarly, several studies have reported protein interactions for the 
gammaherpesvirus tethering proteins such as LANA and EBNA1. LANA associates 
with methyl CpG-binding protein 2 (MeCP2) and DEK to bind to mouse 
chromosomes [137]. LANA also binds directly to histone proteins H2A and H2B [14], 
in addition to interacting with cellular Brd4 and Brd2/Ring3 proteins 
[163,194,204,264,283]. More recently, interaction of the C-terminus of LANA with 
the nuclear mitotic apparatus protein (NuMA) has been reported to contribute to 
KSHV genome maintenance and partitioning [241]. Another recent study also 
demonstrates that LANA binds the centromeric protein CENP-F and the kinetochore 
associated protein Bub1, on host chromosomes of KSHV infected cells [275]. Thus, 
all of the studies so far seem to indicate that the mechanism of LANA mediated 
chromosome tethering function is complex and involves interactions among multiple 
protein partners. Similarly in the case of EBNA1, EBNA1 binding protein 2 (EBP2) 
was initially identified as an interacting partner [239]. This interaction was shown to 
be essential for EBNA1 mediated partitioning of terminal repeat containing plasmids 




In addition to protein-protein interactions, protein-RNA interactions can also 
be implicated in mediating chromosomal tethering functions. Recently EBNA1 was 
shown to bind to G-rich RNA that formed G-quadruplex structures, through its 
chromosome binding domains [187]. Moreover, treatment of EBNA1 expressing cells 
with compounds like BRACO-19 that interacts with G-quadruplex structures 
interfered with the EBNA1 dependent viral replication and chromosome tethering 
functions [187]. These observations suggested that EBNA1 binds to RNA structures 
and thus, interaction with RNA plays an important role in regulating EBNA1 
functions [187]. As described previously, the chromosome binding domains of 
EBNA1, rich in GR and RS repeats that are the RNA binding motifs share sequence 
similarity with the chromosome binding regions of HPV8 E2 protein. Hence, it is 
possible that similar RNA interactions could mediate HPV8 E2 chromosome binding. 
Additionally, the structural fold of the RNA recognition motif (RRMs) of the 
heterogeneous nuclear ribonucleoprotein A1 is very similar to the dimeric beta barrel 
structure of the PV E2 CTD [57]. Crystallographic studies have shown that the RRMs 
form a compact alpha/beta structure in which the four beta strands form the major 
RNA binding surface [265]. Thus, the similarities in the structural fold of the RRMs 
and the E2-CTD, further, raise the possibility of the E2 protein interacting with RNA 
during chromosomal tethering.  
All of the above described observations propelled us to examine whether the 
HPV8 E2-chromosomal interaction was mediated through either protein-protein or 
protein-RNA interactions. One of the means to obtain a comprehensive list of cellular 




potential cellular factors that mediate E2 chromosomal association, our laboratory 
had previously isolated protein complexes in association with various E2 proteins 
using tandem affinity purification (TAP) and mass spectrometry (Moon Kyoo Jang, 
Eric Anderson and Alison McBride unpublished data). A number of proteins 
including nuclear matrix proteins, splicing factors, chromatin remodeling proteins and 
enzymes involved in post-translational modifications were identified in the HPV8 E2 
immunoprecipitated complexes (Moon Kyoo Jang, personal communication). 
Notably, a large number of HPV8 E2 protein complexes that were 
immunoprecipitated using TAP were RNA binding proteins, further highlighting a 
potential interaction of the E2 protein with RNA. One of the aims of the study 
described in this chapter was to determine if the chromosomal association of the 
truncated 240-255-CTD E2 protein correlated with interaction with the identified 
interacting partners of HPV8 E2 protein isolated from the TAP immunoprecipitated 
complexes. The objective of the study was to validate the interaction of the HPV8 E2 
protein with some of the candidate proteins identified in the TAP immunoprecipitated 
complex. Additionally, since the HPV8 E2 protein colocalizes with the RNA 
polymerase I transcription factor, upstream binding factor (UBF), we also examined 
if the full length and the truncated HPV8 E2 proteins interact with UBF in vivo. 
Hence, this study is useful in determining the role of cellular proteins in the molecular 
interaction of the HPV8 E2 protein with mitotic chromosomes. The second aim of the 
study described in this chapter was to analyze the role of RNA interactions in 




HPV8 E2 expressing CV-1 cells were treated with RNAse A and the mitotic 
localization of the E2 protein was examined by indirect immunoflourescence. 
Results 
Validation of interactions of the HPV8 E2 protein with candidate proteins 
identified from the TAP/mass spectrometry study 
For this study, we generated C33A cell lines expressing different flag tagged 
HPV8 E2 proteins. We included the full length HPV8 E2 protein along with a 
truncated version called 8E2ΔHC that lacks both the N-terminal domain and the C-
terminal half of the hinge region from residues 312-402.  We also expressed the wild-
type 240-255-CTD protein along with mutated E2 proteins S253A, R250A, R251A 
and the DNA binding defective protein (DB-) in the truncated 240-255-CTD 
background (Figure 6.1). Nuclear extracts prepared from E2 expressing cells were 
used to immunoprecipitate E2 protein using M2 flag beads. The protein complexes 
were eluted twice from the beads; once with a flag peptide and the second time with 
2% sarkosyl.  The eluates were mixed in a 1:1 ratio and separated on 4-12% gradient 
NuPage polyacrylamide gels with 5µl of input (10% protein). Using western blot 
analyses, we analyzed the complexes for some of the candidate proteins previously 
identified from the proteomics study as shown in figure 6.2. Cellular proteins such as 
SAF-A, matrin3, SRPK1 and WSTF were detected in the protein complexes 
immunoprecipitated with the full length HPV8 E2 protein but failed to show any 
interactions with the truncated 240-255-CTD protein. However, the following 
candidate proteins were selected for screening from the TAP/mass spectrometric 




SAF-A- Scaffold attachment factor A (SAF-A) or heterogeneous nuclear 
ribonucleoprotein-U (hnRNP-U) is a nuclear scaffold protein that interacts with the 
DNA sequences of nuclear matrix attachment regions (MARs). SAF-A interacts with 
the MAR sequences in the nuclear matrix via its SAF-box domain [139] and binds to 
RNA through its RGG-box domain [139]. The nuclear matrix is important for the 
structural organization of the nucleus and for maintaining the integrity of the nucleus. 
SAF-A plays an important role in chromatin organization and transcriptional 
regulation by interacting with proteins such as heterochromatic HP1 [8]. SAF-A has 
been recently reported to localize to mitotic spindles during mitosis and is an essential 
component of the mitotic apparatus [157]. RNAi mediated repression of SAF-A 
expression results in mitotic delay and abnormal alignment of chromosomes [157]. A 
recent genome-wide RNAi screening also identified SAF-A as one of the proteins 
required for chromosome segregation [121]. Moreover, SAF-A has also been 
observed on mitotic chromosomes in mouse cells where it binds to pericentromeric 
satellite regions [139]. It has been hypothesized that, to stably maintain viral genomes 
during persistent infection, PV E2 proteins might require additional cis-elements on 
the viral genome in addition to E2 binding sites. One such candidate is the (MARs) 
that could be potentially bound by the SAF-A protein. MAR sequences have been 
mapped to the PV genomes in vitro [253]. There are studies that show that the 
interaction of MAR elements with SAF -A allows for stable maintenance of a MAR 
element containing plasmid by attachment to cellular mitotic chromosomes [128]. 
Since the above described evidence implicated SAF-A in genome maintenance and 








Schematic representation of the different HPV8 E2 proteins used for the 
immunoprecipitation assay. These included the full length HPV8 E2 protein (8E2), a 
truncated version that lacks both the N-terminal domain and the C-terminal half of the 
hinge region from residues 312-402 (8E2ΔHC), the 240-255-CTD wild-type protein, 
mutated E2 proteins S253A, R250A, R251A and the DNA binding defective protein 















played any role in the chromosome tethering function of the HPV8 E2 protein. In the 
western blot analysis, interaction of SAF-A could be observed with the full length 
HPV8 E2 protein and the truncated 8E2ΔHC protein. This indicates that SAF-A 
interacts with the full length HPV8 E2 protein and likely plays a role in E2 functions. 
But no SAF-A was immunoprecipitated with the wild-type 240-255-CTD protein 
compared to the control samples.  
 
U5 116 – U5 is a small nuclear ribonucleoprotein (snRNP) of 116 kDa molecular 
weight and is a component of the spliceosome complex. It is a GTP binding protein 
involved in splicing [153]. This snRNP protein undergoes dephosphorylation by the 
PP1/PP2A phosphatases during the splicing process [238]. As described previously, 
HPV8 and HPV5 E2 protein interact with components of the spliceosome complex 
and hence, we examined if U5 116 protein was immunoprecipitated with the different 
HPV8 E2 proteins. In our immunoprecipitation assay, we could not demonstrate any 
specific interaction between U5 116 and HPV8 E2 proteins. 
 
SRPK1- Serine-arginine protein kinase 1 (SRPK1) is a kinase that specifically 
phosphorylates serine residues within the serine-arginine (SR) or arginine-serine (RS) 
dipeptide motifs. This kinase phosphorylates SR splicing proteins in a cell cycle 
regulated manner, which is important for the assembly of the spliceosome complex 
and for the splicing process to form mature mRNAs [95]. Moreover, different SRPKs 
also play a role during viral infection. Viral proteins such as ICP27 of herpes simplex 




interaction of ICP27 with SRPK results in lower host splicing activity (Bell, Martin et 
al., 2007). The E1^E4 protein is phosphorylated by SRPK [21,230]. In addition, 
SRPKs interact with nuclear matrix protein scaffold attachment factor (SAF-B) 
proteins, which negatively regulate SRPK activities [259]. The hinge regions of E2 
proteins from the betapapillomaviruses such as HPV8 and HPV5 are rich in arginine-
serine/serine-arginine repeats which make them ideal candidate substrates for SRPK 
activities. Additionally, HPV5 and HPV8 E2 proteins have been shown to colocalize 
with the spliceosome factor SC-35 [141,235]. Furthermore, many splicing factor 
proteins are a part of the TAP immunoprecipitated HPV8 E2 protein complexes. 
Given the possibility of a functional interaction between the HPV8 E2 protein and 
SRPK1, we wanted to determine if SRPK1 could be immunoprecipitated with HPV8 
E2 proteins. It is clear that both the full length HPV8 E2 protein and the 8E2ΔHC can 
specifically immunoprecipitate SRPK1. These interactions are potentially mediated 
through the previously described RS/SR rich domains of the hinge region of E2 
proteins. However, the 240-255-CTD wild-type protein does not interact with 
SRPK1. The 240-255-CTD protein carries only 16 residues of the hinge fused to the 
CTD and thus, lacks most or all of the RS/SR dipeptide motifs required for 
interaction with splicing factors and possibly SRPK1. Hence, it appears that SRPK1 
interacts with the full length E2 protein and might be involved in playing a role in the 
HPV8 lifecycle but is most likely not involved in chromosome binding. 
 
WSTF- Williams syndrome transcription factor (WSTF) is a subunit of the ATP-




including the nucleosome assembly complex (WINAC), WSTF-ISWI chromatin 
remodeling complex (WICH) and B-WICH. It is involved in a number of diverse 
functions such as chromatin assembly, histone modifications, RNA polymerase I and 
III transcription and DNA repair [17]. Members of the B-WICH family have been 
found to play a role in nucleosome remodeling to allow RNA polymerase I and III 
gene transcription. Although the mechanism is unclear, WSTF, along with other 
chromatin remodelers, has also been reported to regulate ribosomal gene expression 
[202]. Additionally WSTF accumulates at pericentromeric heterochromatin in mouse 
cells and stably binds to mitotic chromosomes [33]. Since, the HPV8 E2 protein also 
targets the pericentromeric regions on mitotic chromosomes and binds to ribosomal 
DNA, we wanted to examine whether there is any in vivo interaction between WSTF 
and the E2 protein. From the complex purification assay, it appears that the full length 
HPV8 E2 protein and the truncated 8E2ΔHC protein do show some interaction with 
WSTF compared to the pMEP control. However, WSTF was not a part of the 
immune-complex pulled down with the truncated 240-255-CTD wild-type protein. 
Thus, interaction of WSTF with the HPV8 E2 protein indicates it is likely involved in 
mediating some function of E2 protein, however, it is most likely not involved in the 
HPV8 E2 tethering function. 
 
PRMT5- Protein arginine methyltransferase 5 (PRMT5) are members of the 
methyltransferase family that methylate proteins at the arginine residues within the 
RGG, GRG or RXR motifs. They have been implicated in a number of cellular 




protein transport [195,272].  Interestingly, PRMT5 has been also shown to methylate 
the chromosome binding regions of EBNA1 tethering protein of EBV [240].  
Although most of the EBNA1 protein is expressed in the nucleus, inhibition of 
PRMT5 methylation altered the localization of the EBNA1 protein resulting in a peri-
nucleolar ring suggesting that, it might be involved in regulating interaction of 
EBNA1 with RNA or RNA binding proteins [240]. Since the chromosome binding 
region of the HPV8 E2 protein contains GR dipeptides similar to the EBNA1 
chromosome binding region, we wanted to investigate whether PRMT5 played a role 
in the tethering function of HPV8 E2. In the complex purification assay, we could not 
observe any specific interactions between PRMT5 and the HPV8 E2 proteins.  
 
UBF- UBF is an RNA polymerase I transcription factor that plays an important role 
in maintaining the euchromatic state of rDNA chromatin. It is one of the few 
transcription factors that remain bound to chromosomes during mitosis when rDNA 
transcription is shut down [92]. UBF binds not only to high affinity sites on the 
promoter region but also binds to the transcribed region of the rDNA genes [217]. 
Since the HPV8 E2 protein localizes to the rDNA loci and colocalizes with RNA 
polymerase I UBF, we wanted to examine if HPV8 E2 protein interacts in vivo with 
UBF. The immunoprecipitation assay revealed no interaction between the different 
HPV8 proteins and UBF. However, UBF might weakly interact with the HPV8 E2 
protein, such that, complex isolation using high salt results in loss of weakly 
interacting partners or conversely, it might be tightly bound to chromosomes such 




TRIM28- Tripartite motif-containing protein 28 (TRIM28) or KAP-1(Krab-
associated protein-1) is a cofactor of Kruppel-associated box zinc finger proteins 
(KRAB-ZFPs) that act as transcriptional repressors. It interacts with the 
multimolecular repressor complex containing histone methyl transferases (SETDB1) 
and histone deacetylases (HDACs) to repress gene expression [7]. It also interacts and 
colocalizes with the heterochromatin protein (HP1) and results in heterochromatin 
mediated gene silencing [267]. Recently, a truncated E2 protein of HPV31 known as 
E8^E2C protein was reported to interact with cellular repressor molecules such as 
HDACs, SETDB1 and the TRIM28 protein [9]. The E8^E2C protein lacks the N-
terminal domain of E2, which is instead replaced with the 12 residues long E8 
domain fused to the CTD of the E2 protein. This truncated E2 protein acts as a 
repressor of E2 mediated replication and transcription functions [250]. Interaction of 
the E8 domain with TRIM28 is thought to be one of the mechanisms of E8^E2 
mediated transcriptional repression [9]. In our immunoprecipitation assay, no specific 
interaction was observed with the different HPV8 E2 proteins. 
 
Nucleophosmin/B23- B23 protein has been shown to associate with rRNA to 
stimulate rRNA transcription. But during mitosis inactivation of its RNA binding 
activity by cdc2 kinase-mediated phosphorylation causes B23 to be released from 
chromatin. From the complex purification studies, it is interesting to note that B23 
expression is almost completely lost in the cells expressing the HPV8 full length E2 
and DNA binding defective E2 proteins as observed in the input samples. Whether 




E2 protein needs to be further investigated. Some B23 is immunoprecipitated with the 
8E2ΔHC protein suggesting, that the 8E2ΔHC can interact with B23. However, the 
truncated 240-255-CTD protein does not interact with B23. 
 
WDR5- WD repeat containing protein 5 (WDR5) is a member of the 
methyltransferase family mixed-lineage leukemia (MLL) complex that methylates 
lysine 4 residue of histone H3. This interaction is also important for rDNA 
transcription [82]. Additionally, WDR5 also associates with chromatin remodeling 
proteins such as chromodomain helicase DNA binding protein 8 (CHD8) [256]. It has 
been recently shown to be involved in induction of type I IFN response triggered 
during viral infection [156]. Although in the immunoprecipitation assay no specific 
interaction was observed between WDR5 and the different HPV8 E2 proteins, the 
level of WDR5 protein appeared to be reduced in cells expressing the full length 
HPV8 E2 protein. It would be interesting to investigate the effect of WDR5 down 
regulation on the papillomaviral life cycle.  
 
Matrin 3- Matrin 3 is another abundant protein present in the nuclear matrix that 
binds DNA through MAR sequences. It is involved in many nuclear processes 
including retention of hyper-edited RNA within the nucleus [285]  and is mainly 
observed in the euchromatic regions of the nucleus [159]. Additionally, matrin 3 has 
been demonstrated to colocalize and co-immunoprecipitate with SAF-A and other 






Validation of the protein interactions in the immunoprecipitated HPV8 E2 protein 
complexes. C33A cell lines expressing full length HPV8 E2, truncated 8E2ΔHC, 240-
255-CTD WT, mutated E2 proteins S253A, R250A, R251A and the DNA binding 
defective protein also in the truncated 240-255-CTD background were used to 
prepare nuclear extracts (NE). E2 proteins were immunoprecipitated with M2 anti-
flag antibody and the immunoprecipitated complexes were analyzed by western 









 involved in RNA processing and chromatin structural organization. Furthermore, 
viral kinases such as alphaherpesvirus US3/ORF66 protein kinase phosphorylate 
matrin 3 and affect its nuclear localization [77]. However in the immunoprecipitation  
assay, matrin 3 co-immunoprecipitated with only full-length HPV8 E2 protein but did 
not interact with any other truncated HPV8 E2 proteins. Further investigations are 
required to determine whether matrin 3 is involved in regulating the functions of 
HPV8 E2 along with the SAF-A protein.  
 
PP2A- Protein phosphatase 2A (PP2A) belongs to the family of protein 
serine/threonine phosphatases that are important regulators of mitosis. PP2A plays a 
crucial role in regulating sister chromatid cohesion during mitosis. It has also been 
implicated in preventing premature mitotic exit by dephosphorylating many mitotic 
proteins [258]. PP2A acts as a tumor suppressor and hence is targeted by DNA tumor 
viruses.  In the case of small DNA tumor virus (SV40), small t antigen inhibits PP2A 
activity. This inhibition contributes to SV40 mediated transformation [12]. 
Additionally, PP2A has been shown to a play a role in activation of the LCR region 
of HPV16 through its interaction with Sp1 [246]. However, in our 
immunoprecipitation assay PP2A was not immunoprecipitated in complex with any 
of the HPV8 E2 proteins, suggesting that there is no interaction between PP2A and 







RNAse treatment of E2 expressing cells did not affect the chromosome binding 
function of the HPV8 E2 protein  
From the immunoprecipitation assays we could not identify a protein binding 
partner for HPV8 E2 and so we wanted to investigate the role of RNA binding in E2-
chromosomal association. To examine the role of RNA interactions in mediating the 
chromosome binding functions of the HPV8 E2 protein, E2 expressing CV-1 cells 
were seeded onto glass slides and grown for two days. E2 expression was induced for 
4h with cadmium sulfate. Following E2 induction, the cells were permeabilized with 
PBS containing 0.1% Triton X 100 and 0.1% Tween-20 for 15 minutes at room 
temperature. The permeabilized cells were treated with 1mg/ml RNAse A for 10 
minutes at room temperature. Following RNAse treatment, the cells were washed 
twice with 1X PBS and fixed in 4% PFA for 20 minutes.  
 Fibrillarin staining is often used as a marker for nucleolar RNA staining. It 
was used as a marker to detect efficiency of the RNAse A digestion. Fibrillarin is a 
component of the snRNP particle and is involved in ribosomal RNA maturation. In 
normal cells, fibrillarin staining gives a globular pattern within the nucleolus. 
However, following RNAse A treatment, the globular appearance is lost and staining 
is uniform and dispersed (Figure 6.3). After RNAse treatment, the cells were stained 
for immunofluorescence with anti-flag and anti-fibrillarin antibodies and observed by 
confocal microscopy (Figure 6.3). From the microscopic analysis, it appears that 
treatment of E2 expressing CV-1 cells with RNAse A does not affect the 
chromosome binding phenotype of the HPV8 E2 protein. However following RNAse 




pattern, but the HPV8 E2 protein is still bound to mitotic chromosomes as distinct 
foci.  
To confirm these findings, the E2 expressing cells were stained with SYTO 
RNASelect green, a fluorescent cell stain that selectively stains RNA (Figure 6.4). 
This stain was used to further confirm the efficiency of RNAse A treatment. It 
exhibits bright green fluorescence when bound to RNA and weak fluorescence when 
bound to DNA. Thus, under normal conditions, maximal fluorescence is seen in the 
nucleoli with weak staining in the rest of the nucleus. However, following RNAse 
treatment, the nucleolar staining pattern is completely lost and the intensity of nuclear 
staining is reduced significantly. However, the SYTO RNASelect stain is sensitive to 
formaldehyde fixation and hence, the samples had to be fixed instead using methanol-
acetone. E2 expressing cells were permeabilized with 0.1% Triton X 100, treated with 
RNAse A for 10 minutes at room temperature followed by fixation with methanol and 
acetone at -20OC. Although co-staining with E2 weakens RNASelect RNA staining, it 
was clear that the SYTO RNASelect stained the nucleolus brighter than the nuclear 
staining in the absence of RNAse A treatment. But following RNAse treatment, the 
nucleolar staining pattern was lost. On the contrary, the HPV8 E2 protein was 








RNAse A treatment of 240-255-CTD expressing CV-1 cells does not affect HPV8 E2 
chromosome binding. CV-1 cells expressing HPV8 E2 protein were either untreated 
or treated with RNAse A and examined for E2 and fibrillarin localization in 
interphase cells or on mitotic chromosomes using indirect immunofluorescence. E2 
was detected using anti-flag antibody (green), fibrillarin using anti-fibrillarin antibody 















Thus, in the above experiments the association of the HPV8 E2 protein with 
mitotic chromosomes was not affected by RNAse treatment. 
Discussion 
 
Though one of the objectives of this study was to validate cellular factors 
interacting with the HPV8 E2 protein that might be involved in mediating the E2-
chromosomal association function, we were unable to conclusively identify a 
chromosome tethering partner of the HPV8 E2 protein. For the immunoprecipitation 
assay, we used HPV8 E2 wild-type and mutated proteins. These included the full 
length HPV8 E2 protein, truncated 240-255-CTD wild-type protein and the S253A 
mutated E2 protein. Using indirect immunofluorescence, we have shown that both the 
full length HPV8 E2 and the truncated 240-255-CTD E2 proteins bind mitotic 
chromosomes as large distinct pericentromeric foci. Moreover, the wild-type protein 
can bind chromosomes whereas the S253A mutated E2 protein is defective in 
chromosome binding. Thus, one would expect that the proteins involved in 
chromosome binding will not be immunoprecipitated with S253 mutated protein. Our 
rationale behind using these proteins for the complex purification assay was that, we 
could possibly identify an interacting partner for HPV8 E2 protein by comparing the 
complexes immunoprecipitated by these proteins.  
Some cellular proteins such as SAF-A, matrin3, SRPK1 and WSTF interact 
with the full length HPV8 E2 protein but failed to show any interactions with the 
truncated 240-255-CTD protein. Notably, since proteins like SAF-A, matrin3 and 






Full length HPV8 E2 chromosomal association is not mediated through RNA binding. 
CV-1 cells expressing HPV8 E2 protein were either untreated or treated with RNAse 
A and examined for E2 localization in interphase cells or on mitotic chromosomes 
using indirect immunofluorescence. (A) Efficiency of RNAse treatment was detected 
using the RNASelect stain in 2 examples of untreated and RNAse treated samples. 
(B) Co-staining of E2 and RNA using anti-flag antibody (red), RNASelect stain 
(green), respectively. Cellular DNA was stained using DAPI (blue). In B, the first 






interaction of these proteins with HPV8 E2 could be mediated through binding to 
RNA rather than actual protein-protein interactions. This is not unexpected since, 
many RNA binding proteins were identified in the protein complexes 
immunoprecipitated in the original TAP/mass spectrometry study (Moon Kyoo Jang, 
personal communication). Moreover as described previously, the HPV8 E2 hinge 
region is rich in RG repeats that might have RNA binding properties and the CTD 
shows similarity to the structure fold of the RRMs.  Thus, one of the caveats of our 
immunoprecipitation assay was that we did not treat protein complexes with RNAse 
before immunoprecipitating the complexes. Hence, we cannot conclusively state 
whether interaction with these proteins is mediated through direct protein-protein 
binding or through binding to RNA.  
In the case of the SRPK1 protein, interaction with the HPV8 E2 protein is not 
surprising considering the fact that the hinge region of the E2 protein carries a 
number of SR/RS dipeptide motifs that are potential consensus sites for the SRPK1. 
Additionally, the HPV8 E2 proteins have been shown to colocalize with splicing 
factor SC35 suggesting their involvement in mRNA transcript splicing. Thus, further 
detailed studies could shed light on the role and the mechanism of the interaction of 
SRPK1 with E2 protein in the HPV8 life cycle. Notably, the expression levels of the 
proteins nucleophosmin/B23 and WDR5 were found to be low in the full length 
HPV8 E2 expressing cells. Likewise the levels of B23 have been reported to be low 
in cells undergoing apoptosis and differentiation [198][119]. Moreover, high-risk 
HPV16 and HPV18 E2 proteins have been shown to induce apoptosis in different cell 




of nucleophosmin/B23 and WDR5 proteins on the functions of the full length HPV8 
E2 protein in future studies. Notably, there was no interaction observed between these 
proteins and the HPV8 E2 proteins in the immunoprecipitation assay. 
None of the candidate proteins tested interacted with the truncated 240-255-
CTD protein. One of the reasons for the differences in the interactions of the full 
length HPV8 E2 protein and the truncated 240-255-CTD protein with different 
cellular proteins could be attributed to the fact that the truncated 240-255-CTD 
protein lacks many regions of interaction present in the full length protein. Another 
explanation for the lack of interactions we observed in our validation study could be 
the use of high salt concentration in our extraction protocol that resulted in proteins 
with weaker interactions to be lost during purification. Conversely, it is also possible 
that proteins that are tightly bound to chromatin are not extracted at the salt 
concentration used for purification. Although many different candidate proteins that 
seemed relevant to HPV8 E2 functions were screened in the study, the chromosome 
tethering partner of the HPV8 E2 protein still remains elusive.  
The second objective of the study was to examine if the interaction of the 
HPV8 E2 protein with mitotic chromosomes was mediated through RNA binding. 
Although we did not see any effect on E2-chromosomal association following RNAse 
treatment, it is possible that E2 masks the interaction of RNA with mitotic 
chromosomes and hence, the E2-RNA interaction is not inhibited by RNAse 
treatment. Notably, the markers fibrillarin and RNASelect, used to detect efficiency 




confirming the efficiency of RNAse treatment. Hence, in our assay RNAse treatment 
did not abrogate the E2-chromosomal association. 
 
As described previously, the E2 protein is multi-functional and is involved in 
viral DNA replication and transcription in addition to genome partitioning. In the 
following chapter (Chapter 7), we examined whether alanine substitution of residues 




























Chapter 7:  The effect of the chromosome binding motif on the 
transactivation and replication functions of the HPV8 E2 protein 
Introduction 
 
In addition to its role in viral genome maintenance, the E2 protein functions in 
transcriptional regulation and viral genome replication. As described previously, the 
major determinants of the transactivation function of the E2 proteins have been 
mapped to the N-terminal domain with residues R37 and I73 identified as being 
important for Brd4 mediated transcriptional regulation [35,167]. Transcriptional 
activation by E2 involves interaction with many different transcription factors such as 
CBP/p300 and Sp1 [22,34,104,145,150,199]. There are also reports that E2 proteins 
are capable of stimulating transcription in the absence of the E2 binding sites 
[107,111]. In the case of the HPV8 E2 protein, the hinge region has also been shown 
to be capable of transactivation [248]. The hinge region of the HPV8 E2 protein was 
observed to interact with the transcription factor Sp1 and activate transcription of the 
human promoter p21WAF1/CIP1 [248].  Thus, one of the objectives of this study was to 
determine if alanine substitutions of residues R250 or S253 within the chromosome 
binding region affected its transcriptional activation function. To this end, we used 
the luciferase assay system to determine the transactivation function of the mutated 
HPV8 E2 proteins. 
PV genome replication is dependent on the host cellular replication machinery 
and is tightly linked to the differentiation state of the host keratinocytes [288]. The PV 
replication cycle can be divided into three different stages: the first stage involves 




second, maintenance replication that involves partitioning of the viral genome to 
daughter cells at the end of mitosis; third, vegetative amplification of the viral 
genome that provides genomes for packaging into newly synthesized viral particles. 
The PV genome undergoes bidirectional (theta-type) replication that requires the viral 
replication proteins E1 and E2 in addition to the viral origin of replication [211,261].  
PVs are highly species and tissue specific, which limits the availability of the 
cell types that can support viral replication.  This has been particularly challenging in 
the case of betapapillomaviruses that infect the cutaneous epithelia of the hosts. Until 
recently, no cell culture based system had been reported that could be used to study 
their genome replication. However, in contrast replication of PV origin containing 
plasmids has been achieved relatively easily in various cell types, by co-transfecting, 
expression vectors encoding viral proteins E1 and E2 along with the plasmid 
containing the origin [48,211]. However, recently the human osteosarcoma cell line 
U2OS was reported to support replication of different papillomaviral genomes 
including high-risk, low-risk and betapapillomaviruses [93]. Thus, in our study to 
examine the effect of R250 and S253 mutations on the replication function of the 
HPV8 E2 protein, performed HPV8 replication assays in U2OS cells. 
 
Results 
Alanine substitutions of residues R250 and S253 within the HPV8 E2 hinge 





For the transactivation assay, we used pMEP-E2 expression plasmids 
expressing either full length HPV8 E2 protein or HPV8 E2 proteins carrying 
mutations R250A, S253A or the double mutation R250A/S253A in the full length 
background. BPV1 E2 was included as a positive control and pMEP4 as a negative 
control. The luciferase gene was encoded by the plasmid pBS1073 that consisted of 
four alpha HPV E2 binding sites upstream of the thymidine kinase promoter. CV-1 
cells were co-transfected in triplicate with different concentrations of pMEP-E2 
expression plasmids ranging from 25ng, 100ng, 250ng, 500ng to 1000ng and 1μg of 
the pBS1073 plasmid using the Fugene 6 transfection reagent. Cells were harvested 
40 h post transfection in cell culture lysis reagent. Luciferase activity was measured 
as relative light units per second or RLU/sec using the Zylux Femtomaster FB12 
luminometer. In the luciferase assay, there is a dose dependent increase in the 
transactivation of the luciferase gene by the different E2 proteins (Figure 7.1). As E2 
expression increases from lower levels to higher levels with respect to increasing 
concentration of E2 expression plasmids, there is a concomitant increase in the levels 
of luciferase activity. However, the alanine substitutions of R250 or S253 do not 
significantly affect the transactivation function of the HPV8 E2 protein. The overall 
levels of transactivation appear to be similar at different concentrations of the wild-  
type E2 protein and the alanine substituted E2 proteins (Figure 7.1). The HPV8 and 
BPV1 E2 proteins transactivate to similar levels, although, at the highest plasmid 
concentration, the levels of luciferase activity induced by BPV1 E2 drops likely due 
to high expression of the E2 protein. At high concentrations of the E2 protein, the 




transcriptional activation in a process known as squelching [2]. Thus from the 
luciferase transactivation assay, we observe that the alanine substitution of residues 
R250 and S253 does not affect the transactivation function of the HPV8 E2 protein.  
Alanine substitutions of residues R250 and S253 within the HPV8 E2 hinge 
region have no effect on the replication function of the HPV8 E2 protein in 
U2OS cells  
To examine the replication of the HPV8 genome in U2OS cells, we 
transfected them with either recircularized HPV8 wild-type genome or HPV8 
genomes carrying either R250A or S253A mutations in the E2 gene.  Low-molecular 
weight DNA was isolated at three days post-transfection using the Hirt DNA 
extraction protocol to determine and compare the levels of transient HPV replication 
in U2OS cells.  The isolated DNA was cleaved with BamHI to linearize the HPV 
genome and with DpnI. Digestion with the DpnI enzyme cleaves the methylated input 
DNA. Following Southern blot analysis using HPV8 wild-type genome as probe, we 
observed that all HPV8 genomes replicated in U2OS cells irrespective of the presence 
of mutations within the E2 gene (data not shown). Meanwhile, a transient replication 







R250A and S253A mutations within the HPV8 E2 hinge do not affect the 
transactivation function of the HPV8 E2 protein. CV-1 cells were co-transfected in 
triplicate with different concentrations of pMEP-E2 expression plasmids ranging 
from 25ng, 100ng, 250ng, 500ng to 1000ng and 1μg of the pBS1073 plasmid.  
pMEP-E2 expression plasmids encoding HPV8 E2 full length protein, HPV8 E2 
proteins carrying mutations R250A, S253A or the double mutation R250A/S253A in 
the full length background, BPV1 E2 and pMEP4 were used for the assay. (A) 
Graphical representation of the levels of luciferase activity recorded as relative light 
units per second (RLU/second) for the different E2 plasmids that were transfected 
into CV-1 cells. The error bars represent the standard deviation of the experiments 
done in triplicate. (B) Immunoblot showing expression levels of the wild-type and 











termination linker inserted into the E2 ORF indicated that HPV8 genome was capable 
of replicating in the absence of E2 protein in U2OS cells (Raymond Fernalld, 
personal communication). Hence, for our studies aimed at examining the role of wild-
type and mutated E2 proteins on the HPV8 genome replication, U2OS cells did not 
prove to be a useful replication assay system. However, we employed the U2OS 
replication assay to examine the replication of the plasmid containing the HPV8 
origin in the presence of plasmids expressing the wild-type HPV8 E1 protein and 
wild-type or mutated HPV8 E2 proteins (Figure 7.2). In our assay, we included 
plasmids that expressed either the R250A mutated or S253A mutated HPV8 E2 
proteins in addition to plasmids expressing the wild-type E1 or E2 proteins. We also 
included control plasmids that did not express either HPV8 E1 or E2 proteins. 
Moreover, we also used a plasmid that encoded a mutated HPV8 E2 protein that was 
defective in binding to E2 binding sites. Following day after transfection, E1 and E2 
protein expression was induced at low levels with 0.1μΜ cadmium sulfate.  Low 
molecular weight DNA was isolated from U2OS cells three days post transfection and 
digested with EcoRI and DpnI. Southern blot analysis with the HPV8 ori plasmid as 
probe revealed that, the HPV8 ori plasmids could replicate transiently in the presence 
of the R250A and S253A mutated E2 proteins. However, no replication was observed 
in the absence of the wild-type E1 or E2 protein. Notably in the presence of the 
mutated HPV8 E2 protein carrying the DNA binding mutation, no replication of the 
ori plasmid was observed (Figure 7.2). These observations indicate that the 







HPV8 ori plasmid can replicate in the presence of both R250A or S253A mutated E2 
in U2OS cells. U2OS cells were co-transfected with HPV8 ori plasmid, wild-type 
HPV8 E1 and wild-type or mutated HPV8 E2 (R250A, S253A, RSAA, E2DB) 
expressing pMEP plasmids. RSAA is the HPV8 E2 protein carrying R250A and 
S253A mutations. Empty vectors pMEP4 (pM4) and pMEP9 (pM9) were used as 
negative controls. Low molecular weight DNA was digested with EcoRI and DpnI. 
Lanes labeled 0.01ng and 0.1ng marker represent the EcoRI linearized HPV8 ori 





Additionally, these results also show that R250A and S253A mutations within the 
HPV8 E2 protein do not have any effects on the replication of the HPV8 ori plasmid 
in U2OS cells. 
Discussion 
 
In the studies presented in this chapter, we used a luciferase assay and a 
replication assay in U2OS cells to examine the effects of alanine substitutions of 
R250 and S253 on the HPV8 E2 functions of transcriptional activation and 
replication, respectively. Although, we did not observe significant differences in the 
functions of the wild-type and the E2 mutated proteins, it is premature to conclude 
that these mutations do not affect E2 functions other than chromosome binding. One 
of the best examples illustrating such a scenario was observed in the studies 
characterizing the phenotype of the BPV1 E2 mutation at phosphorylation residue, 
S301. Substitution of S301 with alanine within E2 in an expression plasmid did not 
affect any of the E2 functions. However, when the alanine substitutions were made in 
the E2 ORF in the context of the entire BPV1 genome, increased E2-specific 
transactivation and a high genome copy number phenotype were observed [166]. 
Similarly, in the case of the HPV8 E2 proteins, it is possible that the phenotypes 
observed with serine to alanine substitutions in the E2 gene expressed from an 
expression plasmid are different from those observed in the context of the entire 
HPV8 genome. We cannot rule out the possibility of E2 mutations alters its 
expression when expressed from the viral genome. As described previously, we have 
shown that both the R250A and S253A mutated E2 proteins are defective in 




role of S253 phosphorylation in chromosome binding, we propose that as cells exit 
from mitosis during cell cycle, E2 proteins are dephosphorylated at S253 residue such 
that they are available to perform the transactivation function of the E2 protein. In 
such a scenario, it is possible that these mutations do not have an effect on the HPV8 
E2 functions. However, further detailed studies in the background of the HPV8 
genome are needed to conclusively demonstrate the effect of hinge mutations on the 




















Chapter 8: Summary and general discussion 
 
Summary of the findings described in the dissertation 
A key challenge for all persistent viruses infecting replicating cells is to 
maintain their viral genomes in dividing cells. Several studies have shown that E2 
proteins from different PVs bind mitotic chromosomes as a means to tether the viral 
genome; however, there are variations to this theme from one genus to another. 
Different E2 proteins show varied patterns of mitotic chromosome binding indicating 
that they associate with distinct chromosomal targets [191,205,262]. We assume that, 
analogous to other PVs, HPV8 E2-chromosomal association is crucial for the virus to 
tether its genome to host chromosomes during persistent infection.  
To unravel the mechanisms of HPV8 E2 chromosomal interactions, we 
identified a 16 amino acid long region in the hinge that, when fused to CTD was 
crucial and sufficient for E2 chromosomal association. Further mutational analyses 
revealed that two specific residues in the mapped hinge region, R250 and S253, 
which lie within a common RXXS motif, are critical for the E2 mitotic chromosome 
binding. Notably, the identified RXXS motif, and residues R250 and S253, are 
completely conserved among the betapapillomaviruses that have been sequenced to 
date. Thus, the fact that this region is evolutionarily highly conserved in an otherwise 
divergent part of the beta E2 proteins, underscores its functional significance in the 




it would be interesting to determine if this conserved hinge region plays additional 
roles in the biology of the beta PVs. 
In comparison with other PVs, a unique feature of beta PV E2 proteins is the 
unusual composition and length of their hinge region. The hinge of beta PVs is 200 
amino acids long and contains a large number of RG and RS dipeptide repeats. The 
RS dipeptide repeats of beta E2 proteins such as HPV5 and HPV8 are important for 
localization to nuclear speckles that are enriched in splicing factors and are adjacent 
to active transcription sites [141,235]. We observed that progressive removal of SR 
dipeptide motifs in the HPV8 E2 hinge results in loss of nuclear speckle localization. 
Additionally, for nuclear speckle localization the CTD of HPV8 E2 is essential. 
Regulation of the HPV8 E2 chromosome binding function  
In our attempt to understand the regulation of the HPV8 E2 chromosome 
binding function, we investigated the role of S253 phosphorylation. We demonstrated 
that S253 is most likely phosphorylated by PKA. Further S253 phosphorylation 
specifically increased during the S-phase of the cell cycle and remained high through 
mitosis, suggesting that phosphorylated E2 bound mitotic chromosomes. Our finding 
that PKA phosphorylates S253 in S-phase is in accordance with studies that have 
shown that PKA is active in the S-phase during which it is required for chromosomal 
DNA replication [53]. Notably, various PV proteins appear to utilize the cellular PKA 
pathway to influence the process of malignant progression. For example, PKA is 
involved in HPV16 E7 mediated transformation by promoting the process of cellular 




degradation of the Bax protein and thereby, inhibits apoptosis of transformed 
epithelial cells [189]. Additionally, the PDZ binding motif of high-risk HPV E6 
proteins is phosphorylated by PKA [138]. The expression of the E6 and E7 proteins is 
regulated by the E2 protein, with increased E2 expression resulting in repression of 
E6 and E7 [70]. Moreover, E2 protein has been shown to bind to both E6 and E7. 
Binding of E2 to E7 increases the stability of E7 but reduces its transforming 
potential [87]. Similarly, binding of E2 to E6 results in inhibition of E6 mediated 
degradation of PDZ proteins [100]. Since, E2 potentially interacts with E6 and E7, it 
is intriguing to think how the interaction of E2, E6 and E7 proteins will be affected by 
PKA during the course of viral infection when the levels and activities of each of 
these proteins changes. Likewise, it is essential to examine whether there is a 
differential regulation of PKA activity as cells transition from basal layer to 
differentiated layers. Analyzing the effect of PKA activity on E2 proteins in the 
presence of other PV proteins will ultimately help to determine how all these findings 
fit in the context of viral life cycle. Our findings clearly add another dimension to the 
role of PKA in the HPV lifecycle.  
14-3-3 proteins are members of a highly conserved family of small acidic 
proteins [3]. These specifically bind to phosphorylated proteins and alter the sub-
cellular localization, protein-protein interactions and enzymatic properties of the 
target proteins [3]. These proteins are involved in regulating a myriad of cellular 
processes including cell cycle regulation, apoptosis, cell proliferation, chromatin 
structure, metabolism, nucleolar function, among others [276]. A proteomics study 




mitosis identified a number of novel protein partners [172]. Among the proteins 
identified, one protein of interest was a protein kinase A anchoring protein (AKAP) 
[172]. AKAP plays an important role in regulating PKA activities in cells by 
controlling their spatial distribution. AKAP95 is responsible for recruitment of PKA 
to mitotic chromosomes and is important for chromatin condensation at mitosis 
[50,142]. Moreover, the consensus binding site of 14-3-3 proteins, RSXpSXP, 
somewhat resembles the R-X-X-S motif observed in the HPV8 E2 chromosome 
binding region (reviewed in [112]). To determine whether 14-3-3 proteins interact 
with the phosphorylated E2 protein we can perform protein immunoprecipitation 
assays and probe for the different isoforms of 14-3-3 proteins. Thus, examining 
whether 14-3-3 proteins are involved in regulating the HPV8 E2 chromosome binding 
function will provide further insights into the regulation of chromosome binding 
function. Additionally, recent studies have identified 14-3-3 sigma (also called 
stratifin) as the isoform that is expressed in keratinocytes (reviewed in [112]). It is 
believed to be a tumor suppressive gene and is silenced in many carcinomas 
(reviewed in [112]). Co-culturing of keratinocytes with fibroblasts results in secretion 
of statifin in differentiated keratinocytes that in turn results in increased expression of 
matrix metalloproteinase 1 (MMP1) (reviewed in [112]). Importantly, HPV8 E2 
protein was recently shown to upregulate expression of another metalloproteinase, 
MMP9 in keratinocytes by binding to the E2 binding sites within the MMP9 promoter 
[5]. It would therefore be interesting to determine if there is any crosstalk between E2, 





HPV 8 E2 phosphorylation and E2 stability 
One of the observed effects of PKA phosphorylation of HPV8 E2 is that it 
enhanced both chromatin binding and protein half-life. However, it is unclear whether 
E2 phosphorylation directly regulates protein half-life or whether phosphorylation 
regulates chromatin binding and chromatin bound E2 has a much longer half-life than 
unbound protein. Nonetheless, our findings are supported by a recent report that states 
that HPV16 E2 has both increased phosphorylation and extended half-life in S-phase 
[129]. Another recent study showed that the EBNA1 chromosome binding GR repeat 
regions inhibit its proteasomal degradation [52]. These findings are in fact in 
accordance with the hypothesis that phosphorylation of S253 regulates chromatin 
binding and chromatin bound E2 has a much longer half-life than unbound protein as 
was observed in the pulse-chase experiments in chapter 4. It is important to keep in 
mind that our studies were conducted in the background of the truncated HPV8 E2 
protein that consists of the 16 residues long chromosome binding hinge region fused 
to the CTD. In preliminary studies conducted in our laboratory, we observed that the 
full length HPV8 E2 protein appears to have a number of elements distributed within 
the hinge region that are responsible for regulating E2 stability (Alison McBride, 
personal communication). It is unlikely that the 16 amino acid long hinge region 
alone is responsible for regulating E2 stability. We believe that the enhanced 
phosphorylation of S253 residue within the chromosome binding region of HPV8 E2 
results in increased chromatin binding and thus, longer half-life of chromosome 







Model to explain the regulation of the HPV8 E2 chromosome binding by PKA 
phosphorylation. PKA phosphorylates the E2 protein at S253 residue during S-phase, 
resulting in a stabilized population of E2 that binds to chromatin strongly and can be 
observed as E2 associated pericentromeric foci in interphase. In mitosis, 
phosphorylated E2 remains bound as pericentromeric foci and unphosphorylated E2 












Based on our findings, a simplified model explaining the role of PKA in regulating 
the chromosome binding function of the HPV8 E2 protein is shown in figure 8.1. 
During S phase of the cell cycle, PKA phosphorylates E2 protein at S253 residue, 
resulting in a stabilized population of E2 that binds to chromatin strongly and can be 
observed as E2 associated pericentromeric foci in interphase. As cells transition to 
mitosis, the phosphorylated E2 population remains bound to chromosomes whereas 
the unphosphorylated and chromatin unbound population is labile and degraded. 
When cells exit from mitosis, the phosphorylated E2 proteins undergo 
dephosphorylation and are available to perform the transcription function of E2 
during interphase. 
Similarities between the tethering proteins E2, EBNA1 and LANA 
Similar to PVs, the gamma herpesviruses also cause long term infection of 
their hosts and maintain their genomes as extrachromosomal elements in infected 
cells. Comparison of the chromosome binding regions of the gammaherpesvirus 
tethering proteins, LANA and EBNA1 with the HPV8 E2 protein reveals that there 
are sequence similarities within these regions in all three proteins as shown in figure 
3.9  in Chapter 3 [235]. Interestingly, the identified RXXS kinase motif is also present 
in the chromosome binding regions of the LANA and EBNA1 tethering proteins. The 
two chromosome binding domains of EBNA1 have been mapped to the N-terminal 
domain and are called domain A (residues 33-89) and domain B (residues 328-378) 
[160].  These regions have been shown to carry A-T hook motifs that are required for 
chromosome binding and partitioning [232]. Notably, several of the A-T hook motifs 




motifs are phosphorylated and substitution of these serines disrupts the EBNA 
partitioning function [240]. In the case of KSHV LANA, the chromosome binding 
motifs have been mapped to the N-terminus (residues 5-22) [13].  Additionally the 
LANA CTD can associate with mitotic chromosomes at pericentromeric and 
telomeric regions [133]. In LANA, substitution of residues overlapping the RXXS 
motif also disrupts episomal persistence, chromosome binding and interaction with 
histones H2A and H2B [13]. Thus, from these observations we can propose that 
although the three tethering proteins may have different chromosomal targets, a 
common mechanism regulates their chromosome binding functions.  
Importantly, similarities among the three tethering proteins do not end with 
similarities in their chromosome binding regions. Despite no strong sequence 
similarity between the proteins, E2, EBNA1 and LANA CTDs form similar 
structures. The EBNA1 protein has been shown to form a similar dimeric beta-barrel 
structure to that of the E2 CTD [29]. The LANA DBD has also been predicted to fold 
into a similar structure as the EBNA1 CTD [101,105]. Thus, it is tempting to 
speculate that the similarity in CTD structures of the three proteins further supports 
the hypothesis of common mechanism of regulation of chromosome binding. Our 
mapping studies demonstrate that the HPV8 E2 CTD is also essential for the 
chromosomal association function of the HPV8 E2 protein [235]. However, the 
contribution of the CTD in the E2 chromosomal association function is not 
completely clear. The CTD could be involved in mediating E2-chromosome 
association either through direct DNA binding or protein-protein interactions. From 




mediated through RNA interactions. Due to the similarity between the CTD structures 
of EBNA1 and E2 and the predicted structure of LANA, using homology between 
EBNA1 and E2, a computer model of the LANA DNA binding domain can be 
developed. Based on a study by Kelley-Clark et. al wherein they identified LANA 
CTD residues important for chromosome association, the homology model would 
serve as a powerful tool to identify residues in analogous position in the HPV8 E2 
CTD and determine whether they are required for HPV8 E2 chromosomal interaction. 
 
General Discussion 
The members of the betapapillomavirus genus share a number of unique 
characteristics that distinguish them from other PVs. Beginning with their genomic 
organization to composition and features of the viral proteins they express, beta PVs 
are different. The fact that the genome size of beta PVs is smaller (7654 bp) and the 
LCR is shorter (350-500 bp) compared to other genera of PVs underscores their 
uniqueness (reviewed in [144]). The LCR has unique transcriptional regulatory 
elements, which indicates a different regulatory mechanism of the early promoter 
region of beta PVs (reviewed in [144]). Likewise the genome of these viruses does 
not encode the E5 gene. The E5 ORF encodes a small hydrophobic protein in 
cutaneous and genital alpha PVs that is believed to contribute to hyperproliferation of 
cells together with E6 and E7 [65]. E5 protein is primarily localized to the 
endoplasmic reticulum and is believed to play a role in transit of signaling factors 
[146,210] thereby augmenting the oncogenic activities of E6 and E7. High expression 




have shown that E5 proteins play an important role in many PV pathogenesis [186]. 
An interesting question to ponder over is how the lack of E5 might affect the beta PV 
biology. Loss of E5 gene function in the HPV31 genome was reported to result in 
inactivation of late viral functions in differentiating cells [79]. A provocative 
speculation could be that the beta E2 proteins because of their unique characteristics 
can compensate partly for the loss of the E5 ORF in the beta PV life cycle. The fact 
that beta E2 proteins seem to possess oncogenic potential underscores this possibility. 
One means to check for the ability of E2 to compensate for lack of E5 would be to 
compare the cellular targets of E5 with beta E2s and examine if they share any 
protein interactions. 
Several studies on beta E2s are throwing light on their unique properties. The 
E2 proteins of PVs are not thought to be oncogenic. In fact, they are usually pro-
apoptotic as seen in case of many high-risk E2s such as HPV18 and HPV 16 [63]. 
However, HPV8 E2 proteins appear to possess oncogenic potential. Recent studies 
expressing either the HPV8 early gene regions or HPV8 E2 protein under the kertain-
14 promoter in transgenic mice resulted in formation of skin tumors in mice 
[203,221]. Additionally, UV treatment of transgenic mice results in rapid onset of 
tumor development [203]. These studies suggested that they are two possible 
explanations for the enhanced E2 induced tumor development. One possibility is that 
increased oncogenesis is due to increased E2 expression as a consequence of 
upregulation the keratin-14 promoter. The E2 protein is a transactivator and it is 
possible that it could upregulate expression of cellular genes. For example, HPV8 E2 




differentiation [103]. The second possibility is that E2 interferes with the UV induced 
damage response pathway and thus, induces cell proliferation by inhibiting apoptosis. 
This is supported by reports that have shown that HPV8 E2 interacts with a number 
of UV DNA damage response factors such as TopBP1, p53 and Poly (ADP-ribose) 
polymerase (PARP) [169]. Hence, these studies clearly indicate that the HPV8 E2 
protein is different from the alpha E2s. It is not clear as to what interactions of the 
HPV8 E2 protein or which domains of the E2 protein are responsible for the observed 
oncogenic potential. It would not be out of context to speculate that the unique 
composition of the HPV8 E2 hinge plays a role in the oncogenic potential of the 
virus. It would be critical to determine whether other beta HPV E2 proteins such as 
HPV5 E2 also show similar carcinogenic capabilities.  
Like other PVs, betapapillomaviruses cause persistent infection of the host, 
the clinical manifestations of which are especially seen in immunocompromised 
individuals. For instance, EV patients that show a high susceptibility to infection with 
cutaneous HPVs like HPV5 and HPV8 specifically but not to other genera of PVs 
such as alpha PVs [192]. There is wide speculation about the contribution of EVER 
genes in exerting intrinsic immunity against beta PV infections. Moreover, it has been 
suggested that lack of E5 gene could be compensated for by EVER mutations during 
induction of EV lesions [186]. Another aspect linked to the phenomenon of host 
restriction of beta PVs is their inability to replicate in normal human keratinocytes. 
Both EVER genes are transcribed in normal human skin [208]. It would be 
worthwhile therefore, to determine whether down regulation of EVER genes allows 




important co-factor for a number of pathological effects of beta PVs. Treating 
keratinocytes with UV before transfecting the beta PV genomes would be an 
interesting approach to test for successful replication.  
Use of PV vectors in therapy 
The recent advent of the two prophylactic HPV vaccines is believed to 
significantly reduce the burden of HPV associated infections. Nevertheless, due to the 
fact that these vaccines are not effective against pre-existing infections and infections 
with viral types other than the ones included in the vaccines, there is still a need for 
specific antiviral therapy. The multifunctional E2 proteins of papillomaviruses are 
indispensable to the viral life cycle and hence, it makes them an attractive target for 
antiviral therapy. One line of therapy that could potentially interfere with the viral life 
cycle is to use compounds that would inhibit the binding of E2 to the E2 binding 
sites. However, there are important considerations to keep in mind while employing 
such a strategy. Many times during viral integration of high risk HPV genomes, the 
E2 ORF is lost during the process and hence, such an approach would be beneficial 
only prior to integration. Moreover, interfering with E2 binding can also upregulate 
E6 and E7 expression, which would lead to tumor progression. However, this 
approach might be beneficial against low risk E2s. A class of polyamides was 
specifically found to interfere with the binding of HPV18 E2 to its E2BS in vitro 
[220]. But one of the major limitations in using these compounds has been their 
limited bioavailability in cells. Recently an HIV DNA vaccine has been developed 




Our studies aimed to understand the molecular interactions of E2 proteins 
with host chromosomes and have added to our knowledge of how E2 proteins can act 
as a molecular bridge to bind chromosomes. However, it is important to determine if 
the chromosome binding region of the HPV8 E2 protein can contribute to plasmid 
maintenance by efficiently tethering and maintaining a reporter plasmid. Developing 
a papillomavirus partitioning assay has been challenging because of the role that the 
E2 protein plays in transactivation and replication initiation. In different approaches 
that have been tried in the laboratory, the reporter readout for plasmid maintenance 
has been problematic since we are unable to determine if the reporter readout 
observed is due to plasmid maintenance or due to E2-mediated transactivation. 
However, the regions required for chromosomal association of HPV8 are different 
from that of other E2s and do not include the transactivation domain. Thus, the read 
out of the partitioning assay will likely be much clearer with the truncated HPV8 E2 
proteins in the background of 240-255 amino acids of the hinge fused to the CTD. If 
we can successfully test the role of the chromosome binding region in the tethering 
and partitioning assay, it would prove to be a useful tool in the development of 
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